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Abstract
The myeloid cell lineage represents a diverse collection of cell types arising from a common 
progenitor. Two extreme phenotypes of this lineage belong to the osteoclast and the dendritic cell. 
This thesis evaluates differential expression of a discrete selection of genes in these two cell types, 
as they differentiate from their monocyte precursor, utilising well-characterized in vitro 
differentiation systems and microarray gene technology.
A custom made microarray, including all known chemokine and chemokine receptor genes and 
related G protein-coupled seven transmembrane (7TM) receptors and ligands, was employed. 
Expression of transcripts encoding chemokine and chemokine receptors by dendritic cells, and a 
study of protein expression / production by these cells, served as validation for the microarray gene 
technology used. In particular, the array data revealed two interesting findings, which were 
investigated further.
GPR105 gene expression by immature DCs was confirmed by Northern blot analysis. UDP-glucose, 
an agonist for GPR105, induced calcium responses uniquely in immature DCs, correlating with the 
gene expression data. This response demonstrated partial sensitivity to pertussis toxin, implicating a 
7TM receptor linked to a G ia containing G protein, such as GPR105. Moreover, immature DCs 
from some donors treated with UDP-glucose exhibited an increase in expression of the co­
stimulatory molecule CD86, which correlated with the intensity of an UDP-glucose-induced 
calcium flux, suggesting a role for this GPCR and its agonist in DC activation.
Production of the angiogenic chemokine CXCL5 by in v/fro-derived osteoclast cultures was 
confirmed by ELISA and attributed to multinuclear cells by immunocytochemistry. Supernatants 
from osteoclast cultures induced chemotaxis of neutrophils, which was decreased in the presence of 
an antibody to CXCL5. A role for osteoclast produced CXCL5 in angiogenesis is discussed.
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Introduction
1.1 Haematopoiesis, bone and the immune system
Blood cells and certain other cells located throughout the body are continuously regenerated 
throughout life by a process called haematopoiesis. Many haematopoietic cells are short lived, some 
surviving for only a day or two, and thus haematopoiesis serves to maintain a steady renewal of 
these cells on physiological demand. Reconstitution of the haematopoietic system is believed to be 
the function of a single haematopoietic precursor cell called the pluripotent stem cell (Morrison et 
al., 1995). In addition to being self-renewing, haematopoietic stem cells undergo multi-lineage 
differentiation driven by cytokines and cell-cell interactions. There is a vast literature regarding this 
differentiation process. Figure 1.1 summarises some of the relevant steps in the process.
The pluripotent haematopoietic stem cell undergoes lineage commitment and subsequent sequential 
differentiation along distinct lineage pathways, giving rise to all blood cell types. The common 
lymphoid progenitor cells differentiate into NK cells, B lymphocytes and T lymphocytes. The stem 
cells committed to the myeloid lineage (common myeloid progenitors) differentiate into platelets, 
red blood cells, granulocytes, monocytes, macrophages, and myeloid dendritic cells (DCs). 
Osteoclasts and other specialised cell types such as microglial cells, Kupffer cells and alveolar 
macrophages also develop from the myelomonocytic lineage (Kaur et al., 2001; Nicholson et al., 
2000).
In general, haematopoietic cells are highly mobile, migrating within the cardiovascular system or 
the lymphatic system. Many of these cells also cross-migrate between these two circulatory systems 
and many migrate directly into peripheral tissues, particularly under the influence of inflammatory 
cytokines and chemokines. These cells represent the immune system, constituted by a surprising 
variety of different cell types disseminated throughout the body and collectively defining our
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capacity to mount an immune response to infectious pathogens such as viruses and bacteria. The 
immune system is typically divided into two categories, innate and adaptive, although these 
distinctions are not mutually exclusive. Innate immunity refers to non-specific defence mechanisms 
that come into play immediately or within hours of an antigen's appearance in the body. These 
mechanisms include physical barriers such as skin, chemicals in the blood, activation of the 
complement system and release of cytokines and chemokines. The cells involved in the innate 
immune system include: cells that release inflammatory mediators, such as basophils, mast cells and 
eosinophils; NK cells that specialise in killing tumour cells and virally infected cells; and 
phagocytic cells, such as neutrophils, monocytes and macrophages, which bind to microorganisms 
using primitive non-specific recognition systems, internalise them and destroy them. Adaptive 
immunity refers to an antigen-specific immune response. The adaptive immune response is more 
complex than the innate. The antigen first must be processed and recognised. Once an antigen has 
been recognised, the adaptive immune system creates an army of immune cells specifically 
designed to attack that antigen. Adaptive immunity also includes immunological memory that 
makes future responses against a specific antigen more efficient and involves: antigen-presenting 
cells such as macrophages and dendritic cells; the activation and proliferation of antigen-specific B- 
lymphocytes; the activation and proliferation of antigen-specific T lymphocytes; the production of 
antibody molecules, cytotoxic T lymphocytes (CTLs), activated macrophages, NK cells and 
cytokines.
The interdependence of bone and the haematopoietic system has long been apparent. Bone 
remodelling depends upon the resorption of bone by specialised osteoclasts, which arise from the 
haematopoietic myelomonocytic lineage. Indeed development of bone marrow, the home of 
haematopoiesis in the adult, depends upon the excavation of cartilage and bone by osteoclasts. 
Furthermore, mice lacking c-Fos, a component of the AP-1 transcription factor complex, 
demonstrate an osteopetrotic phenotype and altered haematopoiesis, with decreased numbers of
16
splénocytes and thymocytes (Wang et al., 1992). There is also evidence that megakaryocytes play a 
role in the regulation of bone remodelling, particularly as they express the osteoclastogenic factor 
RANKL (Receptor activator of NF-kB ligand) (Kartsogiannis et al., 1999).
Relationships between bone remodelling and the immune system are perhaps less obvious. 
Osteopetrotic syndromes, arising from a deficiency of bone resorption, often include associated 
immune defects. However, this is generally a secondary consequence of the failure to establish a 
normal haematopoietic environment. Glucocorticoids and other immunosuppressive drugs are 
known to cause a net loss of bone that can predispose to fracture (Canalis, 2003). Similarly, many 
cytokines and other regulatory molecules that are important regulators of immune cell 
differentiation and maturation also have potent effects on osteoblasts and osteoclasts. However, it is 
for the most part unclear whether the effects on bone remodelling reflect interactions between bone 
cells and immune cells or, instead, independent effects of the agents on the two systems. Perhaps 
the strongest link of bone to the immune system has emerged from the discovery of the RANK 
(Receptor activator of NF-kB) / RANKL / OPG (osteoprotegrin) system. RANKL has been 
identified as a key osteoclast differentiation factor, a regulator of dendritic cell functions and is 
essential for lymph node organogenesis (Kong et al., 1999a). T cells express RANKL and can 
directly trigger osteoclastogenesis and bone loss (Kong et al., 1999b). The contribution of bone 
marrow T cells relative to stromal cells in osteoclastogenesis is unknown. Intriguing also is the 
common progenitor of two highly specialised cell types with central roles in bone and the immune 
system, the osteoclast and the dendritic cell respectively.
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Adapted from; Kuby Immunology, 4*^  edition, Chapter 3: Antigens
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Figure 1.1 Haematopoiesis
Haematopoietic cells are continuously regenerated throughout life by the process of 
haematopoiesis: steadily renewing these cells on physiological demand. Haematopoiesis is believed 
to arise from the function of a single precursor cell called the pluripotent stem cell. In addition to 
being self-renewing, stem cells undergo multi-lineage differentiation. Stem cells are shown in grey; 
progenitor cells in green and fully differentiated cell types in blue.
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1.2 Myeloid cell differentiation pathways: macrophages, dendritic
cells and osteoclasts
There are three major pathways of myeloid cell differentiation; erythroid, megakaryocytic and 
phagocytic. The erythroid lineage gives rise to red blood cells; the megakaryocytic lineage 
generates blood platelets, while the phagocytic pathway undergoes complex subdivisions, firstly 
into the monocytic and the granulocytic lineages. The granulocyte lineage divides into the 
neutrophilic, eosinophilic, and basophilic pathways. Blood monocytes, which mature in all tissues 
and organs of the body to various types of macrophages, are also capable of differentiating into 
dendritic cells and osteoclasts (Fig. 1.1).
1.2.1 Macrophages
Macrophages can be classified into either resident or inflammatory macrophages. Resident 
macrophages, such as those found in the connective tissue (histiocytes), liver (Kupffer cells), lung 
(alveolar macrophages), kidney (mesangial cells) and peritoneal macrophages to name but a few are 
renewed by local proliferation and differentiation of progenitor cells. Inflammatory macrophages 
are characterized by various specific markers, including peroxidase activity, and are derived 
exclusively from recruited monocytes. Macrophages are a population of ubiquitously distributed 
mononuclear phagocytes responsible for numerous homeostatic, immunological and inflammatory 
processes. Their range of tissue distribution makes these cells perfectly suited to provide an 
immediate defense against foreign pathogens prior to adaptive immune responses. Since 
macrophages participate in both specific immunity via antigen processing and presentation and 
innate immunity against bacterial, viral and fungal pathogens, it is not surprising that macrophages 
display a wide range of functional and phenotypic properties. The microbiocidal and cytotoxic 
activity of macrophages occurs mainly via the production of reactive oxygen intermediates, 
allowing the killing of phagocytosed microorganisms. In addition, macrophages are capable o f
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antibody-dependent cell-mediated cytotoxicity (ADCC), insofar as they are able to kill or damage 
antibody-opsonised extracellular microbes. Macrophages may also take part in the initiation of 
specific T cell activation through the processing and presentation of foreign antigen. Finally these 
cells are central effector and regulatory cells of the inflammatory response, acting through the 
release of numerous immunoregulatory or inflammatory cytokines (Gordon, 1996a; Gordon, 
1996b).
1.2.2 Dendritic cells
The term dendritic cell represents a heterogeneous group of cells, which, under different 
microenvironmental conditions, can induce such contrasting states as T cell driven immunity and T 
cell tolerance. That is, the immune system is uniquely characterised by its highly diverse and 
clonally expressed repertoire of lymphocyte receptors that can recognise a very broad spectrum of 
both foreign and self-antigens. Those cells with receptors for self-antigens are eliminated, or 
tolerised, in healthy individuals by a variety of active mechanisms to prevent pathogenic 
autoimmunity. These same mechanisms operate during the induction of tolerance to foreign 
antigens and may be exploited to inactivate specific, detrimental immune responses without 
compromising the ability to respond to the remaining universe of pathogens, because tolerance is 
induced only in those lymphocytes that recognise the offending antigens. Therefore, presentation of 
processed antigen to T cells by dendritic cells can result in either tolerance induction or initiation of 
an immune response.
Despite the heterogeneity of human dendritic cells they have many factors in common: they are all 
able to internalise and process antigen; they possess the ability to migrate to lymphoid tissue in 
response to danger signals and they have the ability to stimulate a primary T lymphocyte response 
to foreign antigen / self major histocompatability (MHC) complexes. The pathways responsible for 
generating DCs in vivo remain to be clearly defined. However, in vitro, dendritic cells can be
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derived from the myeloid (Inaba et ah, 1992; Scheicher et ah, 1992) or lymphoid (Steinman et ah, 
1997; Wu et ah, 1996) lineages, resulting in either the interstitial or Langerhans DCs in the case of 
the myeloid progenitor, or plasmacytoid DCs from the lymphoid lineage (Fig. 1.2). Recent evidence 
suggests that the myeloid and lymphoid DC subsets play differing roles in the immune response. 
The lymphoid (plasmacytoid) DCs have been proposed to play a regulatory role, containing 
immune responses (Austyn, 1998; Shortman and Caux, 1997). In contrast myeloid DCs have a 
stimulatory role on an immune response. The myeloid DCs are located at anatomical sites where 
many pathogens enter the body and are initially exposed to foreign agents at the site of infection. 
They undergo critical activation and maturational changes, resulting in the release of inflammatory 
cytokines and chemokines that recruit inflammatory cells to these sites. These mature myeloid DCs 
then transport the antigen to the T cell zone of the draining lymph nodes where they present 
antigenic peptides in the context of MHC class II molecules to antigen-specific T cells, thereby 
initiating an adaptive immune response. While there have been many recent advances in the 
understanding of the DC, there are still many unanswered questions about the signals required for 
this important maturation process.
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Figure 1.2 Three subsets of human dendritic cells
Myeloid CD34+ progenitors differentiate into monocytes (CD 14+ CD 11 c+ DC precursors) that 
give rise to immature interstitial DCs in response to GM-CSF and IL-4. Myeloid progenitors also 
differentiate into CD 14- CDl lc+ precursors, which give rise to Langerhans cells in response to 
GM-CSF, IL-4 and TGF-p. Lymphoid CD34+ progenitors differentiate into immature DCs in 
response to IL-3. The immature dendritic cells differentiate into mature cells in response to 
maturation signals such as CD40L, LPS and MCM.
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1.2.3 Osteoclasts
Osteoclasts are formed from myelomonocytic haematopoietic lineage cells that are recruited from 
the blood to the bone surface, where they undergo further differentiation and fusion to form 
multinucleated cells. Polarisation of the osteoclast occurs on contact with bone and in response to 
osteoclast-inducing cytokines (to be discussed below); the cells undergo rearrangements of the 
actin cytoskeleton and formation of a tight sealing zone between the bone surface and the basal 
membrane to form a specialized compartment. Within this resorption pit (Howship’s lacunae) 
osteoclasts secrete acids and lytic enzymes that solubilise the bone mineral and collagen matrices 
and through this process the osteoclast erodes the underlying bone (Fig. 1.3). The bone resorption 
activity of osteoclasts is essential for bone remodelling which occurs throughout adult life. A 
balance between osteoblastic bone formation and osteoclastic bone resorption is critical, since 
imbalances of remodelling result in skeletal diseases such as osteoporosis and rheumatoid arthritis. 
These diseases are mostly caused by excess osteoclastic activity and, as such, the osteoclast and the 
mechanisms of bone resorption have become major targets for therapeutic intervention.
The differentiation of osteoclasts in vitro, utilizing mouse bone marrow cultures of spleen cells and 
stromal cells has led to the discovery of RANKL and macrophage-colony stimulating factor (M- 
CSF) as the two factors necessary for osteoclast differentiation (Yasuda et al., 1998). RANKL 
induces the activation of NF-kB and, together with M-CSF, induces the expression o f genes 
associated with the osteoclast lineage, such as TRAP, calcitonin receptor, cathepsin K and the |33 
integrin (Lacey et al., 1998). The importance of RANKL for osteoclastogenesis came initially from 
the discovery of osteoprotegrin (OPG), a soluble receptor that prevents RANKL from binding the 
RANK receptor on osteoclast precursor cells. Mice deficient in RANK or RANKL are 
osteopetrotic, with fragile bones (Kong et al., 1999c; Li et al., 2000; Simonet et al., 1997) as are 
mice over expressing OPG, the naturally occurring soluble inhibitor of the RANK / RANKL
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interaction (Li et al., 2000). The importance of M-CSF in bone was demonstrated by the discovery 
of a mutation in the M-CSF gene in the op/op (osteopetrotic) mutant mouse (Marks, Jr. and Lane, 
1976).
RANKL
Adapted from; Modulation o f  osteoclast differentiation, 
Suda et al., (1992)
Endocrine Reviews 13, 66-79
RANK
Calcitonin
Ruffled border
H X OCalcitonin
receptor Chloride 
Channel ysosome
Proton
PumpTRAP
ly ^som a l
enzyme
Figure 1.3 A schematic representation of osteoclast molecules and functions
The osteoclast attaches to bone and, in the presence of RANKL, formation of the ruffled border 
occurs. Numerous aVP3 molecules and receptors for calcitonin and RANKL are expressed on the 
osteoclast plasma membrane. Osteoclasts possess high levels of TRAP activity, which is 
conveniently used as a specific histochemical marker. A resorptive microenvironment is achieved 
beneath the cell by the synthesis of hydrochloric acid from the hydrogen ions provided by proton 
pumps and secretion of chloride ions into the resorption pit via chloride channels. Lysosomal 
enzymes are secreted into the resorbing area and facilitate degradation of the organic bone matrix.
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1.2.4 Macrophages, dendritic cells and osteoclasts
Perhaps osteoclasts and myeloid dendritic cells represent specialised cell types displaying 
developed but mutually exclusive features of macrophages. Indeed, early reports of collagen and 
bone resorption by osteoclasts referred to this as phagocytosis (Everts et al., 1985), a fundamental 
property of macrophages. Furthermore, activated macrophages are able to degrade the osteoid 
covering the bone surface (Lassus et al., 1998) and macrophages are capable of antigen presentation 
(Unanue, 1984), but unlike dendritic cells, macrophages do not have the capacity to activate naïve T 
cells (Liu and MacPherson, 1993).
There is increasing evidence for a common precursor for myeloid dendritic cells and osteoclasts. 
Murine bone marrow Flt3-positive monocyte precursors have been demonstrated to commit 
sequentially to DCs and osteoclasts (Servet-Delprat et al., 2002). Each time frame corresponds to 
expression of a specific differentiation potential: day 6 monocyte precursors show preference for 
osteoclast differentiation while day 8 precursors have a preference for DC differentiation. The 
bipotential of common precursor cells to differentiate into osteoclasts and dendritic cells has been 
demonstrated at the single cell level (Miyamoto et al., 2001). In these studies, dendritic cell 
differentiation was inhibited using M-CSF, a co-factor for osteoclastogenesis; in contrast, osteoclast 
differentiation was inhibited by granulocyte macrophage-colony stimulating factor (GM-CSF), a 
factor essential for dendritic cell differentiation. The authors were also able to demonstrate 
concomitant regulation of the proto-oncogene associated with commitment to the osteoclast lineage 
(Grigoriadis et al., 1994). The use of in vitro differentiation systems to derive dendritic cells and 
osteoclasts from a common precursor cell should enable investigation of phenotypic changes that 
occur during the differentiation process, as well as exploration of the function of any differentially 
expressed molecules, perhaps yielding clues to the biology behind the very different functional 
capabilities of these two cell types.
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1.3 DC isolation and differentiation pathways
Human DC can be isolated in two ways. Firstly, populations can be isolated by negative selection 
from peripheral blood, or enzymatically digested lymphoid tissue using a range of sophisticated 
flow cytometry and immunomagnetic bead systems. These systems capitalise on the absence of 
certain lineage-specific markers on DCs that are expressed on other defined leukocyte populations, 
e.g. T lymphocyte (CD3), B lymphocyte (CD 19, CD20), NK cells (CD 16, CD56), monocytes (high 
density CD 14) and granulocytes (CD 15) markers. The negative selection is then followed by 
positive selection using anti-CD83 (Zhou and Tedder, 1995), or mAbs with specificity for other 
DC-specific cell-surface molecules such as BDCA-2, -3, -4 and CD lc (Dzionek et al., 2000). 
Secondly, density gradient centrifugation over various gradient media such as Percoll (Amrad, 
Pharmacia Biotech) (Young and Steinman, 1988) or Nycodenz (Nycomed Pharma) (McLellan et 
al., 1995a) exploits the low density of DCs following a period of in vitro culture. However, these 
media may induce phenotypic or functional changes in the cells (McLellan et al., 1995b). While ex 
vivo isolation of DCs is desirable for the study of DC biology, the aforementioned methods of 
isolation are complicated and time consuming. In addition, they may require large amounts of 
human blood or tissue in order to obtain sufficient numbers of cells for study. Therefore 
development of simple in vitro differentiation protocols for generating large numbers of 
functionally and phenotypically relevant DCs provides a means of gaining important insights into 
the mechanisms controlling the physiological generation of DCs and their functions.
Human DCs can be derived in vitro using several cellular sources: CD34-positive progenitor cells 
isolated from cord blood or peripheral blood, adherent peripheral blood mononuclear cells (PBMC) 
or peripheral blood monocytes (PBM). Cord blood cells cultured in GM-CSF and TNF-a produce a 
population described as dendritic Langerhans cells, with marked allo-stimulatory properties (Caux 
et al., 1992). Caux et al. have also demonstrated that lL-3 can substitute for GM-CSF in this system
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(Caux et al., 1996). Furthermore, the addition of transforming growth factor-(TGF-)(3 promotes the 
formation of these cells (Strobl et al., 1996). Peripheral blood CD34-positive progenitors cultured in 
GM-CSF (Bernhard et al., 1995) or GM-CSF plus IL-4 with a cocktail of stem cell factor (SCF), 
erythropoietin (EPO), IE-1(3, IL-3 and IL- 6  (Mackensen et al., 1995) gives rise to populations of 
immunostimulatory Langerhans cells, with varying success. Peters et al. (Peters et al., 1987) 
demonstrated the differentiation of a population of dendritic cells capable of antigen presentation 
from cultured peripheral blood monocytes with GM-CSF and IL-4. Sallusto and Lanzavecchia 
further demonstrated phenotypical and functional changes in this population, akin to dendritic cell 
maturation, on treatment with TNF-a (Sallusto and Lanzavecchia, 1994). Bender et al. showed that 
dendritic cells derived from lymphocyte depleted peripheral blood in the presence of GM-CSF and 
IL-4 required the addition of a monocyte-conditioned medium (MCM) to give phenotypically and 
functionally mature DCs (Bender et al., 1996). A plethora of factors have since been shown to 
activate or mature in v//ro-derived immature DC populations, including LPS (Granucci et al., 1999) 
and CD40 Ligand (Wurtzen et al., 2001). Lastly, despite initial shortcomings in the ability of 
cytokine cocktails to replace monocyte-conditioned medium as a myeloid DC maturation factor 
(Reddy et al., 1997), a cytokine cocktail containing GM-CSF, IL-4, IL-ip, TNF-a, IL- 6  and 
prostaglandin E2 (PGE2) has recently been shown to be as efficient, and potentially more 
reproducible, than MCM in activating immature DCs (Choi et al., 2000; Spisek et al., 2001).
The human immature DCs derived in vitro from peripheral blood monocytes in the presence of 
GM-CSF and IL-4 represent a population that mimic the common characteristics of a DC (Fig. 1.4). 
These cells express the chemokine receptors CCRl and CCR5 (Pashenkov et al., 2002; Sallusto et 
al., 1999). This is consistent with their requirement to migrate to areas of inflammation where 
ligands for these receptors, such as CCL3 (macrophage inhibitory protein- (M lP-)la), CCL4 (MIP- 
IP), CCL5 (RANTES) and CCL15 (MIP-5) are expressed (Pashenkov et al., 2002; Sozzani et al., 
1997). Exposure to a variety of inflammatory or bacterial stimuli, including monocyte-conditioned
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medium (Bender et al., 1996; Reddy et al., 1997), leads to maturation of monocyte-derived DCs. 
Coordinated changes in gene expression occur upon DC maturation, including decreased expression 
of CCRl and CCR5 and increased expression of CCR7 (Sallusto and Lanzavecchia, 2000; Sozzani 
et al., 1998; Caux et al., 2000). This change in chemokine receptor expression enables the 
chemotactic recruitment of DCs to areas of lymph nodes abundant in T cells that express the CCR7 
ligands CCL19 (ELC, MIP-3P) and CCL21 (SEC, 6 Ckine) (Baekkevold et al., 2001). DC 
maturation also results in increased expression of many proteins other than chemokines, such as the 
co-stimulatory molecules CD40, CD80 (B7.1) and CD8 6  (B7.2) (Fig. 1.4), fundamental to the 
ability of DCs to interact with and activate naïve T cells (Ni and ONeill, 1997). The fact that 
CD40L expressed by activated T cells is used as a potent maturation factor for DCs, demonstrates 
the importance of two-way communication between DCs and T cells. The maturation process 
further affects some of the functional properties of DCs (Fig. 1.4). Immature DCs demonstrate 
efficient antigen uptake, whereas mature DCs show a reduced ability to endocytose antigen and an 
increased ability to present peptide / MHC complexes to naïve T cells. Although the terms 
immature and mature are used for these cell types, with the mature cells capable of being induced 
from the immature population (Reddy et al., 1997), relevant terminology such as activated or 
primed could also be used to describe mature DC.
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Figure 1.4 The differentiation and maturation of m vitro monocyte-derived DCs
DCs acquire specific abilities upon maturation and lose certain others relevant to their roles at each 
stage of the differentiation process. Immature DCs have powerful antigen uptake and processing 
capabilities, express MHC class II and low levels of co-stimulatory molecules consistent with their 
ability to activate antigen-specific T cells. Mature DCs have lost the antigen uptake and processing 
capacity and have increased MHC class II and co-stimulatory molecule expression, allowing more 
efficient activation of antigen-specific T cells.
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1.4 Osteoclast isolation and differentiation pathways
Several techniques have been developed for isolating osteoclasts from long bones. Commonly, 
osteoclasts are prepared from embryonic chicken tibia by removing the marrow and releasing the 
osteoclasts using calcium-free and magnesium-free buffers. Enrichment of multinucleated 
osteoclasts then occurs, by sieving through a nylon mesh, followed by density gradient 
centrifugation (Osdoby et al., 1982). Isolation of osteoclasts from juvenile rabbit long bones 
recovers large numbers of osteoclasts (Tezuka et al., 1994). However, these complicated methods 
result in heterogeneous populations with variable bone resorption capabilities.
Mouse bone marrow culture systems have been established in which Tartrate Resistant Acid 
Phosphatase (TRAP)-positive multinucleated cells form in 5 to 6  days and are capable o f bone 
resorption (Takahashi et al., 1988). These methods have been extended to human bone marrow 
cultures, with the addition of 1,25-dihydroxyvitamin D3, in which osteoclast cells develop in 3 
weeks (MacDonald et al., 1987; Thavarajah et al., 1991). Co-culture systems then started to emerge 
where mouse spleen cells were used as a source of osteoclast precursors that formed multinucleated 
cells on culture with bone marrow-derived stromal cell lines (Udagawa et al., 1989). These co­
cultures can be established on collagen-coated plates from which osteoclast-like cells can be 
released by collagenase (Akatsu et al., 1992). The immortalisation of osteoclast precursors has 
resulted in cell lines capable of generating high numbers of bone resorbing osteoclasts (Hentunen et 
al., 1998; Chen and Li, 1998).
Since the description of RANKL, a TNF superfamily member capable of replacing stromal cells in 
co-culture systems to induce osteoclast formation (Yasuda et al., 1998), in vitro differentiation 
systems using precursor cells on their own have been developed. Treatment of adherent human 
PBMCs with RANKL and M-CSF induces TRAP-positive, multinucleated osteoclast-like cells 
expressing aVp3 and calcitonin receptors (CTRs) (Matsuzaki et al., 1998; Quinn et al., 1998). The
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formation of osteoclast-like cells from the culture of CD 14-positive mononuclear cells with 
RANKL and M-CSF, confirms these peripheral blood monocytes as the osteoclast precursor 
contained in the PBMC fraction (Massey and Flanagan, 1999). Indeed, enhanced osteoclast 
formation is observed when the adherent fraction of PBMC is used for osteoclast cultures. 
Otherwise, TGF-(3 is required to restore osteoclast differentiation in the presence of the non­
adherent fraction to a level equivalent to using the adherent fraction alone as a precursor population 
(Massey et al., 2001).
Culturing of human peripheral blood monocytes in the presence of M-CSF and RANKL gives rise 
to a population of cells that have all the characteristics of osteoclasts. They are multinucleated, 
TRAP-positive, CTR-positive, aVpS-positive and, most importantly, are capable of bone resorption 
(Fig. 1.5). This, therefore, represents a system amenable to the further study of osteoclast generation 
and function.
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Figure 1.5 Schematic for the in vitro differentiation of osteoclasts and characteristics of these 
cells
M-CSF and RANKL are essential for the differentiation of osteoclasts from peripheral blood 
monocytes. During this differentiation process TRAP is expressed and CTR and aV(33 are acquired. 
Pre-osteoclasts fuse in the presence of RANKL to form multinucleated osteoclasts. These 
multinucleated osteoclasts are capable of bone resorption.
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1.5 Gene expression: mRNA transcript analysis
The aim of this project was to analyse the expression of a selected set of genes in differentiated 
osteoclasts, differentiated dendritic cells and their monocyte precursors. Each cell type has a unique 
pattern of gene expression, the analysis of which can reveal the underlying physiologies of the cell. 
There are several ways o f performing such analysis. The most straightforward way is to construct a 
representative cDNA library from the cell type of interest and sequence every cDNA clone. This is 
obviously a monumental task. While this approach is probably the most objective, a more focussed 
approach around gene families may reap greater rewards in the short term. To analyse the 
expression o f specific genes, mRNA can be isolated from the cells and subjected to reverse 
transcription-PCR (RT-PCR) using a panel of specifically designed oligonucleotide primer pairs 
(two short single-stranded DNA fragments with sequences complementary to those that flank the 
stretch of cDNA to be amplified). Detection of specific RNA sequences can be confirmed by 
Northern blotting in which RNA isolated from cells is electrophoretically separated by size in the 
presence of a denaturing agent, such as formaldehyde, and then transferred to a solid-support 
nitrocellulose membrane. Hybridisation of specifically designed probes (labelled radioactively for 
example) to the membranes allows specific RNA sequences to be identified. However this process 
is best suited to analysis of a small number of defined genes. Where a large numbers o f genes are to 
be investigated, comparative gene expression profiling is used.
One application of RT-PCR is a method for differential mRNA screening called differential display 
RT-PCR (Liang and Pardee, 1998). In this technique, two or more cell populations can be compared 
and mRNA is isolated from each population. Reverse transcription of mRNA into single strand 
cDNA followed by PCR is performed in the presence of a source of radiolabelled nucleotide using 
an oligo-dT primer, which will anneal to the 3 ' poly A tail of all mRNA species, and a set of 
random primers (usually lOmers), which will anneal to complimentary sequences upstream of the
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poly A tail. Since the upstream primer will anneal to different cDNA species at different relative 
positions, the lengths of the PCR products will vary for multiple mRNA species detected. The 
products from these reactions are then separated on a high-resolution gel and exposed to X-ray film. 
The presence of bands with a greater intensity in one lane compared with another represents 
increased expression of an mRNA species in one cell population compared with another. The 
cDNA can be subsequently recovered from the gel for further analysis and identification.
Another technique termed serial analysis of gene expression (SAGE) involves sequencing a small 
and unique fragment of each expressed gene (called a SAGE tag). The number of times this 
fragment appears (the SAGE tag number) directly reflects the abundance of the corresponding 
transcript. The generation of a SAGE cDNA library does not require any prior knowledge of what 
genes are expressed in the cell of interest and is also able to detect and quantify the expression of 
previously uncharacterized genes. SAGE is based on two fundamental principles; since a 10 base 
pair sequence has 4*° possible combinations and there are aproximately 30,000 genes within the 
human genome, a short (10-11 bp) oligonucleotide fragment (SAGE tag) is sufficient to uniquely 
identify any transcribed human gene. Secondly, multiple 10 base pair SAGE tags can be 
concentrated in one plasmid, meaning that a single sequencing reaction can provide information for 
30 to 35 different genes.
A further approach for comparing gene expression profiles is the use of DNA microarrays. Two 
basic types of DNA microarrays are commonly used: oligonucleotide arrays and cDNA arrays. Both 
approaches involve the immobilization of DNA sequences on a girded array using a solid support 
surface, such as a glass microscope slide or nitrocellulose membrane. In the case of oligonucleotide 
arrays, fragments of known DNA sequence, typically 20 to 25-nucleotides in length are synthesized 
in situ on the surface of the support, allowing as many as 300,000 distinct sequences representing 
over 6,000 genes on a single 1.3cm x 1.3cm microarray. In the case of cDNA microarrays, PCR 
amplified cDNA fragments are deposited onto the solid support using a robotic spotting device. For
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both microarray approaches, the next step involves the purification of RNA from the source of 
interest (for example, in vfrro-derived cells), labelling of the RNA, and hybridisation of the labelled 
material to the microarray. Hybridisation events are then captured by scanning the surface of the 
microarray, with the intensity of each spot on the array proportional to the level of expression of the 
gene represented by that spot (outlined in Fig. 4.1). This technology provides the ability to monitor 
the expression levels of thousands of genes simultaneously.
1.6 mRNA transcript analysis of a selection of genes in myeloid cells
DNA microarray technology could be used to evaluate the differential expression of candidate 
genes in lineage related dendritic cells and osteoclasts and their monocyte precursors. G protein 
coupled receptors have emerged as excellent targets for therapeutic intervention, that is, greater than 
30% of all currently marketed pharmaceuticals are modulators of specific GPCRs (Wise et al.,
2002). The defined distribution and function of a subset of these receptors (chemokine receptors) 
and their ligands (chemokines) in one of the myeloid cell populations, namely dendritic cells, led to 
the proposal that differential expression of G protein coupled receptors and their ligands in 
osteoclasts and dendritic cells could bring new knowledge to the biology of these cell types and 
help to identify important new therapeutic targets. Expression of chemokine and chemokine 
receptor genes, related G protein-coupled seven transmembrane receptors and their ligands were 
therefore evaluated in immature and mature DCs, osteoclasts and their monocyte precursors using a 
custom-made DNA microarray. The following passages introduce the gene families represented on 
the microarray and their significance in dendritic cell and osteoclast biology.
1.7 The GPCR superfamily
Seven-transmembrane (7TM) receptors, or G protein-coupled receptors (GPCRs), form the largest 
gene superfamily of cell-surface receptors. GPCRs, also known as Serpentine Receptors are plasma
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membrane proteins that span the membrane seven times, containing an extracellular NH2-terminus 
and a cytoplasmic COOH-terminus. More than 2000 GPCRs have been reported since the 
discoveries of bovine opsin (Nathans and Hogness, 1983) and the (3-adrenergic receptor (Dixon et 
ah, 1986). GPCRs are grouped into four defined classes; receptors related to rhodopsin (class A), 
those related to secretin receptors (class B), receptors related to the metabotropic receptors (class C) 
and the frizzled receptors. Other less defined families include the fungal pheromone receptor family 
(class D) and the cyclic adenosine monophosphate (cAMP) receptors (class E) (G protein-coupled 
receptor database, www.gpcr.org). Each class of GPCRs shows substantial differences in their 
transmembrane sequences and cannot be traced to a single evolutionary origin.
The central role of GPCRs in multicellular organisms is reflected by their diversity. GPCRs 
respond to a wide range of stimulants including light, hormones, nucleotides and odorants (Pierce et 
al., 2002). Ligand binding occurs at varied sites on these receptors, including sites within the 
hydrophobic core formed by the transmembrane a-helices, within the NH2-terminus and 
extracellular hydrophobic loops that link the transmembrane domains (Gether and Kobilka, 1998). 
Ligand occupancy induces a conformational change in the GPCR that recruits and activates various 
G-proteins which in turn stimulate the generation of cAMP, phosphoinositides, diacylglycerol and 
other second messengers. This then triggers such events as activation of kinase cascades and 
phosphorylation of cytosolic factors and nuclear transcriptional factors (Brivanlou and Darnell, Jr., 
2002).
Modulation of GPCR function has resulted in a wide range of important therapeutic agents. Thus, 
the identification of new GPCR ligands, may lead to important discoveries in human physiology. 
There are numerous orphan GPCRs, representing new families, possibly with distinct and novel 
ligands (Wilson et al., 1998). Recent advances in 7TM receptor biology include many successes in 
the pairing of orphan 7TM receptors with their cognate ligands. However there are few remaining 
endogenous ligands whose receptor partners have not yet been identified and many receptors
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remain orphans, prompting efforts to find previously unknown ligands that might activate 7TM 
receptors (Howard et ah, 2001). Recent research indicates receptor-protein interactions 
demonstrating 7TM receptor signalling via G protein independent mechanisms, such as the 
angiotensin lA  receptor interacting through its carboxyl tail with the Janus kinase, JAK2, leading to 
transcription factor activation (Marrero et al., 1995). Furthermore the first 7TM receptor, rhodopsin, 
has now been crystallised (Palczewski et al., 2000), allowing for the evaluation of receptor / ligand 
interactions at a molecular level.
1.8 Chemokine receptors
There is a vast literature encompassing chemokines and chemokine receptors. Table 1.1 attempts to 
summarise the current knowledge about chemokines, chemokine receptors and their presumed 
functions. Chemokine receptors belong to the class A (rhodopsin like) GPCR subfamily. These 
chemokine receptors are classified into four families: XCR, CCR, CXCR and CX3CR, binding to 
the C, CC, CXC and CX3C chemokines respectively. To date, four CXC chemokine receptors 
(CXCRl -  CXCR4), ten CC chemokine receptors (CCRl -  CCRIO) and one CX3C chemokine 
receptor (CX3CR) have been cloned and characterized. Most known chemokine receptors are 
reported to bind to several ligands of the same class and most chemokines can interact with more 
than one receptor, generating considerable redundancy within these families o f molecules. In 
addition to chemokine receptors with known ligand(s), numerous orphan receptors that look to be 
members of the chemokine receptor family have been reported.
1.8.1 CXC receptors
CXCRl and CXCR2, previously known as IL-8 RA, or type I IL - 8  receptor, and IL-8 RB, or type II 
IL- 8  receptor, share 77% amino acid sequence identity. CXCL8  (IL-8 ) binds to both receptors with 
high affinity and induces rapid elevation of cytosolic Ca^^ levels (Murphy and Tiffany, 1991; Lee et
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al., 1992; Holmes et al., 1991). CXCR2 has been shown to bind with high-affinity to other Glu-Leu- 
Arg (ELR) motif containing chemokines including CXCLl, CXCL2, CXCL5, CXCL6  and CXCL7. 
In contrast, CXCL4, CXCL9 and CXCLIO, CXC-chemokines that lack the ELR motif, have been 
shown not to bind CXCRl and CXCR2 (Clark-Lewis et al., 1993). CXCRl and CXCR2 are 
expressed by neutrophils, but not B lymphocytes or T lymphocytes. CXCR3, also known as the IP- 
10 / Mig receptor, shares 40% protein sequence identity with CXCRl and CXCR2 (Loetscher et al., 
1996). CXCR3 is highly expressed by IL-2-activated T lymphocytes but is absent from resting T 
lymphocytes, B lymphocytes, monocytes and granulocytes. CXCR3 binds CXCL9 and CXCLIO 
with high affinity and mediates Ca^^ mobilization and chemotaxis. CXCR3 does not bind CXCL4 
or any of the CXC chemokines containing the ELR motif. CXCR4 previously termed fiisin or 
LESTR was originally discovered as an orphan receptor with structural similarity to chemokine 
receptors (Feng et al., 1996; Loetscher et al., 1996). CXCR4 was subsequently identified as a 
necessary cofactor for entry of T cell-tropic HIV viruses into CD4-positive T cells (Oberlin et al., 
1996). The CXC chemokine CXCLl2 (SDF-1) has now been shown to be the ligand for CXCR4 
and a powerful inhibitor of infection by T cell-tropic HIV-1 strains (Bleul et al., 1996; Oberlin et 
al., 1996).
1.8.2 CC receptors
CCRl was the first identified CC chemokine receptor and is expressed on monocytes, neutrophils 
and eosinophils. CCRl binds CCL3 (M IP-la), CCL5 (RANTES) and CCL7 (MCP-3) with high 
affinities and also CCL2 (MCP-1) and CCL4 (MIP-ip) with lower affinities (Neote et al., 1993; 
Gao et al., 1993). CCR2 binds all four members of the Monocyte Chemoattractant Protein (MCP) 
family, CCL2, CCL8 , CCL7 and CCL13 also known as MCP-1-4 respectively; CCL7, CCL8  and 
CCL13 also interact with CCRl and CCR5 (Baggiolini et al., 1997; Ruffing et al., 1998). CCR2 is 
expressed on monocytes but not on human neutrophils or eosinophils, while CCR3 is expressed
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predominantly on eosinophils. CCR4 was originally cloned from a human immature basophilic cell 
line and has since been shown to be expressed in T cells and IL-5-primed basophils. CCR4 has been 
shown to mediate the biological activities of CCL2, CCL3 and CCL5. CCR5 is expressed on 
primary adherent monocytes, but not on neutrophils or eosinophils. CCR5 mediates the activities of 
CCL3, CCL4 and CCL5. Recently CCR5 has also been shown to be a co-receptor on CD4-positive 
target cells for infection with primary monocyte-tropic human immunodeficiency virus-1 (HIV-1) 
viruses. CCR6  is expressed on activated T cells and dendritic cells and binds CCL20 (MIP-3a) 
(Baba et al., 1997; Greaves et al., 1997). CCR7 has been shown to bind the chemokines CCL19 
(MIP-3p) and CCL21 (SLC) and is involved in homing of T cells and DCs to lymphoid tissues 
during a primary immune response (Yoshida et al., 1998a; Yoshida et al., 1998b). CCR8  mediates 
the biological activities of CCLl (1-309), CCL4 and CCL17, demonstrates lymphoid tissue 
restricted expression and there is evidence that it is up-regulated in Th2-type T lymphocytes, 
suggesting a role in lymphocyte migration, activation and differentiation (Napolitano and Santoni, 
1999). CCR9 currently has only one known ligand, CCL25 (TECK), whereas CCRIO has several 
ligands including CCL27 (CTACK) and CCL28 (MEC). CCL25, CCL27 and CCL28 are all 
epithelial-expressed and prevalent in the small intestine, skin and mucosa respectively. As such a 
role for CCR9 and CCRIO in lymphocyte homing to these peripheral sites has been postulated 
(Kunkel and Butcher, 2002).
1.9 Chemokines
Chemokines are a family of small structurally related molecules with a major role in regulating 
leukocyte recruitment and mediate their activities through binding to chemokine receptors. There 
are four classes of chemokines, defined by the arrangement of the conserved cysteine (C) residues 
of the mature proteins: the CXC chemokines have one amino acid residue separating the first two 
conserved cysteine residues; the CC chemokines in which the first two conserved cysteine residues
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are adjacent; the C chemokine class lacks two (the first and third) of the four conserved cysteine 
residues and the CX3C chemokine category, in which the cysteines are separated by three residues.
Within the CXC subfamily, the chemokines can be further divided into two groups. One group of 
the CXC chemokines have the characteristic three amino acid sequence ELR (glutamic acid- 
leucine-arginine) immediately preceding the first cysteine residue near the NH2-terminus. A second 
group of CXC chemokines lacks this ELR motif. The CXC chemokines containing the ELR 
domain, including CXCLl (GRO-a), CXCL2 (GRO-P), CXCL3 (GRO-y), CXCL5 (ENA-78) 
CXCL6  (GCP2), CXCL7 (NAP-2) and CXCL8  (IL-8 ), act primarily on neutrophils as 
chemoattractants and activators, inducing neutrophil degranulation with release of myeloperoxidase 
and other enzymes. The CXC chemokines without the ELR domain, such as CXCL4 (PF4), CXCL9 
(MIG) and CXCLIO (IP 10) and the C chemokines XCLl (lymphotactin) and XCL2 are 
chemoattractive for lymphocytes. The CC chemokines, such as CCL2 (MCP-1), CCL3 (M IP-la), 
CCL4 (MIP-iP) and CCL5 (RANTES) chemoattract and activate monocytes, dendritic cells, T 
lymphocytes, NK cells, B lymphocytes, basophils and eosinophils to varying degrees. The only 
CX3C chemokine CX3CLI (ffactalkine), unlike other known chemokines, is a type I membrane 
protein containing a chemokine domain at the NH 2 -terminus tethered on a long mucin-like stalk, 
which has been shown to be involved in adhesion either as the membrane-tethered form or as a 
proteolytically shed form (Rossi and Zlotnik, 2000) and is expressed predominantly by epithelial 
cells (Lucas et al., 2001).
In addition to their roles in regulating leukocyte recruitment and trafficking, certain chemokines 
have been reported to act on haematopoietic progenitor cells and on non-leukocyte cells such as 
fibroblasts, smooth muscle cells, kératinocytes and melanoma cell lines. Other chemokines have 
also been implicated as playing a role in wound healing, in angiogenesis and in viral infection. In in 
vitro assays, chemokines have overlapping and redundant functions. It remains to be determined to
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what extent the various chemokines have unique roles in vivo. To date, over 45 chemokines have 
been described in humans (Nelson and Krensky, 2001). The majority of genes for all CC 
chemokines and CXC chemokines are grouped on two distinct chromosomal loci, 17ql 1.2-12 and 
4ql2-21 respectively (Naruse et al., 1996). The clustering of chemokine genes suggests that many 
chemokine family members arose through gene duplication and subsequent sequence divergence. 
Even the exceptions, CCL17, CCL22 and CX3CLI, which are chromosome 16ql3 chemokines, 
demonstrate synchronised regulation by way of their similar expression patterns in response to Th2- 
type cytokines and in atherosclerotic plaques (Greaves et al., 2001).
Chemokines can be further divided into two groups, inflammatory and homeostatic or homing 
chemokines. Inflammatory chemokines are upregulated in peripheral tissues in response to 
inflammatory cytokines, bacterial toxins and other inflammatory mediators. The ligands for CCRl, 
CCR2, CCR3, CCR5, CXCRl, CXCR2 and CXCR3 belong to this category. Inflammatory 
mediators do not generally induce expression of the homeostatic chemokines; rather, these 
chemokines are produced constitutively within defined areas of lymphoid tissues. The main 
fimction of the homeostatic chemokines is to control the homing of lymphocytes to the lymphoid 
tissues. In general inflammatory chemokines display an element of redundancy, with their receptors 
responding to multiple ligands, whereas the receptors for homing chemokines such as CCR7, CCR9 
and CXCR4 are selective for one, or at the most two, ligands and their expression is restricted to 
lymphocytes and mature dendritic cells.
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SYSTEM IC O TH ER NAM ES RECEPTO R M AIN FUNCTIONS
NAM E USAGE
CXCLl GRO-oc/MGCA-a CXCRl, CXCR2 Neutrophil migration
CXCL2 GRO-p/MGSA-p CXCR2 Neutrophil migration
CXCL3 GRO-y/MGSA-y CXCR2 Neutrophil migration
CXCL4 PF4 Unknown
CXCL5 ENA-78/LIX CXCR2 Neutrophil migration
CXCL6 GCP-2 CXCRl, CXCR2 Neutrophil migration
CXCL7 NAP-2 CXCR2 Neutrophil migration
CXCL8 IL- 8 CXCRl, CXCR2 Neutrophil migration
CXCL9 Mig CXCR3 T cell migration
CXCLIO IPIO CXCR3 T cell migration
CXCLl 1 I-TAC CXCR3 T cell migration
CXCL12 SDF-1 o/p CXCR4 B cell lymphopoiesis
CXCL13 BLC/BCA-1 CXCR5 B cell trafficking
CXCL14 BRAK/bolekine Unknown
CXCLl 5 Unknown
CXCL16 SexCkine CXCR6 T cell migration
CCLl 1-309 CCR8 T cell trafficking
CCL2 MCP-1 CCR2 T cell and monocyte migration
CCL3 MIP-loc/LD78a CCRl, CCR5 T cell and monocyte migration
CCL4 M lP-lp CCR5 T cell and monocyte migration
CCL5 RANTES CCRl, CCR3, CCR5 T cell, granulocyte; monocyte migration
CCL6 Unknown
CCL7 MCP-3 CCRl, CCR2, CCR3 T cell, granulocyte; monocyte migration
CCL8 MCP-2 CCR3 T cell and granulocyte migration
CCL9/10 CCRl
C C Lll Eotaxin CCR3 T cell and granulocyte migration
CCL12 CCR2 T cell and monocyte migration
CCLl 3 MCP-4 CCR2, CCR3 T cell, granulocyte; monocyte migration
CCL14 HCC-1 CCRl T cell and monocyte migration
CCLl 5 HCC-2/Lkn-l/M IP-lô CCR1,CCR3 T cell, granulocyte; monocyte migration
CCLl 6 HCC-4/LEC CCRl T cell and monocyte migration
CCL17 TARC CCR4 T cell and monocyte migration
CCLl 8 DC-Kl/PARC/AMACl Unknown
CCLl 9 MlP-3 p/ELC/exodus-3 CCR7 T cell and dendritic cell migration
CCL20 MIP-3 ot/LARC/exodus-1 CCR6 Dendritic cell migration
CCL21 6kine/SLC/exodus-2 CCR7 T cell and dendritic cell migration
CCL22 MDC/STCP-1 CCR4 T cell and monocyte migration
CCL23 CKP8/MPIF-1 CCRl T cell and monocyte migration
CCL24 MPIF-2/Eotaxin-2 CCR3 T cell and granulocyte migration
CCL25 TECK CCR9  ^ T cell homing to gut
CCL26 Eotaxin-3 CCR3 T cell and granulocyte migration
CCL27 CTACK/ILC CCRIO T cell homing to skin
CCL28 MEC CCR3, CCRIO T cell homing and granulocyte migration
XCLl Lynphotactin/SCM-1 a XCRl T cell trafficking
XCL2 SCM -ip XCRl T cell trafficking
CX3 CLI Fractalkine/Neurotactin CX3 CRI T cell and NK cell trafficking
Table 1.1 Human chemokines, their receptors and main functions
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1.10 Chemokines and their receptors in DC biology
The ability of DCs to both sample the microenvironment within peripheral tissues, and migrate to 
the lymph nodes, where they present antigen to T cells, requires a tight degree of control. The 
coordinated chemokine receptor expression is central to the dual role of these cells. Dendritic cells 
in their immature state are recruited from the blood into the tissues, via the chemokine receptors 
CCRl and CCR5, in response to gradients of their ligands such as the inflammatory chemokines 
CCL2, CCL3, CCL4 and CCL5 (Banchereau et al., 2000; Pashenkov et al., 2002). CCR6  expression 
by immature DCs (Langerhans cells only) allows responsiveness to the inflammatory chemokine 
CCL20 (MIP-3a), consistent with the prevalence of this chemokine in inflamed skin and the role of 
Langerhans cells in surveillance of the skin (Greaves et al., 1997; Power et al., 1997). Exposure to 
inflammatory signals, such as lipopolysaccharide (LPS) and TNF-a, results in a loss of expression 
of these receptors for inflammatory chemokines and a corresponding upregulation of CCR7 
(Sallusto et al., 1998). These mature dendritic cells therefore become responsive to the CCR7 
ligands CCLl9 (MIP-3p) and CCL21 (SLC), and as such are attracted to lymphoid organs where 
these T cell attractive chemokines are expressed.
In addition to the tightly regulated expression of chemokine receptors in immature and mature DCs, 
these cells also demonstrate distinct profiles of chemokine production. In response to inflammatory 
stimuli immature DCs transiently produce large amounts of the inflammatory chemokines CCL3, 
CCL4 and CXCL8 , with more sustained production of CCL2, CCL5 and CXCLIO consistent with 
the requirement of immature DCs to migrate to areas of inflammation (Pashenkov et al., 2002), 
where these inflammatory chemokines will play a central role in calling in the cells involved in the 
ongoing immune response. Following DC maturation the production of CCLl7 (TARC), C C Ll9 
and CCL22 (MDC) are upregulated (Sallusto et al., 1998). These homeostatic chemokines aid the 
recruitment of further DCs and T cells to the T cell rich areas of the lymph nodes (Baekkevold et
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al., 2001). Following migration to this environment, DCs and naïve T cells can interact, thereby 
initiating an immune response.
1.11 Chemokines and their receptors in osteoclast biology
Little is known of the importance of chemokines and their receptors in osteoclast function. What is 
known is that chemokines mediate activities on osteoclast precursors. For instance CCL3 and CCL4 
have been shown to enhance osteoclast formation from precursor cells in vitro and the high levels of 
CCL3 and CCL4 expressed in the bone marrow of patients with multiple myeloma correlate well 
with increased bone destruction in these patients (Abe et al., 2002). Yu et al. demonstrated CXCR4 
expression from murine osteoclast precursors and subsequently showed CXCLl2 (SDF-1 )-mediated 
chemoattraction and transendothelial migration of these precursors (Yu et al., 2003). Other CC 
chemokines, such as CCL5 (RANTES) and CCL23 (CKP-8 ), mediate chemotactic responses in 
osteoclast precursors; indeed CCL23 has been detected at the site of bone turnover, with CCL23 
mRNA transcripts found in osteoblasts by in situ hybridization and CCL23 protein detected in 
osteolytic tissue by immunolocalisation (Votta et al., 2000). CXCL8  can stimulate osteoclast 
formation even in the presence of excess soluble RANK receptor (RANK-Fc), suggesting a 
mechanism independent of RANKL induced osteoclastogenesis. Moreoover, these CXCL8 -driven 
effects correlated with expression of its receptor, CXCRl, on osteoclast precursors (Bendre et al.,
2003). Actively resorbing human osteoclasts also produce CXCL8  and indeed CXCL8  mRNA has 
been demonstrated in resorbing osteoclasts present in the inflamed joints of rheumatoid arthritis 
patients. Furthermore CXCL8  levels increase in osteoclast cultures in response to inflammatory 
mediators, suggesting an autocrine role for CXCL8  in normal bone remodelling and action as an 
inflammatory mediator in pathological bone remodelling (Rothe et al., 1998).
More recently, systematic approaches to identifying the chemokines and chemokine receptors 
involved in murine osteoclast biology have been carried out. Lean et al systematically tested for the
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induction of chemokine and chemokine receptor mRNA in murine bone marrow co-cultures using 
quantitative RT-PCR with real time analysis. They correlated increases in chemokine and 
chemokine receptor message with formation of TRAP in their co-cultures in the presence and 
absence of the osteoclast differentiation factor RANKL. Their results demonstrate the expression of 
CCL9 (MlP-ly), CCL22 (MDC), CXCL13 (BLC) and CCL25 (TECK) by RANKL, with CCRl, 
CCR3 and CXCRl the chemokine receptors expressed. CCL9 and CCRl were identified as the 
major chemokine ligand and receptor expressed by osteoclasts (Lean et al., 2002). CCL9 represents 
a CC chemokine with no known human homologue, however many other CC chemokines mediate 
their actions through CCRl and as such one of these may substitute for CCL9 in human osteoclast 
biology. A systematic approach to identify chemokine and chemokine receptor profiles in human 
osteoclasts or osteoclast like cells has not yet been reported.
1.12 Other GPCRs and ligands: an overview
The other GPCRs included in the custom designed microarray to be utilized in this project were 
limited according to Celltech’s interest in particular GPCR families and indeed individual target 
candidates. As such this overview will be limited to these families and genes (see Appendix 1).
The protease-activated receptors (PAR 1 - 4 )  are involved in activation of platelets and are widely 
distributed throughout the body; as such these molecules have been implicated in inflammatory, 
cardiovascular, digestive and respiratory functions (Kawabata and Kuroda, 2000). Indeed, PAR-1, a 
receptor for thrombin, is a candidate for a cardiovascular therapeutic agent and the antithrombotic 
effect of PAR-1 has already been demonstrated in animal models (Chackalamannil, 2003). Trypsins 
and tryptases are ligands for PAR-2 and thrombin also recognises PAR-3 and PAR-4 (Kawabata 
and Kuroda, 2000). Elastases have also been demonstrated to regulate PAR-2 signaling (Domotor et 
al., 2 0 0 2 ).
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The EDG (endothelial differentiation gene) family of proteins are receptors for the 
lysophospholipids, lysophosphatidic acid (LPA) and sphingosine 1-phosphate (SIP); EDG 2, EDG 
4 and EDG 7 mediate activity via LPA and EDG 1, 3, 5, 6  and 8  via SIP (Chun et al., 2002). The 
diverse physiological activities associated with these receptors include platelet aggregation, wound 
healing, angiogenesis and immune modulation. Therapeutic intervention by agonising or 
antagonising these receptors remains a possibility in immune response mechanisms, coronary artery 
disease and cancer (Goetzl et al., 2002)
The receptors C3aR and C5aR mediate their activity via binding to the complement components 
C3a and C5a, respectively. As such these receptors have a major role in the innate immune 
response. These receptors are present on cells of myeloid origin as well as other immune cells, and 
epithelial cells (Kohl, 2001). The orphan C3AR receptor cDNA was isolated with a probe derived 
from the N-formyl peptide receptor, belonging to the same family as the C3aR and C5aR and shows 
high homology to this family of receptors (Roglic et al., 1996).
Both EMRl and CD97 are members of the epidermal growth factor (EGF)-7TM family, comprising 
large extracellular regions with a variable number of EGF domains linked to a 7TM region. These 
molecules are closely related to another member of this family, the macrophage restricted murine 
F4/80 molecule. In fact EMRl is predicted to be the human ortholog of F4/80. CD97 is expressed 
on a diverse array of leukocytes and has a cell surface ligand, the membrane glycoprotein CD55 
(decay accelerating factor), implicating it in cellular adhesion (McKnight and Gordon, 1998)
P2 Y2 receptor belongs to the purinergic and pyrimidinergic family of receptors and responds to the 
nucleotide ligands UTP and ATP (Williams and Jarvis, 2000). P2 Y2 receptor agonists, which 
enhance ciliary beat and increase mucociliary clearance, are being evaluated in cystic fibrosis 
patients (Kellerman et al., 2002).
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A series of related orphan receptors, at the time of initiation of this study, were also included on the 
array. GPR105, also known as KIAAOOOl and more recently renamed as the P2 Yi4 receptor 
(Abbracchio et al., 2003), was first cloned from an immature myeloid cell line (Nomura et al., 
1994). Chambers et al. (Chambers et al., 2000) have identified Uridine 5’-diphosphoglucose (UDP- 
glucose) as a potent agonist ligand for GPR105, although no function has yet been attributed to the 
receptor. The rat and mouse orthologs for GPR105, exhibiting 81 and 83% amino acid identity 
respectively to the human protein, both respond to the putative ligand UDP-glucose (Freeman et al., 
2001). Nucleotides represent a family of extracellular signalling molecules with wide ranging 
effects. For example, ADP induces platelet aggregation, through binding the P2Yn receptor 
(Hollopeter et al., 2001), and ATP mediates chemotaxis, cytotoxic responses and cytokine secretion 
through the P2Xy receptor (North, 2002).
1.13 Project Aims
The aim of this study is to investigate gene expression by divergent myeloid cell types, focusing on 
chemokines, chemokine receptors, related G protein coupled receptors (GPCRs) and their ligands, 
thereafter allowing further investigation of differentially expressed genes and their functional 
implications in dendritic cell and osteoclast biology. The hypothesis being that by using microarray 
technology to examine the distinct gene expression patterns of highly related, yet functionally 
distinct cell types, one may identify genes with functional relevance to the specific cell types.
Differentiation of osteoclasts and dendritic cells from their monocyte precursors, and the 
subsequent characterisation o f these polarised cell populations will be presented. The change in 
expression of some of the chemokine and chemokine receptor genes in dendritic cells following 
activation / maturation will be compared to information in the scientific literature and an extensive 
study of production / expression of these chemokines and their receptors at the protein level will be 
carried out. Differential expression of chemokines and chemokine receptors in osteoclasts in
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comparison to their monocyte precursors will also be evaluated in the hope to identity molecules 
with a unique role in osteoclast biology. Differential expression of other seven transmembrane 
receptors of interest and some of their known ligands in monocytes, osteoclasts, and immature and 
mature dendritic cell populations will also be evaluated.
Finally, further characterisation of two differentially expressed genes will be investigated. 
Expression of GPR105 by human immature monocyte-derived DC, agonist capabilities of UDP- 
glucose, the putative ligand for GPR105 and the functional effects of UDP-glucose on DCs will be 
investigated, and possible roles for GPR105 in DC biology will be evaluated. Expression of CXCL5 
(ENA-78) by osteoclast cultures will be attributed to multinucleated osteoclasts by 
immunocytochemistry. The functionality of this osteoclast secreted CXCL5 will be investigated and 
possible roles in osteoclast biology alluded to.
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Chapter 2
Materials and Methods
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Chapter 2
2.1 Materials
2.1.1 General reagents
Unless stated otherwise, all chemical and biological reagents were obtained from Sigma-Aldrich, 
Poole, UK. All tissue culture plastic was obtained from Becton Dickinson labware, NJ, USA, with 
the exception of round bottomed 96-well plates which were obtained from Costar, NY, USA. All 
tissue culture media, additives and biological buffers were obtained from Invitrogen, Paisley, UK, 
unless otherwise stated. Heat inactivated foetal calf serum was obtained from Sigma-Aldrich.
2.2 Methods
2.2.1 Purification o f  human PBMC
PBMC were isolated from normal healthy volunteers with informed consent. Whole blood was 
taken by venous puncture using heparinised vacutainers (Becton Dickinson). Blood was diluted 1 in 
3 using RPMI 1640 and centrifuged at 400g for 30 minutes over a Ficoll-Hypaque gradient 
(Amersham Biosciences, Uppsala, Sweden). Cells at the interface were removed and washed once 
in relevant serum-containing medium, followed by a low speed spin to remove platelets.
2.2.2 Purification o f  human PBM
Peripheral blood monocytes (PBM) were purified using a VarioMACS magnetic cell sorter, LS 
separation columns and a monocyte isolation kit (Miltenyi Biotec, Bergish Gladbach, Germany) 
according to the manufacturer’s instructions. This kit allows the isolation of untouched monocytes 
by depletion of non-monocytes with a cocktail of hapten-conjugated CD3, CD7, CD 19, CD45RA,
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CD56 and anti-IgE antibodies. Briefly, PBMC were isolated as in Section 2.2.1, red cells were lysed 
by addition 20mls of red cell lysis buffer (155mM NH4CI, lOmM KHCO3, O.lmM EDTA) and 
rotation on a roller for 5 minutes at room temperature. The cells were then centrifuged at 200g for 5 
minutes, washed in PBS and resuspended in 600|il MACS buffer per 10  ^cells. 20|xl o f FCR block 
and 20|il of hapten Ah conjugate cocktail was added per 10  ^cells. Cells were mixed and incubated 
for 5 minutes on ice, shaking occasionally, then washed twice in lOx volume of MACS buffer 
(PBS/ 0.5% BSA7 2mM EDTA). Cells were then resuspended in 600|xl MACS buffer per 10* cells. 
20|il FCR block and 20|il anti-hapten microbeads were added per 10  ^cells. These were mixed and 
incubated for 15 minutes on ice, shaking occasionally, then washed twice in lOx volume of MACS 
buffer and resuspended in 500|il MACS buffer. A LS+/VS+ column and adapter was located into 
the VarioMacs magnetic separator, the column was washed in 3ml of MACS buffer, following 
which the 500jxl suspension was added to the column and the eluant was collected, a further 6 ml of 
MACS buffer was added to the column and eluant collected, to ensure all monocytes were eluted.
2.2.3 Monocyte-conditioned medium
Monocyte-conditioned medium (MCM) was prepared as previously described (Reddy et al., 1997). 
Briefly, using Ig-coated petri dishes (100mm), 4ml of human gamma globulin (Jackson Immuno- 
Research, West Grove, PA) at lOmg/ml in PBS was incubated in the petri dishes for 2 minutes. The 
petri dish was washed three times in PBS. 1-2 x 10  ^peripheral blood monocytes were added in 5- 
lOmls medium. The cells were incubated for 1 hour at 37°C, and then washed with warm medium 
to remove non-adherent cells. 5ml medium per IdP monocytes (starting number o f cells) was then 
added and the dishes were incubated for 24 hours at 37°C/ 5% CO2 . MCM was collected and stored 
at-20°C.
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2.2.4 Degeneration
For generation of DCs, isolated monocytes were cultured in RPMI 1640 containing 50units/ml 
penicillin and 50|ig/ml streptomycin, 2mM L-glutamine and lOmM HEPES with 5ng/ml GM-CSF 
and 50ng/ml IL-4 (R&D Systems, Minneapolis, MN) at 1.5 x 10  ^cells/well in 6 -well tissue culture 
plates for 6  days at 37°C/ 5% CO2 . Cytokines were replenished on day 3 by adding 0.5ml of fresh 
medium with 30ng/ml GM-CSF and 300ng/ml IL-4. On day 6  non-adherent cells were collected by 
aspiration with a Pasteur pipette and either used directly for RNA preparations, or transferred to 
new 6 -well plates with fresh cytokines as on day 3. To obtain mature and immature day 9 DCs, day 
6  DCs were cultured for a further 72 hours either with (mature) or without (immature) the addition 
of 1ml of MCM. Immature and mature DCs were characterised by flow cytometry, their capacity to 
internalise FITC-dextran and their ability to induce proliferation of allogeneic T cells with 
concomitant IFN-y production (see results).
2.2.5 Flow cytometry
The enrichment of monocytes from peripheral blood was evaluated using BD Biosciences 
Simultest™ flow cytometry two colour reagents: CD45-FITC/ CD14-PE; CD3-FITC/ CD19-PE; 
IgGi-FITC/ IgGi-PE. Dendritic cell surface markers were evaluated using FITC-conjugated 
antibodies to CD8 6  (Serotec) and CD80 (BD Pharmingen, San Diego, CA), and PE-conjugated 
antibodies to CD83 (BD Pharmingen) and HLA-DR (BD Pharmingen) by two-colour flow 
cytometry. Cell surface CCRl and CCR5 were determined using directly conjugated PE- and FITC- 
antibodies respectively (R&D Systems). Cell surface CCR7 was determined using a three-step 
technique employing an unconjugated mouse antibody to CCR7 (Insight Biotechnology, Middlesex, 
UK), anti-mouse biotin (Insight Biotechnology) and streptavidin PE (Insight biotechnology). 
Briefly, cells were washed with ice-cold wash buffer comprising PBS (Invitrogen) with 5% FCS 
and 0.1% sodium azide, and then incubated with optimal concentrations of unconjugated mAbs,
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FITC- and PE-conjugated mAbs or matched isotype controls for 30 minutes on ice. Cells were 
washed in ice-cold wash buffer, following which cells incubated with directly conjugated antibodies 
were analysed immediately. Cells incubated with unconjugated antibodies were then incubated with 
biotin-conjugated anti-mouse IgG for 30 minutes on ice, washed extensively and finally incubated 
with streptavidin-PE for 30 minutes on ice, washed in ice cold buffer and analysed using a 
FACScalibur equipped with CellQuest software (BD Biosciences, San Jose, CA). Live cells were 
gated on their forward and side light scatter properties and where indicated, the percentage of 
positive cells was recorded.
2.2.6 Endocytosis assays
Endocytic ability was measured by the cellular uptake of FITC-dextran (Sigma-Aldrich) analysed 
by flow cytometry. The DC preparations were incubated in tissue culture medium containing 
0.5mg/ml FITC-dextran for 30 minutes at 37°C or washed and incubated in 0.5mg/ml FITC-dextran 
for 30 minutes at 4°C (control). Cells were then washed extensively in ice-cold wash buffer and the 
uptake of FITC-dextran was determined by flow cytometry. Results were expressed as percentage 
of positive cells.
2.2.7 Allogeneic T cell proliferation and IFN-yproduction
The T cell stimulatory capacities of the immature and mature DC populations were assessed by 
their ability to drive proliferation of naïve allogeneic T cells in a mixed leukocyte reaction (MLR). 
T cells were purified from PBMC via negative selection using a pan T cell isolation kit and the 
MACS column system (Miltenyi Biotec), according to the manufacturer’s protocol. The DC 
preparations were washed extensively and y-irradiated for 45 minutes ('*^Cs source). T cells (1x10^ 
cells/ml) were stimulated with 1 x 10'^  irradiated DCs/ml for 5 days at 37°C/ 5% CO2 , in round 
bottomed, 96 well microtitre plates. Culture supernatants were removed on day 5 and assayed for
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IFN-y using a Duoset™ ELISA development kit from R&D Systems, as per manufacturer’s 
protocol. Cellular proliferation was assessed by adding IjiCi/well of methyl-[*H]-thymidine 
(lOCi/mmol; Amersham Biosciences) during the last 16 hours of culture. Cells were then harvested 
onto glass-fibre filter mats using a Skatron plate harvester, and radioactivity was counted using 
liquid scintillation.
2.2.8 IL-12production by DCs
DCs were differentiated from purified PBM by incubation with GM-CSF and IL-4 (see Section 
2.2.4). Day 6  immature DCs were incubated with MCM and culture supernatant was removed at 
various time points, centrifuged at 400g to obtain cell-free supernatants and stored at -20°C prior to 
assay. Samples were assayed for IL-12 p40 and IL-12 p70 using Duoset™ ELISA development kits 
from R&D Systems, as per manufacturer’s protocols. IL-12 p70 production from immature DCs 
was investigated further. To achieve this, day 6  immature DCs were stimulated with lOOng/ml IFN- 
y and/or 0.2% w/v Staphylococcus aureus Cowan’s strain (SAC), also called Pansorbin^"^ 
(Calbiochem, San Diego, CA) and supernatants were removed at 48 hour.
2.2.9 Osteoclast generation
PBM were diluted to 2 x 10  ^cells/ml in complete medium (MEM with 15% heat inactivated FCS, 
50units/ml penicillin, 50|Xg/ml streptomycin and 2mM L-glutamine) and plated out at 0.5ml/well in 
a 24-well plate, incubated for 45 minutes at 37°C/ 5% CO], washed once with warm MEM, 
aspirated and 1ml complete medium plus lOOng/ml RANKL (Peprotech EC Ltd, London, UK) and 
50ng/ml M-CSF (Insight Biotechnology, Wembley, UK) was added to each well. On day 3 and 6 , 
0.5ml/well of medium was removed and replaced with 0.5ml/well medium plus 200ng/ml RANKL 
and lOOng/ml M-CSF. On day 9, non-adherent cells were washed away with PBS. Cells were fixed
54
and stained, used for RNA extraction or removed and re-seeded onto dentine to demonstrate 
formation of resorption pits.
2.2.10 Osteoclast culture staining
24-well tissue culture plates containing osteoclast cultures were washed in PBS and fixed for 20 
minutes at room temperature in PBS/ 3.5% paraformaldehyde/ 2% sucrose. Plates were washed four 
times with PBS and either stained for the presence of TRAP, or permeabilised and stained for the 
presence of aVp3 and the visualisation of nuclei.
TRAP staining
Paraformaldehyde fixed osteoclast cultures were stained for the presence of TRAP using the Sigma 
kit (387A), following the manufacturer’s instructions modified for 24-well plates. Briefly, 45ml of 
deionised water was warmed to 37°C. 0.5ml of fast garnet GBC base solution and 0.5ml of sodium 
nitrite were added to a test tube, mixed by gentle inversion for 30 seconds and allowed to stand for 
2 minutes. The TRAP stain was prepared by adding the fast garnet / sodium nitrite solution to the 
pre-warmed deionised water along with 0.5ml naphthol AS-BI phosphate solution, 2ml acetate 
solution and 1ml tartrate solution, whilst mixing. 1ml of the prepared TRAP stain was then added to 
the fixed and washed osteoclast preparations, which were subsequently incubated at 37°C for 30-60 
minutes. In the presence of TRAP, highly insoluble red-brown dye deposits are formed within cells 
which can be evaluated microscopically.
aV p3 staining
Fixed osteoclast cultures were permeabilised in 20mM Hepes, 300mM sucrose, 50mM NaCl, 3mM 
MgCl] and 0.5% Triton-xlOO for 5 minutes at 4°C. Cells were then washed four times in PBS and 
blocked for 30 minutes at room temperature in PBS/ 5% FCS/ 0.1% sodium azide. 250|xl mouse 
anti-human aVp3 (Chemicon, Temecula, CA) or IgGi isotype control (M0PC21) at 20|ig/ml were 
added to the wells which were incubated at room temperature for 30 minutes, before washing three
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times with PBS. 250}xl/well of HRP-conjugated goat anti-mouse IgG (Jackson Immuno-Research) 
was added to each well at a dilution of 1 in 50 in PBS/ 0.5% FCS and the wells were incubated for 
30 minutes at room temperature. AEC (3 -amino-9-ethylcarbazole) substrate was prepared as 
follows: 1 AEC tablet was dissolved in 5ml DMF (stored at room temperature and covered in foil); 
for use, a 4mg/ml solution was prepared in 50mM NaAC pH 5.0 plus 0.1% H2O2 . The wells were 
washed three times with PBS, then 250|il of AEC substrate was added to each well and the plates 
were incubated for 10-15 minutes at room temperature. Wells were washed twice with deionised 
water. Wells were then counterstained with 250|xl/well Geimsa solution (diluted 1 in 20 in 
deionised water and filtered through a 0.2|im filter) for approximately 30 minutes at room 
temperature. Wells were washed four times with deionised water and evaluated microscopically. 
AEC acts as an electron donor in the presence of HRP and reduction of AEC causes a rust red 
precipitate; Geimsa stained nuclei appear pale blue. Where appropriate, photographs were taken 
using an Olympus inverted light microscope, with phase contrast, and an Olympus SC35 camera.
2.2.11 Osteoclast p it formation
Osteoclasts were removed from 24-well plates by treatment with accutase (TCS Biologicals, 
Buckingham, UK). 1ml accutase was added to each well, incubated at 37°C for 15 minutes, and 
cells were removed gently with a Pasteur pipette and washed in complete medium (see Section 
2.2.9). Sterile dentine discs (IDS, Tyne and Wear, UK) were placed into individual wells of a 96- 
well tissue culture plate (1 disc/well) and pre-incubated at 37°C for 60 minutes in complete 
medium. Dentine discs were seeded at 2 x 10  ^cells/well in complete medium containing lOOng/ml 
RANKL plus 50ng/ml M-CSF and incubated at 37°C/ 5% CO2 for 72 hours. Discs were then 
washed three times with PBS. For TRAP staining, discs were fixed for 20 minutes at room 
temperature in PBS/ 3.5% paraformaldehyde/ 2% sucrose and stained in 24-well plates as described 
in 2.2.9. For pit analysis, cells were removed from the discs by abrasion using filter paper; the discs
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were stained using wheatgerm agglutinin-HRP; 100|il wheatgerm agglutinin-HRP (Vector Labs, 
Burlingame, CA) at 1 in 1000 in PBS was added to each disc in a 96-well tissue culture plate and 
discs were incubated for 30 minutes at room temperature, washed three times with deionised water 
before lOOjil of AEC substrate was added (see 2.2.9) and the discs were incubated for 15 minutes at 
room temperature, washed with deionised water and examined microscopically. Wheatgerm 
agglutinin has been shown to bind to the exposed matrices that become revealed in demineralised 
osteoclast resorption lacunae (Selander et al., 1994) and presents as a rust red precipitate. The area 
of dentine resorbed was estimated using a graticule. Pictures were taken using a Zeiss axioscope 
with a JVC 3 chip colour camera (magnification x40).
2.2.12 RNA extraction and characterisation
For monocyte and dendritic cell samples, total cellular RNA was extracted using an RNeasy mini 
kit (Qiagen, Crawley, UK) following the manufacturer’s protocol. For osteoclast samples, where 
extraction of the RNA in situ prevented degradation, total cellular RNA was extracted using 
RNAzol™B (Biogenesis Ltd, Poole, UK). Briefly, osteoclast cultures were washed twice with PBS/ 
0.2% EDTA, aspirated, 1ml PBS/ 0.2% EDTA was added to each well, then incubated at 37°C/ 5% 
CO2 for 15 minutes. The PBS/ EDTA solution was removed from the wells and 0.5ml RNAzol™B 
was added to the first well, aspirated up and down with a Pasteur pipette and transferred to the 
second well: 0.5ml RNAzol™B was used to lyse the cells in approximately 4 wells. The lysed cells 
were transferred to a 1.5ml eppendorf tube and 0.1ml chloroform was added, the tube was covered 
tightly and agitated for 15 sec, left on ice for 15 minutes and centrifuged at 12000g and 4°C for 15 
minutes. The upper aqueous phase was transferred to a fresh tube, and an equal volume of 
isopropanol was added. The sample was incubated at 4°C for 15 minutes, and then centrifuged at 
12000g and 4°C for 15 minutes. Following aspiration the pellet was reconstituted in lOOjil DEPC 
water (Ambion, Austin, TX). 10|xl of 3M sodium acetate pH 5.2 and 250|ll of 95% ethanol (ice
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cold) were added and the RNA was stored at -70°C until use. Before use, the RNA was pelleted, 
air-dried and washed in 70% ethanol, then re-pelleted, air-dried and reconstituted in 100|il DEPC 
water.
To check the integrity and size distribution of the total RNA, presence of distinct 18S and 28S 
ribosomal RNA subunits were confirmed by denaturing-agarose gel electrophoresis and ethidium 
bromide staining. A 1.2% formaldehyde agarose (FA) gel was prepared (10ml lOx FA running 
buffer (Ambion) plus 1.2g agarose in 100ml RNase-free water (Ambion), microwaved to melt the 
agarose, cooled to 65°C in a waterbath before 1.8ml of 37% (12.3M) formaldehyde was added and 
mixed thoroughly before casting in a gel support) and equilibrated in 1 x FA running buffer for 30 
minutes. RNA samples were diluted in 5x RNA loading buffer (Ambion), 10|ig/ml ethidium 
bromide added to the RNA, which was incubated for 10 minutes at 65°C, chilled on ice and loaded 
onto the equilibrated FA gel. The gel was run at 80 volts for 1-2 hours; a total RNA size marker 
(Ambion) was included. The 18S and 28S ribosomal RNA species should appear as sharp bands on 
the stained gel with the 28S band being approximately twice the intensity of 18S RNA.
2.2.13 RT-PCR fo r RANK and calcitonin receptor
RT-PCR was performed using the RETROscript^'^ first strand synthesis kit for RT-PCR (Ambion, 
Austin, Texas), following the manufacturer’s protocol. Briefly, l-2|xg total RNA plus 2|Ltl random 
decamers were made up to 12|j,l with nuclease tree dH2 0 , mixed, spun briefly, heated at 85°C for 3 
minutes, removed to ice, spun briefly again and replaced on ice. The remaining reverse transcription 
(RT) components were added: 2|il lOx RT buffer, 4fxl dNTP mix, l|Lil RNase inhibitor and Ijxl 
reverse transcriptase enzyme, the tube was mixed gently, incubated at 42-44°C for one hour, then 
92°C for 10 minutes and transferred to -20°C. The PCR reaction was set up using 2-10|Xl o f the RT 
reaction sample, 2|l i 1 lOx PCR buffer (Roche-Applied-Science, Basel, Switzerland), 0.5|l i 1 dNTP
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mix (Roche-Applied-Science) and made up to a volume of 20|il with nuclease free dHiO, then Ijil 
o f the appropriate PCR primers were added (5|xM of each primer) with 1-2U of thermostable DNA 
Taq polymerase (Roche-Applied-Science). GC polymerase and GC PCR buffer (Clontech, San 
Jose, CA) were used for the RANK reactions. For each PCR reaction a negative control, containing 
no reverse transcriptase, was included. The reactions for calcitonin receptor (CTR) (35 cycles) and 
G3PDH (30 cycles) were cycled as follows;
Denature: 94°C for 1 minutes
cycling: 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 60 seconds.
Final extension: 72°C for 10 minutes
The reactions for the GC rich RANK (30 cycles) were cycled as follows;
Denature: 94°C for 1 minutes
cycling: 94°C for 30 seconds, 6 6 °C for 15 seconds, 6 8 °C for 3 minutes.
Final extension: 6 8 °C for 4 minutes
Primers for RT-PCR;
Calcitonin Receptor 5 ’ primer 5 ’-TGCGGTGGTATTATCTCTTGG-3 ’
(Sigma-Genosys Ltd) 3 ’ primer 5 ’-TTCCCTCATTTTGGTCACAAG-3 ’
RANK 5’ primer 5’-GGTGGTGTCTGTCAGGGCACG-3’
(Sigma-Genosys Ltd) 3 ’ primer 5 ’-GGCAGCCTGTGCAGACATCTG-3 ’
G3PDH (Ambion) 5’ primer 5’-ACCACAGTCCATGCCATCAC-3’
3 ’ primer 5 ’-TCCACCACCCTGTTGCTGTA-3 ’
To evaluate the RT-PCR reaction, an aliquot was analysed by horizontal gel electrophoresis. 
Briefly, samples were loaded in 6 x ficoll loading dye and separated at 100 volts on a native 1%
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(w/v) (for RANK) or 2% (w/v) (for CTR and G3PDH) agarose gel in TAB buffer (40mM Tris- 
acetate, 2mM EDTA, pH7.5). l^ig/ml ethidium bromide was included in the gel to allow 
visualization of DNA fragments using a 250nm UV light box. A 100 bp ladder (Invitrogen) was 
included on every gel to allow estimation of amplified DNA fragment size.
2.2.14 cDNA probe synthesis, microarray hybridisation and quantification
Radiolabelled cDNA probes were synthesised in 30pl reactions containing 0.1-lpg total cellular 
RNA, 2pg poly (dT) (Research Genetics), 0.5mM each dATP, dGTP and dTTP (Amersham), 50|iCi 
a-*^P-dCTP (NEN, Boston, MA), 60units SUPERNaseIn (Ambion, Austin, TX), lOmM DTT, 6 |il 
Sxfirst-strand buffer and 300units Superscript II (Invitrogen, Paisley, UK). The reaction was 
incubated at 42°C for 2 hours before the RNA template was hydrolysed at 60°C for 30 minutes in 
0.05% SDS/ 25mM EDTA/ 0.45M NaOH. The reaction was neutralised by HCl to 0.45M, with Tris 
pH7.5 to 250mM and 15|ig human Cot-1 DNA added (Invitrogen). Unincorporated nucleotides 
were removed with Bio-Spin 6  chromatography columns (Bio-Rad, Hercules, CA). In-house 
microarrays printed with approximately 500-900 bp specific sequences corresponding to 3’-UTRs 
for all known human chemokines and chemokine receptors, plus related receptors, GPCRs and their 
ligands, and suitable housekeeping genes (see Appendix 2 for list and Genbank accession numbers) 
were prehybridised at 55°C for 2-3 hours in 8 ml ExpressHyb solution (Clontech) with 200|ig 
salmon testes DNA (Sigma, Poole, UK) and lOjig poly (dA) (Research Genetics). Radiolabelled 
cDNA probes were denatured at 95°C for 3 minutes, then hybridised to the microarray for 16-20 
hours at 55°C. Microarrays were washed with 0.2x SSC/ 0.1% SDS for 1 hour; twice at 55°C and 
once at 65°C. Hybridised microarrays were exposed to low energy phosphorimage screens and 
scanned by Storm860 (Molecular Dynamics). Data was extracted using IMAGENE software 
(BioDiscovery, Los Angeles, CA) and normalised to the average expression level of the 
housekeeping gene panel, with final expression levels expressed as the percent average of this
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panel. Data manipulations were performed with Microsoft Excel, and hierarchical clustering 
achieved using GeneSpring software (Silicon Genetics, Redwood City, CA).
2.2.15 Northern blot hybridization
Northern blots were generated by electrophoresis and transfer of 5|ig of total cellular RNA, 
separated on a 1.2% agarose/ formaldehyde gel and transferred to Zeta-Probe GT membrane (Bio- 
Rad) according to manufacturer’s instructions. *^P-labelled probes were synthesized with a Strip-EZ 
DNA kit (Ambion). A 905 bp GPR105 probe consisted of nucleotides 1427-2332 from NCBI 
accession number XM_00309, a human G3PDH cDNA control probe (Clontech) was also used. 
Probes were purified using Quickspin columns (Boehringer Mannheim), following the 
manufacturer’s instructions. Hybridisation was performed overnight at 65°C. Hybridised 
membranes were stringently washed, wrapped in plastic wrap, and then immediately exposed to X- 
ray film for autoradiography.
2.2.16 DC chemokine ELISAs
For chemokine assays, day 9 immature and mature (MCM-treated) DCs were washed thoroughly 
and re-plated in 24-well plates at 5 x 10  ^cells/well with or without lOOng/ml IFN-y with or without 
0.2% w/v Staphylococcus aureus Cowan’s strain (SAC) or lOOng/ml EPS. Culture supernatants 
were collected at 48 hours, centrifuged at 400g to obtain cell-free supernatants, stored at -20°C prior 
to assay by ELISA. Duoset™ ELISA development kits from R&D Systems were used for CCL2, 
CCL3, CCL4, CCL13, CCL15, CCL17, CCL18 and CCL22, and R&D Systems Quantikine™ 
ELISA kit was used for CCL23 measurement.
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2.2.17 Characterisation ofHEK293 cell lines
Human embryonic kidney cells (HEK293) (ATCC) and an in-house HEK293 cell line, co­
transfected with the promiscuous G protein subunit G(%i6 and haemagglutinin (HA)-tagged GPR105 
cDNA constructs, were cultured in DMEM with 10% FCS, 2mM L-glutamine and 1% non-essential 
amino acids. For the transfected HEK293 cell line, the selection reagents puromycin (l|Xg/ml) and 
geneticin (G418) (1 mg/ml) were also included in the growth medium. The presence of the HA- 
tagged GPR105 construct on the surface of the transfected cell line was confirmed by 
immunofluorescent staining and flow cytometry. An unconjugated rat anti-HA antibody (Roche- 
Applied-Science, Basel, Switzerland) and a PE-conjugated anti-rat IgG antibody (Insight 
biotechnology) were employed. Briefly, cells were washed with ice-cold wash buffer (PBS 
(Invitrogen) containing 5% FCS and 0.1% sodium azide) and then incubated with optimal 
concentrations of rat anti-HA tag or rat IgG isotype control for 30 minutes on ice. Cells were 
washed in ice-cold wash buffer and incubated with PE-conjugated anti-rat IgG for 30 minutes on 
ice, again washed in ice cold buffer and analysed in a FACScalibur equipped with CellQuest 
software. Live cells were gated on their forward and side light scatter properties.
2.2.18 Ca^  ^flux measurement
The response of cells to endothelin (Tocris, Bristol, UK); UDP-glucose (Sigma-Aldrich or ICN 
biomedicals; detailed in appropriate Figure legends); histamine; CCL3 (R&D Systems) and CCL19 
(R&D Systems) was investigated by measuring intracellular calcium (Ca^^(i)) changes using the 
Ca^^-sensitive dye Fluo4-AM, in conjunction with a fiuorometric imaging plate reader (FLIPR) 
(Molecular Devices, Berkshire, UK). Where indicated, cells were pre-treated with lOng/ml pertussis 
toxin for 18 hours. For dendritic cell and monocyte experiments, agonists were prepared in HBSS/ 
0.2% BSA/ ImM M gC y ImM C aC y  20mM HEPES. Fluo-4 (Molecular Probes, Oregon) was 
dissolved in DMSG (HYBRI-MAX™) and pluronic acid (20% v/v in DMSG). Cells were then
62
washed in the above buffer and incubated for 1 hour at 37°C/ 5% CO2 with Fluo-4 (final 
concentration 4|iM) before washing twice and plating into 96-well black-walled clear-bottomed 
microplates (Coming-Costar, Acton, MA) at 0.5 -  1 x 10  ^ cells/100|il/well. The plates were 
centrifuged at 21 Og for 3 minutes, with no brake, and rested at 37°C/ 5% CO2 for 10 minutes. For 
experiments utilising the HEK293 cell lines, 0.71g/l of the organic anion transport inhibitor 
probenecid was included in the buffer throughout and the cell lines were plated into 96-well black- 
walled clear-bottomed microplates at 2 x 10* cells/100|il/well and incubated overnight at 37°C/ 5% 
CO2 . Plates were then aspirated and incubated for 1 hour at 37°C/ 5% CO2 in 4|iM Fluo-4, washed 
twice using a multichannel pipette with a final volume of 1 0 0 |il/well of buffer added to the plates 
and as with dendritic cells and monocytes the plates were then placed at 37°C/ 5% CO2 for 10 
minutes. For all experiments the plates were loaded into the FLIPR and a signal test was taken and 
laser power adjusted to obtain a basal level of approximately 1 0 , 0 0 0  fluorescence intensity units 
(FIU). The cells were then excited at 488 nm using the FLIPR laser and fluorescence emission 
determined using a CCD camera with a bandpass interference filter (510-560 nm). Fluorescence 
readings were taken at 1.5 second intervals for 70 seconds and a further 10 readings were taken at 6  
second intervals. Agonists or buffer (negative control) were added after 15 seconds using the 
FLIPR. Max -Min fluorescence data, with negative control subtraction, was exported for each well. 
Data was then imported into Microsoft Excel and EC50 concentrations were calculated using XLfit 
version 2.0.7a and a one site dose response model: Y -  A+((B-A)/(1+((C/X)°)).
2.2.19 Preparation o f  necrotic cell supernatant
PBMC were prepared as described in Section 2.2.1. Cells were washed twice in HBSS (5 x 10  ^
cells/tube). Viable control cells were reconstituted in 5ml HBSS, while for necrotic cells the pellets 
were subjected to four freeze thaw cycles from -80°C to 37°C, and then reconstituted in 5ml HBSS. 
Tubes were spun at 400g and supernatants were collected and stored at -80°C.
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2.2.20 Osteoclast chemokine ELISAs
For chemokine assays, osteoclast supernatants were removed from 24-well cultures (as detailed in 
Section 2.2.9), centrifuged at 400g to obtain cell-free supernatants and stored at -20°C prior to 
assay. Where appropriate, day 6  osteoclast cultures were stimulated with recombinant human VEGF 
(R&D Systems), recombinant human IL-ip (R&D Systems) or recombinant human TNF-a (R&D 
Systems) and incubated for a further 48 or 72 hours at 37°C/ 5% CO2 before removal of the culture 
supernatant. Duoset™ ELISA development kits (R&D Systems) were used for CXCLl, CXCL5, 
CXCL7, CXCL8 , CXCL9 and CXCLl0 quantification, following the manufacturer’s instructions.
2.2.21 Endothelial cell chemotaxis
HUVECs were fluorescently labelled as follows: 80% confluent HUVECs, in a T175 tissue culture 
flask, were washed in endothelial basal medium (EBM) (Cambrex, East Rutherford, NJ) and 
labelled in situ with 10ml of 0.5|ig/ml Calcein-AM (Molecular Probes, Eugene, OR) in EGM 
(endothelial cell growth medium; consisting of EBM with addition of growth factors, cytokines and 
supplements (Bulletkit^^)) (Cambrex) plus 2% FCS and 0.71g/l probenecid, for 60 minutes at 37°C/ 
5% CO2 . Cells were removed from the tissue culture flask by trypsinisation and washed HUVECs 
were suspended in EBM/ 0.1% BSA (fatty acid free), or EGM/ 0.1% BSA, or EGM/ 2% FCS (cell 
diluents) and plated at a density of 2 x lO'* cells/SOjil/well on top of the insert in a 3|im pore size 96 
well fluoroblock plate (BD Biosciences). Cell diluents plus 10% FCS were employed as 
chemoattractants; therefore cell diluents plus 10% FCS or cell diluents were added to the bottom of 
the fluoroblock chambers using the sample ports. Plates were incubated for 4 hours at 37°C/ 5% 
CO2 . Leaving the plates intact, with the fluoroblock membrane preventing contribution to the 
fluorescence intensity by fluorescently labelled cells that have not migrated (cells in the top 
chambers), the fluorescence intensity of the bottom chamber was measured using an LJL analyst 
and bottom read optics at 485nm (excitation) and 530nm (emission).
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2.2.22 Neutrophil chemotaxis
Neutrophils were purified from peripheral blood by layering on Ficoll-Hypaque, centrifuging at 
400g before discarding the plasma, the PBMC layer and Ficoll, while retaining the red cell and 
neutrophil pellet followed by lysis of the red cells. Recombinant chemokines or osteoclast 
supernatants were placed in a Costar^"  ^ transwell (Coming, Acton, MA) and antibodies were added 
where appropriate and pre-incubated for 60 minutes at 37®C. Inserts (3|xm pore size) were placed 
into the wells and 1 0 0 |il neutrophils at 1 x 1 0  ^ cells/ml were added to the top of each transwell. 
Plates were incubated at 37 °C for 1 hour, with ImM EDTA added to the wells for the last 5 
minutes. Inserts were removed and the cells resuspended and counted on Becton Dickinson 
FACScalibur for 30-seconds each tube, ensuring that the pressure and flow rate remained constant.
2.2.23 Immunocytochemistry
Osteoclast differentiation cultures were grown on 6 -well culture slides (Falcon) for 9 days, in the 
presence of GolgiPlug™ (Ijil/ml) for the last 3 hours of culture. Slides were fixed in PBS/ 3.5% 
paraformaldehyde/ 2% sucrose for 20 minutes at room temperature, then permeabilised in 20mM 
Hepes/ 300mM sucrose/ 50mM NaCl/ 3mM M gC y 0.5% Triton-xlOO for 5 minutes at 4°C. 
Samples were blocked in PBS/ 5% FCS/ 0.1% sodium azide for 1 hour at room temperature, before 
incubation with either 10|ig/ml goat anti-human CXCL5 (R&D Systems) or goat anti-human 
CXCL8  (R&D Systems) or goat IgG control for 1 hour at room temperature. Bound antibody was 
revealed using HRP-conjugated mouse anti-goat IgG (Jackson Immuno-Research) and AEC 
substrate (see Section 2.2.10). Slides were counterstained with Haematoxylin Gill no. 3, rinsed in 
tap water and mounted in aqueous feramount (Dako, Glostmp, Denmark).
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Chapter 3
3.1 Introduction
The recent advances in developing in vitro differentiation systems to mimic fully functional 
specialised cell types, reveals the plasticity of peripheral blood monocytes (PBM). This cell type is 
capable of in vitro differentiation into macrophages, myeloid dendritic cells, osteoclasts, microglial 
cells, foam cells and macrophage giant cells (Palucka et al., 1998; Nicholson et al., 2000; Kaur et 
al., 2001; Hayden et al., 2002; Dugast et al., 1997). Two of the most functionally diverse of these 
cell types are the dendritic cell and the osteoclast. These cell types exist in distinct tissue locations 
and isolating large numbers of purified cells from human and rodent tissue, while possible, is 
difficult. In addition, they exist in vivo in multiple stages of differentiation / maturation and are 
therefore difficult to study due to heterogeneity. The development of techniques to differentiate 
these cell types in vitro from PBM has greatly advanced the understanding of these cell types and 
their activation requirements. Indeed dendritic cells differentiated from peripheral blood monocytes 
demonstrate in vivo functionality, as represented by efforts to use in vfrm-derived antigen pulsed 
dendritic cells as immunotherapy’s for cancer or to modulate the immune response (Brossait, 2002).
Dendritic cells have long been described as sentinels of the immune system (Banchereau and 
Steinman, 1998). They function as antigen presenting cells, sampling the microenvironment for 
foreign antigens, migrating to lymph nodes and presenting processed peptide / MHC complexes to 
T cells. While other cell types may present antigen to T cells, the dendritic cells are far more potent 
and possess the exceptional ability to present to unprimed, naïve T cells. This ability to both sample 
antigen at the site of infection and inflammation and present to naïve T cells in the lymph node 
makes these cells unique and is a result of maturation in response to inflammatory signals (Sallusto 
and Lanzavecchia, 1994). The differentiation of myeloid dendritic cells from PBM is now a well
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characterised in vitro technique. Immature DCs can be derived in vitro from CD 14-positive PBM in 
the presence of GM-CSF and IL-4 (Sallusto and Lanzavecchia, 1994). Immature DCs can then be 
matured or activated by many different factors to initiate a change in phenotypic cell-surface 
molecules and produce a functionally discrete cell type. The term immature is used for DCs 
characterised morphologically by their unique dendritic appearance, by their low expression of 
CD80 and CD8 6  co-stimulation molecules, intermediate expression of MHC Class II (HLA-DR) 
and their efficiency at antigen uptake. These cells are of comparable phenotype and functional 
similarity to the DCs that exist in the blood and tissues, such as Langerhans cells of the skin 
(Austyn, 1998). Mature or activated dendritic cells show increased expression of the co-stimulatory 
molecules CD80 and CD8 6  (B7.1, and B7.2, respectively) and express high levels of CD83. These 
cells show a reduced ability to endocytose antigen and an increased ability to present peptide / 
MHC complexes to naïve T cells. These cells can be compared to the interdigitating DCs present in 
the T cell zones of the lymph nodes, capable of interacting with naïve T cells. Whilst the terms 
immature and mature have been traditionally used for these cell types, and evidence exists that the 
mature can be induced from the immature population (Reddy et al., 1997; Bender et al., 1996; Celia 
et al., 1997), they may also represent functionally distinct states of activation and relevant 
terminology such as activated or primed could be used to describe mature DCs.
Osteoclasts are specialised multinucleated giant cells that adhere to bone matrix. There are many 
defining characteristics of osteoclasts, such as their multinuclear nature, expression of tartrate 
resistant acid phosphatase (TRAP), calcitonin receptors (CTR) and vitronectin receptors (aVP3) 
(Suda et al., 1992; Horton et al., 1993). Perhaps the most fundamental characteristic of the 
osteoclast is its ability to resorb bone. Recently, systems for differentiating osteoclasts from PBM 
have been developed. Multinucleated cells (MNC) expressing TRAP, CTR and aVp3, and capable 
of bone resorption can be differentiated from human PBM in the presence of M-CSF and RANKL 
(Quinn et al., 1998; Flanagan and Massey, 2003). Although other cytokines, such as TNF-a and IL-
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ip  have been shown to enhance osteoclast differentiation in vitro, RANKL is necessary for the 
generation of MNC from their monocyte precursors (Fuller et al., 1998). Where factors such as 
TNF-a have been used to drive this differentiation process, it is reasonable to postulate that soluble 
RANKL has also been present, or induced as a result of a contaminating stromal cell or T cell 
population (Horwood et al., 1999). These in vitro differentiated cells are, for the most part, 
phenotypically and functionally comparable to the multinucleated osteoclasts found at the site of 
bone turnover and have been used extensively to further understand this specialised cell type.
This chapter aims to present experimental procedures for the differentiation of osteoclasts and 
dendritic cells from their monocyte precursors, and the subsequent characterisation of these 
polarised cell populations. Whilst published protocols are being followed, a brief presentation of 
phenotypic and functional data demonstrates that the in vitro differentiated cells are representative 
of those in the scientific literature.
3.2 Results
3.2.1 Purification o f  monocytes from peripheral blood
Monocytes were enriched from PBMC using a MACS™ magnetic bead system and negative 
selection kit. Analysis of the starting PBMC population and the purified monocyte population by 
flow cytometry is shown in Figure 3.1. Forward scatter (FSC) / side scatter (SSC) profiles 
demonstrate the enrichment of a population with higher forward and side scatter properties, 
indicators of size and granularity, respectively (Fig. 3.1 A, B). These enriched cells can be 
identified as CD 14-positive monocytes by immunofluorescent staining (Fig. 3.1 C-F). 
Contaminating cells are mostly CD45-intermediate, CD 14-low, CD3-negative and CD 19-negative 
granulocytes. Monocyte preparations used throughout this study yielded 80 - 95% CD 14-positive 
monocytes (data not shown).
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Figure 3.1 Two colour flow cytometric analysis of PBMC and purified monocytes
Monocytes were purified from PBMC using the MACS magnetic bead system and negative 
isolation kit. The starting PBMC population and the purified monocyte population were 
subsequently analysed by flow cytometry. FSC / SSC profiles of (A) PBMC and (B) purified 
monocytes are shown. B cell (CD 19 positive) and T cell (CD3 positive) populations are 
demonstrated in the (C) PBMC and (D) purified monocyte fraction. Monocyte populations (CD45- 
positive, CD 14 positive) are shown for (B) PBMC and (F) purified monocyte fraction. Percentage 
values for each population are shown in the relevant quadrant. Data shown is one representative of 
numerous donors.
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3.2.2 Differentiation and characterisation o f  dendritic cells from peripheral blood 
monocytes
Myeloid dendritic cells were differentiated from MACS™ purified monocytes (Fig 3.1) in the 
presence of GM-CSF and IL-4 for 6  days, replenished with fresh cytokines on day 3. Day 6  DCs 
were transferred to fresh culture wells with fresh cytokines and cultured for a further 3 days in 
either the presence (mature) or absence (immature) of monocyte-conditioned medium (MCM). 
These dendritic cell preparations demonstrated the classic stellite dendritic cell morphology when 
examined by light microscopy. They were characterised by immunofluorescent staining for CD83, 
CD80, CD8 6  and HLA-DR expression. Immature DCs are CD83-negative, CD8 6 -low, CD80-low, 
and HLA-DR-positive, whereas mature DCs are CD83-positive, CD80-positive, CD8 6 -positive and 
HLA-DR-high (Fig. 3.2). The maturation state of these two DC populations can be characterised 
functionally by their ability to internalise and present processed antigen (Celia et al., 1997; 
Banchereau and Steinman, 1998; Rescigno et al., 1997). The FITC dextran uptake assay is 
characteristically used as an indication of the antigen uptake capabilities of these cell types. 
Immature DCs are more efficient at endocytosing antigen than their mature counterpart; the DCs 
differentiated in this study follow this trend (Fig. 3.3). In humans, a convenient measure of a naïve 
T cells response to antigen is the proliferative response to allogeneic cells. Mature DC preparations 
derived using this in vitro differentiation system induce a greater proliferative response in this assay 
than their immature counterparts (Fig. 3.4); this is indicative of their enhanced antigen presentation 
capabilities. Mature DCs also stimulate more IFN-y production from naïve T cells than immature 
DCs (Fig. 3.5); a readout of functionally stimulated T cell responses.
A further benchmark of functionally complete DCs is the production of IL-12. MCM treatment 
increasingly stimulates the production of IL-12 p40 (Fig. 3.6), however this biologically inactive 
subunit is not known to confer Thl polarising capabilities to the DC (Spisek et al., 2001). The
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bioactive counterpart, IL-12 p70 is not produced at measurable levels in these cultures (Fig. 3.7). 
However, these in v/fro-derived immature DCs are capable of producing IL-12 p70 on stimulation 
with IFN-y and Staphylococcus aureus Cowan’s strain (SAC) (Fig. 3.7).
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Figure 3.2 Cell surface phenotypes of immature and mature DCs
DCs were differentiated from purified PBM by incubation with GM-CSF and IL-4. Day 6  Immature 
DCs were incubated with (mature) or without (immature) MCM for 72 hours and FACS analysed 
for (A) CD83, (B) HLA-DR and (Q  CD80 and CD8 6  expression. Isotype control antibody profiles 
are shown in the left panel: Mean fluorescence intensity (MFI) is indicated in the top right hand 
comer of each histogram. Data shown is representative of many donors.
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Figure 3.3 Comparison of antigen uptake capabilities of immature and mature DCs
DCs were differentiated from purified PBM by incubation with GM-CSF and IL-4. Day 6  DCs were 
incubated with (mature) or without (immature) MCM for 72 hours. Immature and mature DCs were 
then incubated with FITC dextran for 30 minutes at 37°C, washed and analysed for internalised 
FITC-dextran by flow cytometry. MFI data is shown, for the mean + SEM of 3 experiments.
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Figure 3.4 Proliferation of naïve T cells in response to allogeneic immature or mature DCs
Untouched T cells were purified using the MACS magnetic bead system and a pan T cell kit 
(depletion of B cells, NK cells, DCs, monocytes and granulocytes). DCs were differentiated from 
purified PBM by incubation with GM-CSF and IL-4. Day 9 immature (imm) or mature (MCM 
treated) DCs were washed extensively, irradiated ( ‘^ ^Cs) and incubated with allogeneic T cells in 
round bottomed 96-well plates for 5 days. Proliferation was measured by incorporation of 
thymidine over the final 16 hours. Data shown are mean +/- SEM of 3 experiments.
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Figure 3.5 IFN-y production from T cells in response to allogeneic immature or mature DCs
Untouched T cells were purified using the MACS magnetic bead system and a pan T cell kit 
(depletion of B cells, NK cells, DCs, monocytes and granulocytes). DCs were differentiated from 
purified PBM by incubation with GM-CSF and IL-4. Day 9 immature or mature (MCM treated) 
DCs were washed extensively, irradiated ('^^Cs) and incubated with allogeneic T cells, at a ratio of 
1 DC to 100 T cells, in round bottomed 96-well plates for 5 days. Supernatant was removed on day 
5 and assayed for IFN-y levels by ELISA. Data shown are mean of two independent experiments. 
The error bars represent minimum and maximum values.
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Figure 3.6 IL-12 p40 production from DCs following maturation with monocyte-conditioned 
medium
DCs were differentiated from purified PBM by incubation with GM-CSF and IL-4. Day 6  immature 
DCs were incubated with MCM and supernatant was removed at various time points. Samples were 
assayed for IL-12 p40 by ELISA. Data are mean +/- SEM of three experiments.
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Figure 3.7 Induction of IL-12 p70 from monocyte-derived DCs
DCs were differentiated from purified PBM by incubation with GM-CSF and IL-4. Day 6  immature 
DCs were stimulated with 100 ng/ml IFN-y and / or 0.2% w/v SAC. Supernatants were removed at 
48 hour and assayed for IL-12 p70. Data are mean + SEM of three experiments.
76
3.2.3 Differentiation and characterisation o f  osteoclasts from peripheral blood monocytes
Osteoclasts were differentiated in vitro from MACS™ negatively isolated PBM, in the presence of 
M-CSF and RANKL, in tissue culture treated plates. These in vfrro-derived osteoclast preparations 
were routinely characterised for MNC, aVp3 expression and tatrate resistant acid phosphatase 
(TRAP) expression. The cultures contain predominantly TRAP-positive, aVpS-positive MNC; with 
some contaminant of mononuclear cells (Fig. 3.8). Day 9 is optimal for multinuclear cell formation 
with greater than 70% of the nuclei in the culture contained within MNC (Fig. 3.9). At day 10 a 
decrease in the number of TRAP-positive MNC / field reflects the reduced viability o f these cells 
and detachment of dead cells during the staining procedure. To assess the resorption capability of 
these in v/fro-derived osteoclasts, the cells were removed from the tissue culture plastic and re­
seeded onto dentine slices. After a further 72 hours of incubation, TRAP-positive MNC and 
resorption lacunae could be visualised (Fig. 3.10): the shaded striations seen in figure 3.10 reflect 
the inevitable variation in thickness across the dentine slice following cutting. The optimal time 
point for removal of the osteoclasts from tissue culture plastic, considering TRAP-positive MNC 
formation, resorption capabilities and viability, was day 9 (Fig. 3.11). Extracted RNA from these 
osteoclast preparations was shown, by RT-PCR, to contain mRNA species encoding CTR and 
increased levels of RANK mRNA, the receptor for RANKL. RNA extracted from day 0 monocyte 
populations did not contain detectable CTR or RANK mRNA transcripts (Fig. 3.12).
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Figure 3.8 Staining of M-CSF-plus RANKL-derived osteoclast preparations for aV|33- 
positive and TRAP-positive MNC
Osteoclasts were derived from purified PBM by incubation with M-CSF and RANKL. Osteoclast 
preparations in 24-well tissue culture plates were fixed and either directly stained for TRAP (Q  or 
permeabilised and incubated with irrelevant antibody (A) or anti-aV|33 (B). Bound antibody was 
revealed using HRP conjugated goat anti-mouse IgG and AEC substrate; samples (A) and (B) were 
counterstained with Geimsa to reveal nuclei. One representative experiment of many is shown.
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Figure 3.9 TRAP-positive multinucleated cell formation in osteoclast differentiation cultures
Osteoclasts were derived from purified PBM by incubation with M-CSF and RANKL. Osteoclast 
cultures in 96 well tissue culture plates were fixed and stained for tartrate resistant acid phosphatase 
(TRAP) or nuclei using Giemsa stain. The number of TRAP-positive multinucleated cells and the 
percentage of nuclei present within multinucleated cells were counted using an inverted microscope 
at a magnification of x200. Data shown are mean +/- SEM of 3 donors.
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Figure 3.10 TRAP-positive multinuclear cells and resorption lacunae on dentine slices
Osteoclasts were derived from purified PBM by incubation with M-CSF and RANKL. Osteoclast 
preparations in 24-well tissue culture plates were washed and treated with accutase to detach the 
cells, which were then seeded onto dentine and incubated for a further 72 hours. In {A) dentine discs 
were fixed and stained for TRAP. In {B) cells were removed from the discs by rubbing with filter 
paper; the discs were then stained for resorption lacunae using wheatgerm agglutinin HRP, revealed 
with AEC substrate. A resorption lacunae is indicated with an arrow. Pictures were taken using a 
Zeiss axioscope with a JVC 3 chip colour camera (magnification x40). One example of ten is 
shown.
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Figure 3.11 Time course for formation of TRAP-positive multinuclear cells and resorption 
lacunae on dentine slices
Osteoclasts were derived from purified PBM by incubation with M-CSF and RANKL. Osteoclast 
preparations in 24-well tissue culture plates were washed and treated with accutase to detach the 
cells which were then seeded onto dentine and incubated for a further 72 hours. (A) Dentine discs 
were fixed and stained for TRAP and TRAP-positive multinucleated cells were counted using an 
inverted microscope at a magnification of x 200. (B) Cells were removed from the discs by rubbing 
on filter paper, the discs were then stained for resorption lacunae using wheatgerm agglutinin HRP 
and revealed with AEC substrate; the area of pits was quantified using a graticule. Data shown are 
mean + SD of 5 replicates.
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Figure 3.12 RT-PCR analysis of CTR, G3PDH and RANK transcripts, mRNA expression in 
monocytes and osteoclasts
Monocytes were purified from PBMC using the MACS magnetic bead system and negative 
isolation kit. Osteoclasts were derived from purified PBM by incubation with M-CSF and RANKL. 
Total RNA was extracted from monocytes and osteoclasts using RNAzol™. A cDNA template was 
then synthesized using RETROscript^'^ reverse transcriptase (RT) and PCR was performed using 
oligonucleotide pairs specific for CTR (A), G3PDH (B) and RANK (CJ. Controls were PCR 
products from reverse transcription reactions with no RT. PCR products were analysed on an 
agarose gel containing ethidium bromide. One representative example of three monocyte 
preparations and four representative examples (donor 1 -  donor 4) of seven osteoclast preparations 
tested are shown.
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3.3 Discussion
Differentiation of osteoclasts and myeloid dendritic cells from PBM provided a readily available 
source of cells for study. These in vitro differentiation systems are well documented as 
representative of their primary cell type found in vivo. Fully characterised myeloid DC and 
osteoclast differentiation systems have been presented.
Day 9 immature and mature (MCM treated) DCs were characterised for surface marker expression 
by immunofluorescence and flow cytometry. Immature DCs were HLA-DR (MHC class 11) 
medium, CD80-low, CD 8 6 -negative and CD83-negative; conversely mature DCs were HLA-DR 
high, CD80-high, CD8 6 -high and CD83-positive. The two DC populations were also tested in 
functional assays to assess their capability to take up antigen (FITC dextran uptake) and stimulate 
naïve T cell proliferation (allogeneic T cell proliferation). Mature DCs demonstrated a reduced 
capacity to take up FITC dextran and an increased capacity to activate naïve T cells, demonstrated 
by proliferation and IFN-y production in response to alloantigen. The change in expression of cell 
surface molecules described and altered abilities to take up antigen and stimulate naïve T cells, 
correspond with a process commonly referred to as maturation (Banchereau and Steinman, 1998) 
(Reseigno et al., 1997; Sallusto and Lanzavecchia, 1994). These in vfrro-derived cells represent 
immature and mature DC populations suitable for further investigation. There are many 
documented protocols for maturing DC populations. Indeed the most commonly used now, is a 
cytokine cocktail containing prostaglandin E2 , TNFa, IL-1(3 and IL- 6  (Choi et al., 2000). However, 
at the onset of this project, the most reliable method was the use o f MCM (Reddy et al., 1997). A 
further marker for functionally active DCs is the production of the bioactive IL-12 p70 subunit. 
Originally this was thought to be a marker for fully functional mature DCs (Spisek et al., 2001). 
However, literature is now emerging to suggest that bioactive IL-12 is only produced in response to
83
certain stimuli, such as SAC, at early stages of maturation (Ebner et a l, 2001), as was suggested by 
my data (Fig.3.7).
Day 9 in vfrro-derived osteoclast preparations were characterised for TRAP expression, aV(33 
expression, presence of mRNA encoding the osteoclast marker CTR and formation of MNC and 
bone resorption capabilities. Osteoclast cultures contained numerous multinucleated cells 
expressing both TRAP and aVP3; however these cultures were not homogeneous in nature and 
contained many mononuclear cells of macrophage appearance, which were not characterised. These 
osteoclasts also contained mRNA transcripts encoding CTR, which were not found in the precursor 
monocyte population. The TRAP-positive osteoclasts are also capable of adhering to and resorbing 
bone. This corresponds to a series of characteristics and functional capabilities fully convergent 
with a description of these multinucleated cells as in vffro-derived osteoclast cultures. These 
osteoclast populations were therefore suitable for further investigation (Quinn et al., 1998; Flanagan 
and Massey, 2003). Day 9 in vfrro-derived osteoclast preparations were also tested for the presence 
of mRNA encoding RANK. These osteoclasts contained mRNA transcripts encoding RANK, which 
were not found in the precursor monocyte population. Little is known about the regulatory 
mechanism of RANK expression and although RANK is required at some point in an osteoclast 
precursor population, to allow response to RANKL, early stage precursor populations in the mouse 
are RANK-negative. There is evidence to suggest that M-CSF induces RANK expression on 
osteoclast precursors as they commit to the osteoclast lineage (Arai et al., 1999). However, 
investigators from Amgen have characterised CD 14-positive peripheral blood monocytes, capable 
of differentiating into osteoclasts in the presence of M-CSF and RANKL, as positive for the 
RANKL receptor RANK (Shalhoub et al., 2000). With this in mind, human peripheral blood 
monocytes were a poor choice of negative control for the RANK RT-PCR experiments. However, 
the information required to characterise the osteoclast RNA preparations was the presence of 
mRNA transcripts encoding RANK in these samples. Indeed the inability to demonstrate RANK
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transcripts in the three monocyte samples tested suggests an increase of RANK message in the 
osteoelast samples.
The following chapter uses these in vitro differentiated cells to investigate differential gene 
expression in these lineage related, but functionally divergent myeloid cell types.
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Chapter 4
Microarray profiling of monocytes, 
osteoclasts and dendritic cells
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Chapter 4
4.1 Introduction
The previous chapter demonstrates how two phenotypically distinct cell types (and subpopulations 
thereof) may be differentiated from peripheral blood monocytes. But what genes play a role in the 
functions of these distinct cell types? To help address this question microarray gene technology was 
used to analyse the expression of a large family of soluble faetors and their reeeptors and identify 
differentially expressed genes in these in v//ra-derived specialised cell types.
Nucleic acid arrays work by hybridisation of labelled DNA or RNA to complementary gene 
fragments or expressed sequence tags (ESTs) attached to a surface. Commonly, arrays are designed 
based on precise sequence information and carefully selected ESTs are deposited onto specific 
locations on a surface such as glass or nitrocellulose. These arrays are then probed with labelled 
eDNA and hybridisation of complimentary DNA molecules ensues (Loekhart and Winzeler, 2000). 
Using RNA purified from cellular sources as a template for cDNA synthesis allows monitoring of 
gene expression at particular timepoints. While not measuring the actual transcription of genes, the 
accumulation of cytoplasmic mRNA is a commonly used method to assess gene expression, which 
accounts for mRNA stability and accessibility to translation to functional protein. The gene 
expression profile of a cell is a dynamic entity, changing rapidly in response to stimuli or during 
normal cellular events, such as adhesion, migration, proliferation and even cell death. Knowing 
when and where a particular gene is expressed can give us clues to the biological function of its 
translated protein. It is therefore possible to design experiments where the significance of 
differential gene expression might give greater clues to the function of the encoded protein. Indeed, 
DNA microarrays have been used to demonstrate differential gene expression in different tumour 
cell types, indicating proteins involved in tumour progression (Alon et al., 1999; Pérou et al., 1999;
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Ross et al., 2000). In this chapter, a DNA microarray was used to identify differences in expression 
of a discrete selection of genes, in myeloid lineage cells differentiated from a common precursor, 
the peripheral blood monocyte. Figure 4.1 outlines the prineiples of the particular methodology 
used.
The custom-made microarray I used consists of 162 known genes including all known chemokine 
and chemokine receptor genes, related G protein-coupled seven transmembrane receptors, their 
ligands, and a panel of 40 housekeeping genes. Expected results based on data from published 
reports act as an effective internal control, providing a certain amount of validation, therefore giving 
a degree of confidence in the relevance of new information obtained. With this in mind, the change 
in expression of some of the chemokine and chemokine receptor genes in dendritic cells following 
activation / maturation was compared to information in the scientific literature and extensive study 
of produetion / expression of these chemokines and their receptors at the protein level. This study 
also aimed to identify chemokines and chemokine receptors that are differentially regulated in 
osteoclast cells and, therefore, may be of interest in terms of their unique biology. Osteoclasts are 
related to myeloid dendritic cells, at least by way of their shared origins. However, unlike myeloid 
dendritie cells, osteoclasts have so far been sparsely studied with respect to their chemokine and 
chemokine receptor expression profiles. Other seven transmembrane receptors of interest and their 
known ligands were included in the array to identify differential expression of these structurally 
related receptors in monocytes, osteoclasts, immature and mature dendritic cell populations. This 
chapter aims to analyse the differences in expression of a diserete selection of genes in these lineage 
related but functionally discrete cell types, as measured by microarray profiling.
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Figure 4.1 Schematic of a differential gene expression hybridisation experiment
1.
2 .
3.
4.
6 .
7.
The rationale behind differential gene expression experiments is to compare gene 
expression in two or more different cell types, such as osteoclasts and monocytes, or a 
single cell type following different stimuli.
Total RNA is extracted from the cell preparations as described in Materials and Methods, 
Chapter 2.
mRNA is reversed transcribed to P-labelled cDNA using a-' P-dCTP and RT.
The cDNA probe is then hybridised to the microarrays (500 -  900 bp specific 3’ UTR 
sequences printed onto Hybond N+ membranes using an Affymetrix microarrayer). 
Hybridised microarrays are washed thoroughly and exposed to low energy phosphorimage 
screens and scanned hy a STORM860 phosphorimager.
An example of a scanned image. Data is extracted using Imagene software.
Normalised data is analysed using the GeneSpring software, an example of hierarchical 
gene clustering is shown.
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4.2 Results
4.2.1 Characterisation o f monocyte, DC and osteoclast samples for RNA extraction
Monocyte, osteoclast and dendritic cell preparations were characterised and RNA was extracted for 
probing the microarray filters. Monocytes were purified fi*om PBMC by negative selection using the 
MACS monocyte kit; the samples used for array profiling were characterised by FACS analysis for 
CD14 expression as described in Section 3.2. Resulting monocyte preparations were 87.5% +/- 1.5 
(SEM) CD 14-positive, n= 6 . Figure 4.2 shows summary data for the dendritic cell preparations 
subjected to microarray analysis. The immature dendritic cell preparations exhibited very low CD8 6  
expression, were negative for CD83 (that is, not significantly above background) and positive for 
HLA-DR. The mature dendritic cell preparations showed markedly increased levels of CD 8 6  and 
HLA-DR expression and were positive for CD83. Data for the osteoclast preparations subjected to 
microarray profiling is shown in Figure 4.3. A median of 61% of the nuclei present in the cell 
preparations could be attributed to the multinucleated cells. The uncharacterised contaminating 
mononuclear cells were o f macrophage appearance. O f the multinucleated cells present in these 
preparations, over 90% were TRAP-positive. All osteoclast preparations subjected to microarray 
profiling demonstrated expression of the calcitonin receptor and RANK mRNA transcripts by RT- 
PCR, see Chapter 3, Figure 3.12, as would be predicted for osteoclasts.
Total RNA was purified from the cell preparations using either RNeasy™ or RNAzol™ extraction 
methods. RNAzol™ extraction was required to obtain reasonable yields of RNA from the osteoclast 
preparations. Formaldehyde agarose gel electrophoresis and ethidium bromide staining were used to 
check the integrity and size distribution of the total RNA preparations, an example of which is 
shown in Figure 4.4. An estimate of the concentration of RNA present in these samples was also 
made from these analytical gels.
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Figure 4.2 Characterisation of dendritic cell preparations for gene array profiling
DCs were differentiated from monocytes by incubation with GM-CSF and IL-4. Day 6  Immature 
DCs were incubated with (mature) or without (immature) MCM for 72 hours and analysed by 
immunofluorescent staining and flow cytometry for expression of (A.) CD8 6 , (B.) CD83 and (C.) 
HLA-DR. The data presented are mean fluorescence intensity (MPI) minus the MPI for the isotype 
control. Data are mean + SEM of 6  donors.
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Figure 4.3 Characterisation of osteoclast preparations for gene array profiling
Osteoclasts were derived from monocytes by incubation with M-CSF and RANKL for 9 days. 
Osteoclast preparations in 24-well tissue culture plates were fixed and either directly stained for 
TRAP (A), or permeabilised and stained with Geimsa to visualise nuclei (B). Individual 
preparations are represented by individual data points; the median value is indicated.
92
28 S rRNA
18SrRNA
o o 2 O >% 5 o % B(D ft 3 fto o O oo o ’pT 3
ft CA OCL CL CLo o o oB B 1 B 3•"t z:to U) W >
Figure 4.4 The integrity of RNA preparations subjected to microarray profiling, as examined 
by formaldehyde agarose gel electrophoresis
RNA samples were diluted in RNA loading buffer containing lOpg/ml ethidium bromide and 
heated at 65°C for 3 -  5 minutes, chilled on ice and then loaded onto an equilibrated 1.2% 
formaldehyde / agarose gel. Gels were run at 80 volts for approximately 2 hours and photographed 
under short-wave UV illumination. Four representative samples are shown, but the integrity of all 
28 RNA samples used in this array was examined.
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4.2.2 Gene array profiling o f  dendritic cell, osteoclast and monocyte populations
Through use of a custom made gene microarray, the expression by monocytes, immature DCs, 
mature DCs and osteoclasts of the entire superfamily of chemokines and their receptors, as well as 
selected GPCRs was investigated.
Total RNA was extracted from these in vitro differentiated cell types and the mRNA fraction was 
reverse transcribed to produce a radiolabelled cDNA probe which was hybridised to the custom 
made microarrays, consisting of 162 specific 3’-UTR sequences (ranging from 500 -  900 base 
pairs) printed onto Hybond-N+ membranes using an Affymetrix microarrayer. Hybridised 
microarrays were washed thoroughly and exposed to low energy phosphorimage screens and 
scanned by a STORM860 phosphorimager. Data was extracted using Imagene software. The 
resulting gene expression data is listed in tabular form (Appendix 1) and was analysed by 
hierarchical clustering, performed blind with respect to description of cell type. Data were grouped 
together solely on the similarity between gene expression profiles. This analysis resulted in the 
formation of four clearly defined clusters, correlating with the cell populations of immature DCs, 
mature DCs, monocytes and osteoclasts (Fig. 4.5). This grouping of populations into distinct 
clusters according to phenotype suggests significant differences in the pattern of mRNA transcripts 
expressed in these four cell types.
94
Osteoclast 1 
Osteoclast 2 
Osteoclast 3 
Osteoclast 4 
Osteoclast 5 
Osteoclast 6  
Osteoclast 7 
Monocyte 1 
Monocyte 2 
Monocyte 5 
Monocyte 4 
Monocyte 6  
Monocyte 3 
iDC 1 day 9 
iDC 2 day 9 
iDC 3 day 9 
iDC 4 day 6  
iDC 4 day 9 
iDC 5 day 6  
iDC 5 day 9 
iDC 6  day 9 
iDC 6  day 6  
mature DC 1 
mature DC 2 
mature DC 5 
mature DC 3 
mature DC 4 
mature DC 6
Figure 4.5 Hierarchical clustering of mRNA transcript expression data acquired by gene 
microarray profiling
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and IL-4. Day 6  immature DCs were incubated with or without MCM 
(mature DCs and immature DCs (iDC), respectively) for 72 hours. Osteoclasts were derived from 
monocytes in the presence of M-CSF and RANKL for 9 days. RNA was extracted and reverse 
transcribed into ^^P-labelled cDNA, which was hybridized to a gene microarray. Hierarchical 
clustering of microarray gene expression data from monocytes, osteoclasts, immature DCs and 
mature DCs is shown. Genes represented on the array are clustered along the horizontal axis and 
samples are clustered on the vertical axis of the dendogram. The bar on the right hand side gives an 
indication of the level of expression: blue=low, red=high.
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4.2.3 Differentially expressed genes
From the microarray analyses, genes demonstrating clear differential expression, within the four 
cell types examined, are listed in Table 4.1. These were selected as mRNA transcripts which 
showed at least a 3 fold differential expression in a particular cell type when compared to all other 
cell types. For instance, the immature dendritic cell expression of the GPR105 mRNA transcript is 
greater than three times the expression level of this transcript in mature dendritic cells, monocytes 
or osteoclasts. For these analyses, day 6  immature DCs were not included, as they do not actually 
represent a unique cell type. In all cases, day six immature DCs gave transcript expression levels 
very similar to day 9 immature DC: see Appendix 1. Genes with very low expression (less than 20 
arbitrary units for each of the cell types) were excluded from Table 4.1. Only 20 of the 162 genes 
evaluated by array profiling were highlighted by this stringent analysis. Many of the expected genes 
were illustrated here, including differential expression of chemokine and chemokine receptor 
mRNA transcripts in the mature and immature dendritic cell populations: see Section 4.2.4.
Other differentially expressed transcripts included the anaphylotoxin receptors C3aR and C5aR, 
which appeared to be downregulated in the mature DC population and H963, an orphan seven 
transmembrane GPCR which was upregulated on DC maturation. Of note also are two genes that 
were higher in the monocyte population, the chemokine receptors CX3CRI and hm74. However, the 
transcript levels for these receptors were low and their significance would have to be further 
evaluated. Of most interest in the dendritic cell populations was the recently de-orphaned G protein- 
coupled receptor gene, GPR105, which showed a large increase in transcript expression in the 
immature DC population when compared to the monocyte precursor population. This increase in 
GPR105 expression was subsequently reversed in the mature DC population. The CXC chemokine, 
CXCL5 (ENA-78) showed a very significant increase in transcript levels in the osteoclast 
population; whereas CXCL8  (lL-8 ) gene expression, while evident in osteoclasts, was highest in the
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monocyte population. Crucially none of the 40 housekeeping genes demonstrated differential 
expression between the four cell types evaluated.
im m atu re
DC
m atu re
DC
m onocyte osteoclast
H963 8 rv 1 3
GPR105 1 228 43 18 14
C5aR 35 31 37
C3aR 33 21 34
CCL2 33 '326 0 11
CCL3 38 5 261 48
SCYA3L 148 13 268 56
CCL1 30 0 189 19
CCL13 1 231 33 3 4
CCL15 1 82 15 0 0
CCL17 1 1 2 488 7 4
e c u s 447 58 15 21
CCL22 48 ' -343 j 11 13
CCL23 1  124 21 1 2
CCR1 53 38 55
CCR7 11 13 12
CX3CRI 2 2 25 5
hm74 9 4 25 5
CXCL5 1 6 0 46
CXCL8 0 7 175 23
Table 4.1 Differentially expressed genes in myeloid cells
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and lL-4. Day 6  immature DCs were incubated with or without MCM 
(mature DCs and immature DCs respectively) for 72 hours. Osteoclasts were derived from 
monocytes in the presence of M-CSF and RANKL for 9 days. RNA was extracted and reverse 
transcribed into ^^P-labelled cDNA, which was hybridized to a gene microarray. Genes 
demonstrating greater than a 3 fold difference of expression in one cell type, when compared to all 
others, are highlighted. Data are arbitrary hybridisation units, normalised to the average of the 
housekeeping panel and expressed as percentage average of this panel. Data are means of 6  
(monocyte, immature DC, mature DC) or 7 (osteoclast) experiments. A value of 0 indicates that 
gene expression was not detected.
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4.2.4 ' Correlation o f gene array and protein expression data in dendritic cells
To evaluate the significance of the gene array profiles, a number of chemokines and receptors, some 
known to be modulated on DC maturation, were assessed at the protein level. Transcript data was 
taken from the microarray data discussed in Section 4.2.2 and further detailed in Appendix 1. 
Surface expression of chemokine receptors, on both day 9 immature and mature DCs, was assessed 
by FACS analysis. For measurement of chemokine levels, day 9 immature and mature DCs were 
washed thoroughly, re-plated either with or without IFN-y + / - Staphylococcus aureus Cowan’s 
strain (SAC) or lipopolysaccharide (LPS) and supernatants removed for determination of 
chemokine levels by ELISA at 4 and 48 hours. This allowed evaluation of both the constitutive and 
inducible potential of the immature and mature DC populations to produce chemokines at the 
protein level.
The array analysis demonstrated that CCRl and CCR5 mRNA expression was decreased in the 
mature DC population, while CCR7 expression increased in mature DCs. Consistent with this 
result: the percentage of CCRl- and CCR5-positive cells was shown to decrease in the mature DC 
population, while that expressing CCR7 was increased, as demonstrated by surface 
immunofluorescent staining and flow cytometry (Fig. 4.6).
CCL13, CCL15 and CCL23 all showed decreased transcript expression and decreased protein 
production in mature DCs (Fig 4.7). Immature dendritic cells constitutively produced all three of 
these chemokines, although only at a very low level for CCL15. IFN-y + LPS treatment increased 
the levels of CCL13 and CCL15 produced, whilst lowering the amount of CCL23 synthesised. IFN- 
y + SAC increased the amount of CCL15 produced, although not to the level of IFN-y + LPS, 
whereas the amounts of CCL13 and CCL23 were decreased.
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CCL3, SCYA3L and CCL4 mRNA transcripts were decreased on maturation, CCL3 and CCL4 
protein levels were also decreased on DC maturation, SCYA3L protein levels were not examined 
due to lack of available reagents (Fig. 4.8). In all three cases mature DC transcript levels were very 
low. The production of these chemokines by mature DCs, constitutive or induced, was either below 
the limit of detection or at very low levels. Interestingly, CCL3 and CCL4, although exhibiting high 
transcript levels in immature DCs, both required induction by IFN-y + LPS or IFN-y + SAC, before 
protein levels could be detected in the supernatants (Fig. 4.8).
CCL17 and CCL22 transcript and protein levels both increased on maturation (Fig. 4.9). The 
highest levels of protein were expressed constitutively by mature DCs. Further stimulation of the 
mature DC population either resulted in similar or, in the case of IFN-y + SAC, decreased levels of 
chemokines produced. Conversely, CCL18 transcript and protein levels are decreased in mature 
DCs, whereas a high level of CCL18 is produced constitutively from immature DCs and further 
stimulation o f the immature DCs either resulted in similar or, in the case of lFN-y+ SAC, decreased 
levels of chemokine produced.
Finally CCL2 mRNA expression levels increased on maturation of DCs (Fig. 4.10), which is not 
consistent with the protein production data, where larger increases of CCL2 production were 
detected following activation of immature DCs.
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Figure 4.6 Chemokine receptor mRNA and cell surface expression levels
Dendritic cells were differentiated from monocytes by incubation with GM-CSF and IL-4. Day 6  
immature DCs were incubated with or without MCM (mature and immature respectively) for 72 
hours. For mRNA expression, RNA was extracted and reverse transcribed into ” P-labelled cDNA, 
which was hybridized to a gene microarray. Expression levels were calculated by normalising data 
to a panel of forty housekeeping genes. Data are means (+SEM) of 6  experiments. For cell surface 
protein expression, cells were analysed by flow cytometry; data are means + SEM of 3 experiments.
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Figure 4.7 CCL13, CCL15 and CCL23 mRNA and protein levels in DC populations
Dendritic cells were differentiated from monocytes by incubation with GM-CSF and IL-4. Day 6  
immature DCs were incubated with or without MCM (mature and immature respectively) for 72 
hours. For mRNA expression, RNA was extracted and reverse transcribed into ^^P-labelled cDNA, 
which was hybridized to a gene microarray. Expression levels were calculated by normalising data 
to a panel of forty housekeeping genes. Data are means ( t-SEM) of 6  experiments. For chemokine 
production levels, day 9 immature and mature DCs were washed thoroughly and incubated for a 
further 48 hours with the appropriate stimuli. Chemokine levels were measured by ELISA. Data are 
means (+SEM) of 3 experiments.
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Figure 4.8 CCL3, CCL4 and SCYA3L mRNA and protein levels in DC populations
Dendritic cells were differentiated from monocytes by incubation with GM-CSF and IL-4. Day 6  
immature DCs were incubated with or without MCM (mature and immature respectively) for 72 
hours. For mRNA expression, RNA was extracted and reverse transcribed into ^^P-labelled cDNA, 
which was hybridized to a gene microarray. Expression levels were calculated by normalising data 
to a panel of forty housekeeping genes. Data are means (+SEM) of 6  experiments. For chemokine 
production levels, day 9 immature and mature DCs were washed thoroughly and incubated for a 
further 48 hours with the appropriate stimuli. Chemokine levels were measured by ELISA; 
appropriate reagents were not available for SCYA3L. Data are means (+SEM) of 3 experiments.
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Figure 4.9 CCL17, CCL22 and CCL18 mRNA and protein levels in DC populations
Dendritic cells were differentiated from monocytes by incubation with GM-CSF and IL-4. Day 6  
immature DCs were incubated with or without MCM (mature and immature respectively) for 72 
hours. For mRNA expression, RNA was extracted and reverse transcribed into ^'^P-labelled cDNA, 
which was hybridized to a gene microarray. Expression levels were calculated by nonnalising data 
to a panel of forty housekeeping genes. Data are means (+SEM) of 6  experiments. For chemokine 
production levels, day 9 immature and mature DCs were washed thoroughly and incubated for a 
further 48 hours with the appropriate stimuli. Chemokine levels were measured by ELISA. Data are 
means (+SEM) of 3 experiments.
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Figure 4.10 CCL2 mRNA and protein levels in DC populations
Dendritic cells were differentiated from monocytes by incubation with GM-CSF and IL-4. Day 6  
immature DCs were incubated with or without MCM (mature and immature respectively) for 72 
hours. For mRNA expression, RNA was extracted and reverse transcribed into ^^P-labelled cDNA, 
which was hybridized to a gene microarray. Expression levels were calculated by normalising data 
to a panel of forty housekeeping genes. Data are means (+SEM) of 6  experiments. For chemokine 
production levels, day 9 immature and mature DCs were washed thoroughly and incubated for a 
further 48 hours with the appropriate stimuli. Chemokine levels were measured by ELISA. Data are 
means (+SEM) of 3 experiments.
4.2.5 Chemokine and chemokine receptor expression in osteoclasts
In most cases, very little variation was seen between the chemokine and chemokine receptor mRNA 
transcript levels in osteoclasts versus monocytes, suggesting that expression of these genes is not 
modulated upon differentiation of monocyte precursors to osteoclasts. However, some chemokine 
and chemokine receptor transcript levels, such as CCL3, SCYA3L, CCL4, CCL20, CXCL8  and 
CCR2 showed down modulation during the differentiation process (Fig. 4.11). These events were 
not unique to this differentiation process as these genes were also downregulated upon 
differentiation of monocytes to DCs. Yet one chemokine, CXCL5, was notably upregulated in 
osteoclast preparations, suggesting an important role for this chemokine in osteoclast biology (Fig 
4.12).
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Figure 4.11 CCL3, SCYA3L, CCL20, CCL4, CXCL8 and CCR2 gene expression in 
monocytes and osteoclasts
Monocytes were purified from PBMC and osteoclasts were derived from monocytes in the presence
of M-CSF and RANKL for 9 days. RNA was extracted and reverse transcribed into P-labelled 
cDNA, which was hybridized to a gene microarray. Expression levels were calculated by 
normalising data to a panel of forty housekeeping genes. Data are means (+SEM) of 6  (monocytes) 
or 7 (osteoclasts) experiments.
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Figure 4.12 CXCL5 gene expression in monocytes, osteoclasts and DC
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and IL-4. Day 6  immature DCs were incubated with or without MCM 
(mature and immature respectively) for 72 hours. Osteoclasts were derived from monocytes in the 
presence of M-CSF and RANKL for 9 days. RNA was extracted and reverse transcribed into ^^P- 
labelled cDNA, which was hybridized to a gene microarray. Expression levels were calculated by 
normalising data to a panel of forty housekeeping genes. Data are means (+SEM) of 6  (monocytes) 
or 7 (osteoclasts) experiments.
4.2.6 7TM GPCRs expressed in monocytes, osteoclasts and dendritic cells
In contrast to the chemokine receptors, a number of GPCRs show downregulation on differentiation 
of monocytes to osteoclasts as demonstrated in Figure 4.13. EDG 6 , EMRI, CD97 and P2 Y2 
transcript levels are all decreased in the osteoclast preparations. This is not unique to the monocyte 
—> osteoclast axis, as all four genes are also decreased in immature DCs. Interestingly, P2 Y2 
increased again on maturation of DC. The dendritic cell preparations showed examples of 
differential gene expression unique to this arm of myeloid differentiation, with downregulation of 
C3AR, C5aR and C3aR on mature DCs (Fig. 4.14). H963, an orphan GPCR, showed increased 
expression uniquely in mature DCs. GPR105 demonstrated decreased expression in mature DCs
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when compared to immature DCs, the transcript levels were also very low in osteoclasts, and more 
significantly, the DC precursors, monocytes (Fig. 4.15). This result suggested that expression of 
GPR105 is unique to immature DCs amongst these four cell types.
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Figure 4.13 Differential GPCR gene expression in monocytes and osteoclasts
Monocytes were purified from PBMC. Osteoclasts were derived from monocytes in the presence of 
M-CSF and RANKL for 9 days. RNA was extracted and reverse transcribed into ^^P-labelled 
cDNA, which was hybridized to a gene microarray. Expression levels were calculated by 
normalising data to a panel of forty housekeeping genes. Data are means (+SEM) of 6  (monocytes) 
or 7 (osteoclasts) experiments.
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Figure 4.14 Differential GPCR gene expression in DC populations
Dendritic cells were differentiated from monocytes by incubation with GM-CSF and IL-4. Day 6  
DCs were ineubated for 72 hours with or without MCM (mature and immature respectively). RNA 
was RNA was extracted and reverse transcribed into ^^P-labelled cDNA, which was hybridized to a 
gene microarray. Expression levels were calculated by normalising data to a panel of forty 
housekeeping genes. Data are means (+SEM) of 6  experiments.
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Figure 4.15 GPR105 mRNA expression in myeloid cells
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and IL-4. Day 6  immature DCs were incubated for 72 hours, with or 
without MCM (mature and immature respectively). Osteoelasts were derived from monocytes in the 
presenee of M-CSF and RANKL for 9 days. RNA was extraeted and reverse transcribed into ^^P- 
labelled cDNA, which was hybridized to a gene microarray. Expression levels were ealculated by 
normalising data to a panel of forty housekeeping genes. Data are means (+SEM) of 6  (monocytes, 
immature DCs and mature DCs) or 7 (osteoclasts) experiments.
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4.3 Discussion
The use of microarray technology to elucidate gene expression profiles is becoming commonplace. 
The aim of this chapter was not to generate complete profiles for the cell types investigated, 
requiring labour intensive, quantitative real time PCR for confirmation, but to look at differential 
expression patterns in specific gene families, to identify genes of interest.
Day 9 immature and mature (MCM treated) DC populations, prepared for RNA extraction and 
microarray profiling, were characterised for surface marker expression by flow cytometry. 
Immature DCs were HLA-DR (MHC class II)-medium, CDSO-low, CD8 6 -negative and CD83- 
negative; mature DCs were HLA-DR-high, CD80-high, CD8 6 -high and CD83-positive. This is 
characteristic of immature and mature DCs (Banchereau and Steiijman, 1998; Reddy et ah, 1997; 
Spisek et ah, 2001). More extensive analysis of these DC populations is described Chapter 3.
Monocyte populations prepared for microarray profiling yielded high purity of CD 14 expressing 
cells. Day 9 osteoclast preparations yielded populations where approximately of 65% of the nuclei 
present could be attributed to multinucleated cells, of which over 90% were TRAP-positive. 
Although the populations were clearly not homogenous, a high degree of the nuclear material could 
be attributed to the osteoclast like cells. Boissy et ah have provided evidence that the nuclei of 
resorbing osteoclasts isolated from embryonic chick long bones, or differentiated in vitro from 
murine spleen cells, are all transcriptionally active (Boissy et ah, 2002). This evidence suggests 
assessing the percentage of nuclei attributed to multinucleated cells will correlate with the 
contribution of these cells to transcriptional activity. RNA was extracted from these osteoclast 
preparations and all demonstrated message for RANK and calcitonin receptor by RT-PCR. 
Expression of both these receptors is necessary to allow description of these as osteoclast-like 
cultures. It should be noted that calcitonin receptor mRNA cannot be detected in macrophage 
polykaryons (Arai et ah, 1999; Takahashi et ah, 1995). Neither CTR nor RANK mRNA transcripts
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were detected in the precursor monocyte population. As discussed in Chapter 3, RANK has 
previously been detected on CD 14-positive peripheral blood monocytes (Shalhoub et ah, 2000), but 
the inability to demonstrate RANK transcripts in the three monocyte samples tested suggests an 
increase of RANK message in the osteoclast samples. These characteristics are consistent with in 
vzfm-derived osteoclast cultures previously described (Quinn et ah, 1998; Flanagan and Massey, 
2003). More extensive characterisation of these osteoclast populations can be seen in Chapter 3.
Formaldehyde gel electrophoresis and ethidium bromide staining was used to evaluate the integrity 
and size distribution of total RNA. Each sample demonstrated 18S and 28S ribosomal RNA as 
sharp bands on a stained gel. These RNA samples were then used to make labelled cDNA probes 
with which to probe the custom made microarray. Each cDNA sample was hybridised to a 
microarray and transcript expression data obtained.
The transcript expression data acquired from the microarray profiling, was normalised to a panel of 
forty housekeeping genes and subjected to hierarchical clustering using the Genespring software. 
Data are grouped together solely on the similarity between gene expression profiles. This analysis 
resulted in the formation of four clearly defined clusters, correlating with the cell populations of 
immature DCs, mature DCs, monocytes and osteoclasts. This relationship between cell specificity 
and similarity of expression profiles suggests that patterns of transcript changes between cell types 
are present.
For most genes, changes in mRNA abundance relate to changes in protein abundance. However, 
during the microarray experiments mRNA is reverse transcribed to cDNA, this is necessary as RNA 
is prone to being destroyed and therefore difficult to work with. A problem with cDNA production 
is that not all mRNAs are reverse transcribed with the same efficiency. This leads to reverse 
transcription bias, which can change relative amounts of different cDNA measured in the same 
sample. However, when comparing the same gene across two cell populations this should not be a
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problem, unless the mRNA is not transcribed at all. Another problem caused by bias is that mRNA 
may be transcribed for only part of their lengths, making them less likely to bind and stay bound to 
their compliments on the array. Again this phenomenon is likely to remain consistent across cell 
populations when looking at the same gene. With this in mind it should be noted that all expression 
levels are arbitrary and will depend in part on the transcription efficiency from the mRNA and in 
part on the design of the 500 -  900 base pair UTR sequences that comprise the microarray. 
Therefore the most reliable data obtained from a microarray is comparative data, where obvious 
changes in the level of expression of a particular gene are seen.
Differentially expressed genes were highlighted where an expression level of greater or less than 3 
times that seen in the other cell types could be attributed to one cell type. Most of the genes selected 
by this analysis are chemokines and chemokine receptors where differential expression can be 
attributed to one of the dendritic cell populations, many of which will be considered on validation 
of the microarray. All genes selected in this process will be discussed in the relevant section.
The use of a custom made array allowed concentration on specific areas of interest for the cell types 
investigated, but also required an element of validation in order to gain confidence in the 
information obtained. Examining the chemokine and chemokine receptor data obtained for dendritic 
cells and comparing with a study of protein production and surface expression in these cells, and the 
body of literature available in this field, allowed this validation.
Microarray gene expression profiles of immature and mature DCs revealed patterns of chemokine 
and chemokine receptor expression that distinguish both stages of maturation. When compared to 
mature DCs, immature DCs exhibit higher levels of expression of CCL3 (M lP-la), CCL4 (MIP- 
IP), CCL13 (MCP-4), CCL15 (MlP-5, HCC-2), CCL18 (PARC, MlP-4), CCL23 (Ckp-8 , MPlF-1), 
CCRl and CCR5, while mature DCs exhibit increased expression of CCL2 (MCP-1), CCL17 
(TARC), CCL22 (MDC) and CCR7.
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Expression of particular chemokine receptors has previously been associated with DC development, 
including CCR7 with mature DCs and CCRl, CCR5 and CCR6  with immature DCs (Yang et ah, 
1999; Power et ah, 1997; Greaves et ah, 1997; Sallusto et ah, 1998; Sozzani et ah, 1997). As 
expected, CCR7 markedly increased and CCRl and CCR5 decreased significantly on maturation. 
Cell surface levels of these chemokine receptors, as analysed by immunofluorescent staining and 
flow cytometry, correlated well with the transcript levels. Significant levels of CCR6  were not 
observed in these in vzYro-derived DCs (data not shown), consistent with several reports that 
monocyte-derived DC do not express CCR6 , unlike CD34+ progenitor-derived DCs (Yang et ah, 
1999; Power et ah, 1997; Greaves et ah, 1997). Expression of CCRl and CCR5 by immature DCs is 
appropriate in their role as immune sentinels, residing within peripheral tissues and sampling the 
microenvironment for foreign antigens. CCRl and CCR5 expression are consistent with their 
requirements to migrate to areas of inflammation, where ligands for these receptors, such as CCL3, 
CCL4, CCL5 (RANTES) and CCL15 are expressed (Pashenkov et ah, 2002; Sozzani et ah, 1997). 
Coordinated changes in chemokine receptor expression on DC maturation, including downregulated 
expression of CCRl and CCR5 and upregulated expression of CCR7, allows the chemotactic 
recruitment of DCs to T cell rich areas of the lymph nodes that express the CCR7 ligands CCL19 
and CCL21 (Baekkevold et ah, 2001). Here they can interact with naive T cells and initiate an 
immune response.
The study in this chapter looks at constitutive and inducible chemokine production by immature and 
mature DCs. The stimuli used to induce chemokine production fi"om DCs were IFN-y plus either 
LPS or SAC. IFN-y is a potent Thl cytokine, associated with strong cellular immune responses and 
inflammation, which is produced by T cells in response to contact with monocyte-derived DCs and 
their products (Romagnani, 1999; Spellberg and Edwards, Jr., 2001). Thus, monocyte-derived DCs 
are generally considered to be Thl polarising (Zou et ah, 2000) and as such, would experience high 
levels of IFN-y on contact with naïve T cells. With this in mind, IFN-y was selected as a stimulus
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for chemokine production by in v/Yro-derived immature and mature DCs, along with classic Thl 
inducing agents, LPS and SAC (Cameron et ah, 2001).
Changes in production of chemokines on DC maturation have been widely reported (Wan and 
Bramson, 2001; Rescigno et ah, 1999). Expression of CCL13 by human in vitro monocyte-derived 
DCs has been previously noted (Hashimoto et ah, 1999), but the effect of maturation on regulation 
has not been studied extensively. Transcript and protein data in this chapter confirmed the 
expression of this molecule in DCs and demonstrated a downregulation on maturation. CCL13 is a 
chemoattractant for monocytes, activated T cells and NK cells, working through the CCR2 receptor. 
As such it is widely expressed at disease sites and fimdamental in the induction of cellular infiltrates 
(Miotto et ah, 2001; Taha et ah, 2000). This role is concurrent with the presence of immature DCs 
at these sites. CCL23 is reportedly constitutively produced by monocyte-derived DCs and its 
expression downregulated by inflammatory mediators (Nardelli et ah, 1999a), as was demonstrated 
in the transcript and protein analysis. Expression of CCL15 by DCs has not been previously 
reported but, intriguingly, this chemokine has high protein homology and functional similarities 
with CCL23 (Youn et ah, 1997b), CCL15 also showed reduced transcript and protein expression in 
mature DC. Both CCL15 and to a greater degree CCL23 protein are produced constitutively from 
immature, but not mature, monocyte-derived DC. Interestingly, stimulation of immature DCs with 
IFN-y and either LPS or SAC resulted in much increased levels of CCL15, but reduced levels of 
CCL23. Both CCL15 and CCL23 have been reported to bind to CCRl, and CCL15 also acts 
through CCR3 (Nardelli et ah, 1999b; Forssmann et ah, 2001). Both chemokines are implicated in 
inducing migration of neutrophils, monocytes and lymphocytes to sites of inflammation via these 
receptors (Wang et ah, 1998; Forssmann et ah, 1997). However, the differing expression patterns of 
these proteins observed in DC subpopulations may suggest a new functional distinction between 
these ligands in the sequence of an immune response.
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Other inflammatory chemokines such as CCL3 and CCL4 are reported to be produced at high levels 
in DCs in response to maturation signals, however the increase is transient, lasting only for a few 
hours (Sallusto et ah, 1999; Fischer et ah, 2001). Transcript levels for these chemokines were 
markedly reduced in mature DCs, probably a reflection of analysing the cells 72 hours after addition 
of the maturation stimulus. Indeed, upon stimulation with IFN-y and LPS and in particular, IFN-y 
and SAC, both CCL3 and CCL4 protein levels were upregulated. Whereas most other chemokines 
associated with immature DCs showed constitutive protein production by these cells, CCL3 and 
CCL4 required a stimulus for any protein levels to be detectable. This is concurrent with these 
chemokines being widely described as inducible chemokines, with a very well defined role in the 
build up of cellular infiltrates at disease sites; working through the receptors CCRl, 3 and 5 and 
calling in macrophages, lymphocytes, eosinophils, dendritic cells and NK cells (Driscoll, 1994; 
Cook, 1996). Production of these chemokines only on activation of immature DCs would ensure 
that inflammatory infiltrates only occur where required and only in response to signals, such as 
IFN-y, that indicate true immune T cell activation. Furthermore, fully mature DCs producing these 
chemokines would not be appropriate as this would result in inflammatory infiltrates at the thymus 
and lymph nodes. There is a second non-allelic gene for CCL3, gene designation SCYA3L (Nakao 
et ah, 1990). The product of this gene has been identified and functionally characterised, it shares 
90% homology with CCL3 and enhanced receptor interactions (Nibbs et ah, 1999). Unsurprisingly, 
the transcript for this gene showed a very similar pattern of expression to CCL3 in inunature and 
mature DCs. Protein levels of SCYA3L were not evaluated due to lack of available reagents.
In this study, CCL17 and CCL22 both showed increased transcript levels in mature DCs and high 
levels of constitutive protein production from these cells. This is consistent with reports that CCL17 
levels are upregulated on maturation (Sallusto et ah, 1999; Vissers et ah, 2001). The high level of 
CCL22 transcript observed upon maturation is consistent with DCs as a major source o f this 
chemokine, both in vitro and in vivo (Vulcano et ah, 2001). CCL17 and CCL22 are both
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constitutively expressed in the thymus and share utilisation of the chemokine receptor CCR4. 
CCL17 is thought to guide the migration of positively selected thymocytes. In contrast, CCL22, 
while capable of attracting thymocytes, also plays a role in attracting monocyte-derived DCs and 
activated NK cells, suggesting that it may act on an additional receptor (Bochner et ah, 1999; 
Schaniel et ah, 1999). Both CCL22 and CCL17 have been implicated in the attraction of activated T 
cells and the formation of lymphocyte-dendritic clusters in inflamed skin and secondary lymphoid 
tissues (Katou et ah, 2001). The production of CCL19 by mature DCs may also have been expected, 
however the transcript levels of this chemokine in mature DCs were unremarkable. This may be a 
reflection of the time-point evaluated, as CCL19 production has been demonstrated in mature DCs 
only at late time-points (Sallusto et ah, 1999).
CCL18 is also expressed at high levels in the lymph nodes, and preferentially attracts naive T cells, 
B lymphocytes and immature DCs (Adema et ah, 1997; Hieshima et ah, 1997). No receptor for 
CCL18 has been identified to date. In concordance with the transcript and protein data seen here, 
CCL18 production from immature DCs represents one of the most abundantly secreted chemokines 
by DCs and is downregulated on maturation (Vulcano et ah, 2003). In this study, immature DCs 
secreted very high constitutive levels of CCL18, with little change on activation with IFN-y and 
LPS or IFN-y and SAC, but vastly reduced levels from mature DCs under all conditions. There is 
evidence that stimulation of naïve T cells with immature DCs induces the generation o f lL-10 
producing T regulatory cells (Jonuleit et ah, 2000). CCL18 is chemotactic for both immature DCs 
and naïve T cells and, as such, a regulatory role for CCL18 production by immature T cells has 
been postulated (Vulcano et ah, 2003).
Consistent with the transcript data in this chapter, the proinflammatory chemokine CCL2 is reported 
to be produced upon maturation of DCs in a sustained manner (Sallusto et ah, 1999). However, 
production of CCL2 protein from LPS and IFN-y stimulated immature DCs was significantly higher
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than from mature DC. As discussed earlier, with respect to CCL3 and CCL4, this may be a 
reflection of the timepoint chosen for study. The culture supernatants were taken 48 hours after 
treatment with the stimuli, if  CCL2 is an early indicator of DC maturation, mRNA may be 
transcribed, translated and indeed degraded in this timescale.
During the analysis of chemokine protein production from DCs, four hour timepoints were also 
evaluated. CCL3, CCL4 and CCL15 levels could not be detected at four hours (data not shown). 
CCL2, CCL13, CCL17, CCL18, CCL22 and CCL23 demonstrated lower levels of protein, with the 
same patterns as the 48-hour timepoint (data not shown).
The purpose of this study was to demonstrate a correlation between transcript and protein levels in 
DC populations. With the exception of CCL2, protein levels could be seen where mRNA was 
present, if  not constitutively, then on activation. These data suggest that expression profiles 
demonstrated by the array profiling are representative of protein production by immature and 
mature DC. The study also describes for the first time, expression of CCL15 by monocyte-derived 
DC. Whilst evaluating chemokine profiles with relation to dendritic cell biology would require 
more extensive assessment, the gross picture fits in well with DC biology and the plethora of 
literature on this topic.
Major changes in DC chemokine and chemokine receptor expression profiles are seen, and can, for 
the most part, be related to the function of these cells. What then of changes in these entities on the 
differentiation of osteoclasts from their monocyte precursors? The differences between the 
expression o f chemokine and chemokine receptor transcripts in osteoclasts and monocytes are 
mostly unremarkable, perhaps a reflection of the relative unimportance of these molecules in the 
biology of osteoclasts, for which the main function is bone resorption, which is carried out in situ at 
the site of differentiation from their precursors. Transcript levels for CCL3, the non-allelic CCL3 
gene SCYA3L, CCL4, CCL20, CXCL8  (lL-8 ) and CCR2 were decreased in osteoclasts. These
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events are not unique to this differentiation pathway, as all were markedly decreased in immature 
and mature DCs as well, suggesting that the significance of these profiles is the important role of 
these chemokines and receptors in monocyte biology.
CCL3 and CCL4 are widely reported as produced from monocytes and macrophages (Wolpe et ah, 
1988) concurrent with the high levels of transcript seen in the monocyte samples (Bug et ah, 1998). 
CCL3 and CCL4 are still expressed at levels in the osteoclast preparations that may be significant, 
as transcript levels were similar to those seen in immature DCs, and high levels of CCL3 and CCL4 
protein were demonstrated on activation of these cells. CCL20 (MlP-3a) is another inflammatory 
chemokine, the major role of which is attracting Langerhans cells, B cells and neutrophils to the site 
of infection (Caux et ah, 2000; Akahoshi et ah, 2003; Liao et ah, 2002), as such it is hard to 
postulate a role for this chemokine in osteoclast biology. Maybe the remaining low levels o f mRNA 
transcript are due to the contaminating mononuclear presence in the osteoclast cultures. CCR2 is 
expressed on monocytes and has been shown to regulate their recruitment to sites o f inflammation 
(Han et ah, 1998). Therefore the decreased expression of the CCR2 transcript in osteoclast and 
dendritic cells could be a loss of requirement for expression of this receptor in these cell types. 
Indeed CCR2 has been shown to be downmodulated in murine bone marrow cultures on treatment 
with RANKL (Lean et ah, 2002).
Two further genes differentially upregulated in the monocyte population were CX3CRI and hm74. 
CX3CRI, the fractalkine receptor, is expressed on CD 16-positive monocytes (activated monocytes 
expressing the Fc receptor CD 16), implicating fractalkine as a mediator of monocyte chemotaxis 
into tissues (Ancuta et ah, 2003). CX3CR1 is reportedly expressed on murine osteoclast cultures 
(Lean et ah, 2002). hm74, a seven transmembrane GPCR for nicotinic acid (Tunaru et ah, 2003) 
was originally cloned from a human monocyte cDNA library (Nomura et ah, 1993), indicating the 
likely expression of the genes in monocytes. These inconclusive results highlight the need for
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confirmation of transcript expression by RT-PCR, Northern blots or indeed, measurement of protein 
expression.
Lean et al. describe the only other extensive study of chemokine ligand and receptor expression in 
osteoclasts by quantitative RT-PCR (Lean et ah, 2002). In their study, CCL9 (MIP-ly) and its 
receptor CCRl are postulated to be the major chemokine ligand / receptor species expressed by 
murine osteoclasts. The study detailed in this chapter is the first, to my knowledge, to examine 
human osteoclast cultures for chemokine and chemokine receptor gene expression. While there is 
no human homologue of the CCL9 gene, this study demonstrated expression of CCRl transcript in 
human osteoclast cultures, with levels comparable to that seen in the immature DC population. In 
addition, CCL3 and CCL4, demonstrated transcript levels similar to that of immature DC. In the 
DCs, these levels of transcript resulted in measurable protein production. Unfortunately, protein 
production was not examined in osteoclasts due to limited cell numbers obtained. However, it is 
interesting to speculate that these alternative CCRl ligands replace the requirement for CCL9 in 
human osteoclasts.
CXCL8  (IL-8 ), a CXC chemokine with a major role to play in inflammation, is produced by many 
cell types, including monocytes (Harada et a l, 1994; Mukaida et a l, 1998). Despite the 
downregulation of mRNA seen in dendritic cells and osteoclasts, CXCL8  production from these cell 
types has also been sited, at least in diseased tissues (Zhu et a l, 2000; Rothe et a l, 1998). Whereas 
CXCL5 (ENA-78) the only gene from our array showing differential upregulation in the osteoclast 
population, has not been previously demonstrated in osteoclasts. Expression of CXCL5 in 
osteoclasts is evaluated further in Chapter 6 .
The panel of other GPCR ligands included on the array showed unremarkable expression patterns, 
with no differential expression seen between cell types. The G protein-coupled receptors and orphan 
GPCRs; EDG 6 , P2 Y2 , CD97 and EMRI, showed some downregulated expression on
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differentiation of monocytes to osteoclasts. As previously, this downmodulation was not unique to 
this arm of the differentiation pathway, as expression also decreased on differentiation to DCs. Both 
EMRI and CD97 message have been reported in cells of the myelomonocytic lineage. Indeed, 
EMRI is predicted to be the human ortholog of the macrophage restricted F4/80 molecule 
(McKnight and Gordon, 1998). These molecules are members of the epidermal growth factor (EGF) 
7TM family, expressing large extracellular regions containing a variable number of EGF domains. 
EDG 6 , a member of the endothelial differentiation gene (EDG) family of proteins, has been 
associated with high levels of expression in lymphoid tissue, including peripheral leukocytes, and 
spleen (Graler et ah, 1999). Indeed, expression of EDG 6  on monocytes and their subsequent 
activation in response to the ligand for EDG 6 , sphingosine-1 -phosphate, has been reported (Fueller 
et ah, 2003). Monocytes have been demonstrated to express P2 Y2 receptors (Jin et ah, 1998); 
therefore the higher levels of transcript seen in this cell type are not surprising. Interestingly, the 
transcript analysis showed increased levels of P2 Y2 on maturation of DCs. P2 Y2 has been 
demonstrated on DCs (Berchtold et ah, 1999), but the effect of maturation needs further 
investigation. This study therefore showed very little difference in the transcript analyses o f GPCRs 
between monocytes and osteoclasts. However, the GPCRs and orphan GPCRs, showed some 
differential expression patterns worthy of note in DCs. The C3 and C5 anaphylotoxin receptors 
(C3aR, C5aR) showed downregulation of expression on mature DCs, with similar expression levels 
on monocytes, osteoclasts and immature DC. Dendritic cells generated from human blood 
monocytes and CD la-positive dendritic cells derived from skin have been shown to express these 
anaphylotoxin receptors (Kirchhoff et ah, 2001). Furthermore, the same study showed 
downregulation of the anaphylotoxin receptors and a loss of activity to their respective ligands on 
maturation, in agreement with the transcript expression data detailed in this chapter. The losses of 
activity to the anaphylotoxins are concurrent with their role in inflammation and the requirement of 
immature, but not mature DCs at these sites. Not surprisingly, C3AR (AZ3B) showed the same 
expression pattern on these cell types as C3aR and C5aR. The C3AR receptor cDNA was isolated
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with a probe derived from the N-formyl peptide receptor, belonging to the same family as the C3aR 
and C5aR and shows high homology to this family of receptors (Roglic et a l, 1996). H963, an 
orphan GPCR, showed upregulation of message on the mature DC population. This GPCR has no 
identified function to date (Jacobs et al., 1997), but this finding of expression in mature DCs might 
suggest a role for H963 in antigen presentation or T cell activation.
The most exciting observation was the strong increase of the GPR105 transcript in immature DCs. 
Immature DCs express GPR105 at substantially higher levels than mature DCs, with expression by 
monocytes and osteoclasts similar to that of mature DCs. This G protein-coupled receptor GPR105 
(KIAAOOOl), a relative of the P2Y family of receptors (Chambers et a l, 2000), recently renamed as 
the P2 Yi4 receptor (Abbracchio et a l, 2003), was first cloned from an immature myeloid cell line 
(Nomura et a l, 1994). No function has yet been attributed to this receptor, although the rat ortholog, 
VTR 15-20, is regulated by in vivo challenge with LPS and has been implicated in neuroimmune 
function (Charlton et a l, 1997). Additional expression studies and possible functional roles of 
GPR105 by DCs are investigated in Chapter 5.
This chapter sought to elucidate differential transcript expression in monocytes, osteoclasts, 
immature and mature DCs of chemokines, chemokine receptors, other seven transmembrane 
GPCRs and their known ligands. Firstly the array was validated by an extensive study comparing 
chemokine and chemokine receptor transcript and protein levels in immature and mature DCs, this 
data has also been discussed here in the context of the plethora of relevant literature available. In 
particular, the presence of CCL13 in immature, but not mature DCs, has been confirmed at the 
protein level, and the expression of CCL15 by DCs (previously unreported), is also confirmed at the 
protein level. Other differentially expressed genes have been highlighted and discussed. Perhaps the 
most interesting of these, the high levels of GPR105 transcript in immature DCs and the increase in 
CXCL5 transcript on differentiation of monocytes to osteoclasts, will be investigated in detail in the 
following chapters.
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Chapter 5
5.1 Introduction
The dendritic cell array data discussed in Chapter 4, revealed an interesting expression profile of the 
G protein-coupled receptor, GPR105 (previously termed KIAAOOOl). The cDNA encoding 
GPR105, a relative of the P2Y family of receptors (Chambers et ah, 2000), and more recently 
renamed as the P2 Yi4  receptor (Abbracchio et ah, 2003), was first cloned from an immature 
myeloid cell line (Nomura et ah, 1994). Uridine 5’-diphosphoglucose (UDP-glucose) was later 
identified as a potent agonist ligand of the GPR105 molecule (Chambers et ah, 2000). No 
physiologic function has yet been attributed to this receptor, although the rat ortholog, VTR 15-20, 
is regulated by in vivo challenge with LPS and has been implicated in neuroimmune function 
(Charlton et ah, 1997). The rat and mouse orthologs for GPR105, exhibiting 81 and 83% amino acid 
identity respectively to the human protein, both respond to the putative ligand UDP-glucose 
(Freeman et ah, 2001), however the existence of other physiological ligands remains a possibility.
Since the demonstration of non-lytic release of ATP from stressed (mechanically agitated) cells 
(Bumstock, 1997)’nucleotides have emerged as a family of extracellular signalling molecules with 
wide ranging effects. For example, ADP induces platelet aggregation, through binding the P2Yn 
receptor (Hollopeter et ah, 2001), and ATP mediates chemotaxis, cytotoxic responses and cytokine 
secretion through the P2X? receptor (North, 2002). As dendritic cells express many P2Y and P2X 
receptors (Berchtold et ah, 1999), there is a possibility that purine or pyrimidine-derived molecules 
influence dendritic cell maturation. Indeed extracellular ATP has demonstrated co-stimulatory 
effects on DCs, synergising with TNF-a to induce DC maturation (Berchtold et ah, 1999; Schnurr 
et ah, 2000) via the P2Yn receptor (Wilkin et ah, 2001).
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Considering the regulation of the rat ortholog of GPR105, VTR 15-20, on in vivo challenge with 
LPS, the emerging role of extracellular nucleotides in modulating the action of LPS is of great 
interest. For instance, extracellular ATP has been shown to enhance TNF-a message levels in the 
LPS treated murine macrophage cell line RAW 264.7 (Tonetti et ah, 1995) and increase IL-ip 
release in LPS-treated human macrophages (Ferrari et ah, 1997). An ATP analogue has even been 
shown to protect mice from a lethal LPS challenge (Proctor et ah, 1994). Indeed stimulation of 
LPS-matured dendritic cells with ATP triggered the release of IL-lp and TNF-a, probably via the 
P2X? receptor (Ferrari et ah, 2000). Furthermore, LPS binding regions have been demonstrated on 
the nucleotide receptor P2X?, suggesting that nucleotide receptors may directly modulate the action 
of LPS (Denlinger et ah, 2001). Little is known of the signalling capabilities of nucleotide sugars 
such as UDP-glucose. However, regulated release of cellular UDP-glucose has been demonstrated, 
implicating it as an extracellular signalling molecule (Lazarowski et ah, 2003). Induction of DC 
maturation through exposure to necrotic tumour cells (Sauter et ah, 2000) has lead to the proposal 
that “danger signals” (Gallucci and Matzinger, 2001) could have a major role in the initiation of an 
immune response. It is an attractive hypothesis that these and other small molecules may be 
released as “danger signals” from cells at inflammatory and / or tumour sites, either through passive 
diffusion following traumatic lysis or through regulated exocytosis.
This chapter aims to confirm the high levels of expression of GPR105 by human monocyte-derived 
immature DCs, concomitant with the lower levels expressed by mature DCs and monocytes. 
Agonist capabilities of UDP-glucose on this receptor using a GPRl 05-expressing HER 293 cell line 
will be substantiated. The functional effects of UDP-glucose on DCs were also investigated, 
through measurement of intracellular calcium release and assays for DC maturation and function. 
Potential synergy of UDP-glucose with LPS will also be described. Thereafter, possible roles for 
GPRl 05 on immature DCs are suggested and discussed further.
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5.2 Results
5.2.1 GPR105 transcript expression in DCs
The dendritic cell gene array data detailed in Chapter 4 demonstrates elevated GPR105 expression 
in immature DCs. Expression of this gene is notably absent in monocytes and osteoclasts and very 
low in mature DCs (Appendix 1, Fig. 4.16). Figure 5.1 confirms that high levels of GPR105 mRNA 
are present not only in day 9 immature DCs but also in day 6  immature DCs, with much lower 
levels detected in day 9 mature DCs. Northern blot hybridisation confirms the expression pattern of 
GPR105 (Fig. 5.2).
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Figure 5.1 GPR105 transcript expression in DC populations
DCs were derived from monocytes in the presence of GM-CSF and IF-4. RNA was extracted from 
day 6  DCs or DCs incubated for 72 hours with (day 9 mature) or without (day 9 immature) MCM 
and reverse transcribed into ^^P-labelled cDNA, which was hybridised to a gene microarray. 
Resulting transcript expression data was normalised to the average expression level of the 
housekeeping gene panel. Data are means (+SFM) of 3 separate experiments.
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Figure 5.2 Northern blot analysis of GPR105 and P-actin mRNA expression
DCs were derived from monocytes in the presence of GM-CSF and IL-4. RNA was extracted from 
day 6  DCs or DCs incubated for 72 hours with (day 9 mature) or without (day 9 immature) MCM. 5 
pg of total cellular RNA was electrophoresed through a 1.2% agarose/16.7% formaldehyde gel, 
transferred to Zeta-Probe GT membrane and probed with a ^^P-labelled 905 bp GPR105 probe or a 
^^P-labelled human actin probe. Hybridisation was performed overnight at 65°C. 3 donors; day 6  
immature DCs (lanes 1, 4, 7); day 9 immature DCs (lanes 2, 5, 8 ) and day 9 mature DCs (lanes 3, 6 , 
9) are represented.
126
5.2.2 UDP-glucose-induced calcium signalling in a GPRlOS-transfected cell line
An in-house HEK293 cell line co-transfected with the g protein subunit Goti^ and HA-tagged 
GPR105 cDNA constructs was used for intracellular calcium flux assays to confirm the agonist 
effects of UDP-glucose on this receptor. Firstly expression of GPR105 in the cell line was 
confirmed by immunofluorescent staining and flow cytometry using an antibody to the HA tag (Fig. 
5.3). Endothelin was utilised as a positive control for the calcium flux experiments, generating 
release of intracellular calcium in the non-transfected HEK293 parent cell line. The effects o f UDP 
and glucose were also investigated. Endothelin and UDP showed similar activity on both the 
GPRl 05-expressing and parent cell lines, whereas UDP-glucose induced release of intracellular 
calcium only in the GPRl 05-expressing cell line; glucose had no effect in either cell type (Table 
5.1, Fig. 5.4). These data demonstrate specific agonist activity of the GPRl05 receptor in HEK293 
transfectants by UDP-glucose.
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Figure 5.3 Expression of HA-tagged GPR105 in HEK293 transfectants
HEK293 cell lines were analysed by immunofluoresence and flow cytometry for HA-tagged 
G PRl05 expression. Isotype control antibody profiles are shown in the left panel and anti-HA 
profiles are shown in the right panel for (A) HEK293 parent and (B) G PRl05/ G ai6 co-transfected 
cell lines. One representative experiment is shown.
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Figure 5.4 Intracellular calcium release in a GPR105/Gai6 expressing and control HEK293 
cell lines
HEK293 cells were co-transfected with Gttie and GPRl 05 and a stable cell line was obtained by 
serial dilution cloning. Calcium responses induced with endothelin, UDP-glucose, UDP and glucose 
were measured in HEK293 parent (A) and GPRl05 / Gais expressing HEK 293 (B) cell lines using 
the calcium sensitive dye Fluo4-AM, in the FLIPR. Peak increases in fluorescence units minus 
basal (F.l.U. Max - Min) are shown; data are triplicates +/- S.D. One representative experiment of 3 
is shown.
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HEK293 parent cell line GPR105/Gai6 HEK293
endothelin 0.94nM 0.7nM
UDP-glucose >3.33|iM 0.46|iM
UDP 276pM 146|xM
glucose > ImM > ImM
Table 5.1 EC50 values for various ligands on GPR105/Gai6 expressing and control HEK293 
cell lines
HEK293 cells were co-transfected with Gaie and GPRl 05 and a stable cell line was obtained by 
serial dilution cloning. Calcium responses induced with endothelin, UDP-glucose, UDP and glucose 
were measured HEK293 parent and GPRl 05 / G ai6 expressing HEK 293 cell lines using the 
calcium sensitive dye Fluo4-AM, in the FLIPR. Dose response curves are shown in Fig. 5.4 EC50 
calculations were performed using Xlfit software.
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5.2.3 Correlation o f  UDP-glucose-induced intracellular calcium release with GPR105 
expression
As immature DCs, in comparison to mature DCs and monocytes, demonstrated increased 
expression of GPRl 05 it was vitally important to determine if this particular subset of DCs would 
respond to the GPRl 05 agonist ligand, UDP-glucose. Calcium signalling in monocytes, immature 
and mature DCs was measured in response to UDP-glucose (Fig. 5.5). CCL3 served as a positive 
control for both monocytes and immature DCs expressing CCRl and CCR5, while CCL19 was 
included as a positive control for mature DCs expressing CCR7. As predicted by the tightly 
regulated expression of CCRl, CCR5 and CCR7 in these cell types (Sozzani et al., 1998), 
monocytes and immature DCs both exhibited increased intracellular calcium concentrations in 
response to CCL3 (EC50 values = 0.025nM +/- 0.0006 SEM (n = 3) for monocytes and 0.22nM +/- 
0.07 SEM (n = 4) for immature DCs) while mature DCs showed elevated intracellular Ca^^ 
concentrations in response to CCL19 (EC50 value = 9 nM +/- 3.9 SEM (n = 4)). No significant 
response was observed from immature DCs to CCL19, mature DCs showed markedly lower, if  not 
insignificant, responses to CCL3, compared to monocytes and immature DCs. Consistent with the 
observed expression pattern of G PRl05, immature DCs increased intracellular Ca^^ concentrations 
in response to UDP-glucose, the GPRl05 agonist ligand (EC50 value = 11.5jLiM +/- 2.1 SEM (n = 
4)), while no significant response to this molecule was observed from mature DCs or monocytes.
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Figure 5.5 Intracellular calcium release in response to UDP-glucose in monocytes and DCs
Monocytes were purified from PBMC. DCs were derived from monocytes in the presence of GM- 
CSF and lL-4. Day 6 DCs were incubated for 72 hours with (mature) or without (immature) MCM. 
CCL3, CCL19 and UDP-glucose-induced calcium responses were measured using the calcium 
sensitive dye, Fluo4-AM, in conjunction with a FLIPR, in monocytes (A), immature DCs (B) and 
mature DCs (C). Peak increases in fluorescence units minus basal (F.l.U. Max - Min) are shown. 
Data are triplicates +/- S.D. One representative experiment of 3 (monocytes) or 4 (immature and 
mature DCs) is shown.
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5.2.4 Phenotypic changes in immature DCs in response to UDP-glucose
As GPRl 05 is expressed on immature but not mature DCs and treatment of immature DCs with 
UDP-glucose elicited an increase in free intracellular calcium levels, the ability of UDP-glucose to 
induce a maturation response from these cells was evaluated. For these experiments TNF-a was 
used as a well defined positive control for maturation (Sallusto and Lanzavecchia, 1994) and UDP, 
which has no GPRl 05 agonist activity (Chambers et al., 2000), was used as a negative control. 
Following treatment, expression of CD80, CD8 6 , HLA-DR and CD83, which are often cited as 
classical markers of DC maturation (Banchereau and Steinman, 1998; Banchereau et al., 2000), 
were then quantified by immunofluorescent staining and flow cytometery. Overall, both UDP- 
glucose- and TNF-a-treated DCs showed an increase in cell surface HLA-DR, CD 80, and most 
strikingly CD8 6  and CD83 levels, consistent with their acquisition of a mature DC phenotype; 
while UDP-treated DCs maintained a predominantly immature phenotype, HLA-DR-medium, 
CD8 O-I0 W, CD8 6 -negative and CD83-negative (Fig. 5.6A). Analysis of percentage CD8 6 -positive 
cells (Fig. 5.6B) and CD83-positive cells (Fig. 5.6C) clearly showed that a larger population of 
UDP-glucose-treated cells express these maturation-associated markers than UDP-treated cells (n = 
11, p = 0.001 for CD8 6  comparison and p = 0.005 for CD83 comparison).
RNA was also extracted from these treated DC preparations and subjected to microarray profiling, 
as detailed in Chapter 4. Analysis of the transcription of chemokines and chemokine receptors 
provided further evidence for UDP-glucose-mediated DC maturation (Fig. 5.7). As expected, DCs 
treated with TNF-a demonstrate a mature phenotype through elevated expression of CCL2, CCL17, 
CCL22 and CCR7 transcripts, and reduced expression of CCL3, CCL4, CCL13, CCL15, CCL18, 
CCL23, CCRl, CCR5 and G PRl05 transcripts, consistent with the expression pattern observed for 
MCM matured DCs (Figs. 4.7 -  4.11). UDP-treated DCs showed similar transcript levels to 
untreated DCs, suggesting UDP has little effect on maturation. However, UDP-glucose-treated DCs
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exhibited a trend towards the TNF-a-treated ‘mature DC’ gene expression profile. In comparison to 
both untreated and UDP-treated DCs, UDP-glucose-treated cells exhibited increased expression of 
CCL2, CCL17, CCL22 and CCR7 transcripts, with a concomitant reduction in CCL3, CCL4, 
CCL13, CCL15, CCL18, CCL23, CCRl, CCR5 and GPRl05 gene expression, consistent with 
induction of the DC maturation process.
An evaluation of the endocytic ability of UDP-glucose-treated DCs, as measured by FITC-dextran 
uptake, is shown in Figure 5.8. As expected, TNF-a-treated immature DCs demonstrate a decreased 
endocytic capability consistent with their differentiation towards maturity. The FITC-dextran 
uptake by immature DCs was unaffected by exposure to the negative control, UDP. O f interest, 
UDP-glucose-treated cells showed a significant reduction in FITC-dextran uptake when compared 
to UDP-treated cells (n = 10, p = 0.0005). These data suggest that UDP-glucose, acting via the 
GPRl 05 receptor, induces a DC maturation process characterised by reduced endocytic function.
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Figure 5.6 CD80, CD86, HLA-DR and CD83 expression on UDP-glucose-treated DCs
D C s were derived from m onocytes in the presence o f  G M -CSF and IL-4. D ay 6 D C s w ere  
incubated for 48 hours w ith or without U D P-glucose (Im M  added to culture on day 6 and again on  
day 7), U D P (Im M  added to culture on day 6 and again on day 7) or T N F -a  (Ip M  on day 6 only) 
and the cells were then stained with fluorescently labelled antibodies to C D 80, C D 86, H L A -D R  and 
CD83 for 30 m inutes at 4°C and analysed by flow  cytom etry. A. C ell-surface expression  o f  C D 80, 
C D 86, H L A -D R  and C D 83 in untreated (open histogram s) or treated (closed  histogram s) D C s. O ne 
representative experim ent o f  11 is shown. B. Summary o f  cell-surface C D 86 expression  o f  
untreated D C S, compared with U D P-, U D P -glu cose- and TN F-a-treated DCs. C. Sum mary o f  ce ll-  
surface C D 83 expression o f  untreated DC S, relative to U D P-, U D P -glu cose- and T N F-a-treated  
DCs. V alues represent the percentage o f  D C s expressing cell-surface C D 86 (B) and C D 83 ( Q .  Data  
shown are m eans (+SEM ), n =  11.
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Figure 5.7 The effect of UDP-glucose on transcript expression profiles in DCs
D C s were derived from m onocytes in the presence o f  G M -C SF and IL-4. D ay 6 D C s w ere 
incubated for 48 hours (n =  2) or 72 hours (n == 2) w ith or without U D P -glu cose (Im M  added to 
culture on day 6, repeated daily), U D P (Im M  added to culture on day 6, repeated daily) or T N F -a  
(Ip M  on day 6 only). R N A  w as extracted and reverse transcribed to ^^P-labelled cD N A , w hich  w as  
hybridised to a custom  gene microarray. V alues are expressed as the percentages o f  expression  
levels exhibited by untreated D C s, data are m eans (+SE M ) o f  4 experiments.
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Figure 5.8 The effect of UDP-glucose on the endocytic ability of DCs
DCs were derived from monocytes in the presence of GM-CSF and IL-4. Day 6 DCs were 
incubated for 48 hours with or without UDP-glucose, UDP (ImM added to culture on day 6 and 
again on day 7) or TNF-a (IpM  on day 6 only) and the cells were then incubated with FITC- 
dextran for 30 minutes at 37°C and fluorescence (indication of FITC-dextran uptake) was analysed 
by flow cytometry. Values are expressed as a percentage of the uptake by untreated DCs. Data 
shown are means (+SEM), n = 10.
137
5.2.5 The effect o f endotoxin contamination on UDP-glucose-induced CD86 expression
Endotoxin has the potential to initiate most of the functional effects demonstrated in Section 5.2.4. 
Therefore UDP and UDP-glucose, purchased from Sigma, were evaluated for endotoxin levels 
using the amebocyte limulus assay. Unfortunately low levels of endotoxin were present in both of 
the UDP-glucose preparations, see Table 5.2. With this in mind, experiments using the endotoxin 
binder and neutraliser, polymyxin B, were performed. The detected increase in CD86 expression 
correlated with the level o f endotoxin contamination in the UDP-glucose preparations. Furthermore, 
polymyxin B abrogated the functional effects of UDP-glucose on CD86 upregulation in this 
experiment (Fig. 5.9). However, intracellular calcium data was not affected by endotoxin, as 
demonstrated by the observed intracellular calcium response to UDP-glucose in both the presence 
and absence of polymyxin B (Fig. 5.10).
Agonist Manufacturer and batch no. Endotoxin Units / ml
UDP-glucose Sigma, #7017 18.9 EU/ml
UDP-glucose Sigma, #7019 1.7EU/ml
UDP Sigma, # 7077 >0.1 EU/ml
Table 5.2. Endotoxin levels in UDP and UDP-glucose preparations
Endotoxin levels in UDP and UDP-glucose preparations were determined using the amebocyte 
limulus assay.
138
CD
COQ
O
0
?
OQ
1 0 0 - ,
75-
50-
25-
0 1(Oco
'■ a
<
o
0  N,
1Q
3
m
03
ON
3
03
Û.
Q3
NM-O
CL
Q
3
S
LL
03
C
no polymyxin B 
+ polymyxin B
I
c/3
CL
03c
Figure 5.9 The effect of polymyxin B on UDP-glucose-induced CD86 expression by DCs
DCs were derived from monocytes in the presence of GM-CSF and IL-4. Day 6 DCs were 
incubated for 48 hours in the presence of UDP-glucose (UDP-glu), UDP, TNF-a or LPS. Batch 
numbers of UDP-glucose and UDP are indicated (also see Table 5.2). Polymyxin B was added 
where appropriate, at a final concentration of 1 mg/ml, four hours before addition of the agonists. 
Cells were then stained with a FITC labelled antibody to CD86 and analysed by flow cytometry. 
The percentages of DCs expressing CD86 are shown. Data are means + SEM of 3 experiments.
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Figure 5.10 The effect of polymyxin B on histamine, CCL3 and UDP-glucose-initiated 
intracellular calcium release in immature DCs
DCs were derived from monocytes in the presence of GM-CSF and IL-4. Calcium responses were 
induced by histamine (lOOpM), CCL3 (IpM ) and UDP-glucose (ImM, containing 3 EU/ml) in day 
9 immature DCs +/- 4 hours pre-treatment with polymyxin B. Calcium respones were measured 
using the calcium sensitive dye Fluo-4-AM in conjuction with a FLIPR. Fluorescence intensity 
units (F.l.U.) are shown. Data are triplicates + SD.
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5.2.6 Endotoxin free UDP-glucose
Endotoxin free UDP-glucose preparations were sourced from ICN Biomedicals (<0.01 EU/ml, 
assayed using the amebocyte limulus assay). Immature (day 6) DCs were cultured either with or 
without this endotoxin-free UDP-glucose and expression of CD86, often cited as a classical marker 
of DC maturation (Banchereau and Steinman, 1998; Banchereau et al., 2000), was quantified by 
immunofluorescent staining and flow cytometry. In general there was an increase in the percentage 
of CD86-positive cells in DCs treated with endotoxin-free UDP-glucose, although not all donors 
respond to this agonist (Fig. 5.11).
Since DCs derived from only certain donors were responsive to UDP-glucose, the possibility that 
UDP-glucose acts in an additive or synergistic manrier with LPS to promote activation of DCs was 
investigated. All immature DC populations exhibited an increase in the percentage of cells 
expressing cell-surface CD86 in response to LPS treatment. The combination of UDP-glucose and 
LPS resulted in a modest, but statistically significant, increase in CD86 expressing cells compared 
to LPS alone. Although LPS markedly increased CD83 expression and decreased FITC-dextran 
uptake in these cells, no statistically significant effect was seen with UDP-glucose for these 
functional parameters (Fig. 5.12). Allogeneic T cell proliferation experiments using these treated 
DC preparations, and IFN-y measurements from the same experiments, show increased responses, 
although not statistically significant, in response to UDP-glucose treatment, both in the absence and 
presence of LPS (Fig 5.13).
Due to donor variability observed in the studies of CD86 upregulation, UDP-glucose-induced 
calcium fluxes and UDP-glucose-induced CD86 expression were evaluated in parallel in four 
donors. These data revealed a correlation between the magnitude of a UDP-glucose-induced 
calcium flux and an increase in CD86 expressing cells in these experiments (r  ^= 0.87) (Fig. 5.14).
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Figure 5.11 The effect of endotoxin free UDP-glucose on CD86 expression by immature DCs
DCs were derived from monocytes in the presence of GM-CSF and IL-4. Day 6 DCs were 
incubated for 48 hours with or without endotoxin-free UDP-glucose (ImM added to culture on day 
6 and again on day 7), following which cells were stained with a FlTC-labelled anti-CD86 antibody 
and analysed by flow cytometry. The percentages of DCs expressing CD86 are shown. Individual 
data points represent individual donors; the median value is indicated.
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Figure 5.12 The effect of UDP-glucose and LPS on CD86 expression and CD83 expression and 
FITC-dextran uptake by DCs
DCs were derived from monocytes in the presence of GM-CSF and IL-4. Day 6 DCs were 
incubated for 48 hours with or without UDP-glucose (ImM added to culture on day 6 and again on 
day 7) and LPS (1 ng/ml added day 6 only). Cells were then stained with fluorescently-labelled 
antibodies to CD86 (A) or CD83 (B) or incubated with FITC-dextran for 30 minutes at 37°C (C) and 
subsequently analysed by flow cytometry. Values are expressed as the percentage of positive DCs. 
Means + SEM are shown; n = 10 for CD83 and CD86 staining, n = 7 for FITC-dextran uptake.
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Figure 5.13 The effect of UDP-glucose pre-treatment of DCs, with or without LPS, on 
allogeneic T cell proliferation and IFN-y production
DCs were derived from monocytes in the presence of GM-CSF and IL-4. Day 6 DCs were 
incubated for 48 hours with UDP-glucose (ImM added to culture on day 6 and again on day 7); 
LPS (1 ng/ml added day 6 only); both UDP-glucose and LPS; or MCM (1ml on day 6 only). T cells 
were purified using the MACS magnetic bead system and a pan T cell kit. DCs were washed 
extensively, irradiated ( 'X s )  and incubated with allogeneic T cells at a ratio of 1 DC to 100 T cells, 
in round-bottomed 96 well plates for 5 days. (A) Supernatant was removed on day 5 and IFN-y 
levels were assessed by ELISA. (B) Proliferation was measured by incorporation of thymidine 
over the final 16 hours of culture (irradiated DCs alone did not incorporate Thymidine or 
produce detectable levels of IFN-y (data not shown)). Data shown are mean + SEM of 3 donors.
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Figure 5.14 Correlation of UDP-glucose-induced CD86 expression and UDP-glucose-induced 
calcium flux
DCs were derived from monocytes in the presence of GM-CSF and IL-4. Day 6 DCs were 
incubated for 48 hours with or without UDP-glucose, stained with a fluorescently labelled antibody 
to CD86 and analysed by flow cytometry. Alternatively, UDP-glucose-induced calcium responses 
were measured using the calcium sensitive dye, Fluo4-AM, in conjunction with a FLIPR. The 
percentages of DCs expressing CD86 were plotted against the peak Ca^^ increases in fluorescence 
units minus basal (F.l.U. Max - Min). Points represent individual experiments; the linear regression 
is shown, r^= 0.87.
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5.2.7 The effect o f  pertussis toxin pre-treatment on endotoxin-free UDP-glucose-induced
calcium flux in immature DC
Pertussis toxin is a well-established inhibitor of certain G proteins. To demonstrate the G-protein 
dependency of the UDP-glucose effect on DCs, the intracellular calcium responses to histamine, 
CCL3 and UDP-glucose were investigated in immature DCs, with and without pertussis toxin pre­
treatment of the cells. The calcium flux of immature DCs to CCL3 was abolished by pertussis toxin 
pre-treatment (Fig. 5.15C) while the response to histamine remained intact (Fig. 5.15A). These data 
are consistent with the pertussis toxin-sensitivity of the Gi proteins known to couple to the CCL3 
receptors, CCRl and CCR5 (Luther and Cyster, 2001) and the pertussis toxin resistant nature of the 
Gq and Gs proteins that couple to the histamine receptors HI and H2 respectively (Hill et al., 1997), 
all of which are present and functional on monocyte-derived immature DCs (Mazzoni et ah, 2001). 
The UDP-glucose-initiated calcium flux was down-modulated in response to pertussis toxin pre­
treatment (Fig. 5.15B). A paired t-test revealed statistically significant down-regulation of the UDP- 
glucose-initiated calcium flux by pertussis toxin pre-treatment for 10|iM UDP-glucose (n = 5, p = 
0.02) and 100|iM UDP-glucose (n = 5, p = 0.003). This demonstrates that the increase in 
intracellular calcium in response to UDP-glucose is at least in part mediated via a pertussis toxin 
sensitive G protein.
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Figure 5.15 The effect of pertussis toxin pre-treatment on the calcium responses of immature 
DCs to histamine, CCL3 and endotoxin free UDP-glucose
DCs were derived from monocytes in the presence of GM-CSF and IL-4, Where indicated, day 8 or 
9 immature DCs were pre-treated with 10 ng/ml pertussis toxin for 18 hours following which A. 
Histamine, B. UDP-glucose and C. CCL3 induced calcium responses were measured using the 
calcium sensitive dye, Fluo4-AM, in conjunction with a FLIPR. Peak increases in fluorescence 
units minus basal (F.l.U. Max - Min) are shown. Data shown is mean +/- SEM of 5 donors. *p = 
0.02, **p = 0.003, paired t-test.
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5.2.8 Intracellular calcium release from GPRlOS-expressing HEK293 cells in response to 
necrotic cell components
UDP-glucose plays a well-established role in metabolism and, as such, provides a potential 
candidate as a molecule for signalling the presence of damaged cells. The possibility that necrotic 
cells could release unusually high levels of UDP-glucose into the extracellular milieu is one such 
scenario. With this in mind, the release of intracellular calcium from GPRl 05 / Gai6-expressing 
HEK293 cells in response to necrotic cell supernatants was investigated. Endothelin generated 
similar calcium flux data in both the GPRl 05 / Gai6-expressing HEK293 cells and the wild type 
HEK293 cell line (Fig. 5.16). UDP-glucose, meanwhile, initiated a calcium flux only in the 
GPRl 05 / Gtti6-expressing cell line. Necrotic cell supernatants, but not control, PBMC 
supernatants, induced a dose-dependant increase in intracellular calcium in GPRl 05 / Ga%6- 
expressing cells and not the wild type cell line (Fig. 5.16).
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Figure 5.16 GPRlOS-expressing HEK293 and control HEK293 responses to necrotic cell 
supernatants
HEK293 cells were co-transfected with Gai6 and GPRl 05 and a stable cell line was obtained by 
serial dilution cloning. Calcium responses induced with endothelin, UDP-glucose, viable cell and 
necrotic cell supernatants were measured using the calcium sensitive dye, Fluo4-AM, in 
conjunction with a FLIPR; in GPRl 05 / Gai6-expressing HEK 293 (A) and HEK 293 wild type (B) 
cell lines. Peak increase in fluorescence units minus basal (F.l.U. Max - Min) are shown, data are 
triplicates +/- S.D. One representative experiment of 2 is shown.
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5.3 Discussion
The most exciting observation from the microarray data detailed in Chapter 4 was the differential 
expression pattern of the GPR105 gene in monocytes and DCs. Immature DCs express GPR105 at 
substantially higher levels than mature DCs, with expression by monocytes similar to that of mature 
DCs. Interestingly, significant ^pression of the GPR105 transcript has not been observed by any 
other cell type analysed with this microarray; including primary human kératinocytes and bronchial 
epithelial cells, in viïro-derived osteoclast cultures and primary T cells, as well as the cell lines 
HUT-78 (T cell line) and Caco-2 (human intestinal cell line) all with and without treatment with 
various proinflammatory stimuli (data not shown). The expression o f GPR105 in day 6 immature 
DCs confirms that lack of expression in mature DCs is due to active down-modulation of gene 
transcription, while the expression by day 9 immature DCs is not solely a result of a lack of 
maturation signals in the later part of the incubation period. GPR105 transcript expression in day 6 
and day 9 immature DCs, but not day 9 mature DCs, was confirmed by Northern blot analysis.
A stable cell line expressing GPR105 and the promiscuous G protein subunit, Gtti6, was used to 
confirm agonist capabilities of the putative GPR105 ligand, UDP-glucose (Chambers et al., 2000). 
Intracellular calcium increases were seen in response to UDP-glucose in the GPR105 / Gai6- 
expressing cell line, and not in the parent HEK293 cell line. Calcium responses to other ligands, 
namely UDP (negative) and endothelin (positive), were equivalent in both the GPRl 05-expressing 
and the parent cell lines. UDP-glucose specific signalling was over two orders of magnitude more 
sensitive than UDP-induced signalling in the GPRl 05-expressing cell line. These data confirm that 
UDP-glucose is an agonist for the GPRl 05 cell-surface 7TM molecule.
Following confirmation of the specificity of UDP-glucose for GPRl 05, the calcium signalling 
responses of monocytes, immature and mature DCs in response to UDP-glucose were evaluated. 
Examining calcium fluxes in response to CCL3 and CCL19 controlled these experiments; the
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receptors that respond to CCL3, CCRl and CCR5 present on monocytes and immature DCs, are 
downregulated on mature DCs, and CCR7, responsive to CCL19 is upregulated on mature DCs 
(Sozzani et ah, 1998). As expected, monocytes and immature DCs both exhibited increased 
intracellular Ca^^ concentrations in response to CCL3 whereas mature DCs showed elevated 
intracellular Ca^  ^ levels in response to CCL19. UDP-glucose initiated a calcium flux in immature 
dendritic cells, but not mature DCs or monocytes. This correlates with the expression pattern of 
GPRl 05 mRNA transcripts, adding support for the expression of functional GPRl 05 by the 
immature DC subset.
Specific signalling of UDP-glucose via GPRl 05 binding in immature DCs warranted further 
investigation of the role of this receptor in DC development. To this end, immature DCs were 
incubated with UDP-glucose and analysed extensively. In this series of experiments, TNF-a was 
used as a positive control for DC activation. Although TNF-a alone is inefficient at inducing fully 
mature DCs (Reddy et ah, 1997), it was employed here as a well defined positive control capable of 
inducing upregulation of CD80, CD83, CD86 and HLA-DR and decreasing the endocytic ability of 
immature DCs (Sallusto and Lanzavecchia, 1994). Flow cytometric analyses revealed increased 
cell-surface expression of CD80, CD83, CD86 and HLA-DR following stimulation with TNF-a and 
a similar phenotypic change following stimulation with UDP-glucose, by way of an upregulation in 
CD80, CD83, CD86 and HLA-DR expression. In particular, significant upregulation of CD83 and 
CD86 was seen when compared to the non-GPR105 binding UDP control. Analysis of mRNA 
transcript expression in UDP-glucose treated DCs revealed a pattern consistent with both TNF-a- 
treated DCs and the MCM-matured DCs analysed in Chapter 4. Increases in transcripts encoding 
CCL2, CCL17, CCL22 and CCR7, with a reduction in CCL3, CCL4, CCL13, CCL15, CCL18, 
CCL23, CCRl, CCR5 and G PRl05 were evident. In addition to the many changes in gene 
expression that occur during DC maturation, downregulation of the antigen internalisation 
capability of DCs is also observed. As antigen uptake can take place via endocytosis (Sallusto and
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Lanzavecchia, 1994), the endocytic capacity of DCs was evaluated by measuring the uptake of 
FITC-dextran, in order to determine if the apparent UDP-glucose-induced shift towards a mature 
phenotype affected this ftmctional marker of DC development. As expected, TNF-a-treated DCs 
exhibited a decrease in endocytic ability consistent with their progression towards maturity, 
whereas the endocytic activity of immature DCs was unaffected by exposure to UDP. UDP- 
glucose-treated immature DCs, meanwhile, also showed a significant reduction in FITC-dextran 
uptake when compared to UDP-treated cells. These data support the hypothesis that UDP-glucose 
induces a mature DC phenotype, both in terms of cell-surface molecule expression and ftmctionally.
Endotoxin is a lipopolysaccharide (EPS), which is a component of the outer membrane of gram- 
negative bacteria. Endotoxin or EPS has long been identified as an initiator of DC maturation 
(Verhasselt et al., 1997). It was therefore essential to eliminate possible endotoxin contamination of 
the UDP-glucose preparations used in these experiments. Unfortunately, the amebocyte limulus 
assay revealed low level endotoxin contamination of the UDP-glucose preparations. Further 
experiments were performed in the presence of the endotoxin binder and neutraliser, polymyxin B. 
CD86 induction by UDP-glucose correlated with the extent of endotoxin contamination in the UDP- 
glucose preparations. Furthermore the induction of CD86 expression was abrogated by the presence 
of polymyxin B. These data suggest that the increase in CD86 initiated by UDP-glucose is, at least 
in part, due to endotoxin contamination of the UDP-glucose preparations. However, UDP-glucose- 
induced intracellular calcium fluxes were not affected by the addition of polymyxin B. Indeed, 
endotoxin, signalling through the Toll-like receptors in an EPS activation cluster, would not be 
expected to induce a calcium signal (Triantafilou and Triantafilou, 2002).
Thereafter, endotoxin-free UDP-glucose preparations were evaluated for their ability to induce 
CD86 in immature DCs. In some donors, UDP-glucose-treated DCs were induced to express 
increased levels of the co-stimulatory molecule CD86. The relatively low level of this response 
suggested that thresholds for activation of the DCs were not effectively reached. Extracellular
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nucleotides, such as ATP, synergise with other molecules to induce dendritic cell maturation 
(Schnurr et ah, 2000), furthermore extracellular nucleotides can modulate the actions of LPS 
(Tonetti et ah, 1995; Ferrari et ah, 1997; Proctor et ah, 1994; Ferrari et ah, 2000; Denlinger et ah, 
2001). Therefore the higher level of CD86 expression observed with the endotoxin contaminated 
UDP-glucose preparations, prompted the investigation of a possible synergy between UDP-glucose 
and LPS. LPS at Ing/ml initiated increased CD86 and CD83 expression and decreased FITC- 
dextran uptake in immature DCs. However, these effects were not of the magnitude seen with 
monocyte-conditioned medium demonstrated in Chapter 3, allowing for potential additive or 
synergistic effects of UDP-glucose to be evaluated. Using a combination of LPS and UDP-glucose 
to induce CD86 expression resulted in a statistically significant increase over the levels of CD86 
seen with LPS alone. However, CD83 expression and FITC-dextran uptake were unaffected by the 
addition of UDP-glucose, either in the presence or absence of LPS. An evaluation of the ability of 
UDP-glucose-treated immature DCs to stimulate naive T cells demonstrated an increase over 
untreated DCs. A slight additive effect with LPS was also evident. These differences are not 
statistically significant and could be considered negligible; however a trend is certainly evident. 
Furthermore, in four donors the induction of CD86 by endotoxin-free UDP-glucose preparations 
was compared to the magnitude of an UDP-glucose-induced calcium flux in these same donors. 
This revealed a very strong correlation between the calcium flux levels and the increase in CD86 
expression. This suggests that where intracellular calcium release is low, UDP-glucose-induced 
signalling has not reached the magnitude required for the induction of dendritic cell maturation.
To further substantiate that UDP-glucose functions through GPRl 05 ligation, the pertussis toxin 
sensitivity of an UDP-glucose-initiated calcium flux was investigated in immature DCs. The ability 
to block a calcium flux with pertussis toxin is limited to receptors coupled with pertussis toxin- 
sensitive Gi G-proteins. A previous report, using transfected cell lines, suggests that GPRl 05 is 
coupled to Gi G-proteins (Chambers et al., 2000). The calcium flux of immature DCs to CCL3 was
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abolished with pertussis toxin pre-treatment and the response to histamine remained intact. These 
data are consistent with the pertussis toxin-sensitive nature of the Gi proteins known to couple the 
CCL3 receptors, CCRl and CCR5 (Luther and Cyster, 2001) and the pertussis toxin-resistant nature 
of the Gq and Gs proteins that associate with the histamine receptors HI and H2 respectively (Hill 
et al., 1997), present and functional on monocyte-derived immature DCs (Mazzoni et al., 2001; la 
Sala et al., 2002; Idzko et al., 2002; Gutzmer et al., 2002). The UDP-glucose-initiated calcium flux 
via GPRl05 was downmodulated in response to pertussis toxin pre-treatment of immature DCs; 
however the signal was not abolished. This demonstrates that the calcium signal obtained in 
response to UDP-glucose is, at least in part, mediated by pertussis toxin-sensitive G proteins. There 
is precedence for GPCRs to associate with different G protein classes and therefore display 
incomplete sensitivity to pertussis toxin (Haribabu et al., 1999; Ahamed and All, 2002).
What is the physiological consequence of UDP-glucose-mediated DC signalling? Although the 
downstream effect of this UDP-glucose initiated calcium flux is not clear, the presence of UDP- 
glucose and other glycolytic metabolites at high levels in tumour cells (Eigenbrodt et ah, 1992) is 
intriguing. This leads to speculation that UDP-glucose could be acting as a tumour-specific ‘danger’ 
signal to the immune system. Indeed, supernatants from necrotic cancer cells, but not other cell 
types, can induce maturation events in immature DCs (Sauter et a l, 2000). Furthermore, 
immunogenic tumours, such as melanomas (Brinckerhoff et ah, 2000), are present in 
microenvironments where immature DCs, such as Langerhans cells, are highly prevalent. Perhaps 
increased levels of UDP-glucose released from necrotic tumour cells might reach a ‘danger’ 
threshold and, via GPRl 05-mediated signalling, in concert with other signals such as LPS, initiate 
an immune response, following induction of DC maturation. Furthermore, UDP-glucose has a well- 
established role in glycolytic metabolism and, until recently, had not been detected extracellularly. 
This leads to the possibility that UDP-glucose could be released inappropriately from damaged or 
dying cells. With this in mind, the agonist activities of necrotic cell supernatants were evaluated
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using GPRl 05-expressing HEK293 cells. Indeed, supernatants from necrotic PBMC induced a 
calcium response in GPRl 05-expressing cells, whereas no response was seen in the parent HEK293 
cell line. However, the release of UDP-glucose from resting cells has also recently been 
demonstrated (Lazarowski et al., 2003). Lazarowski and colleagues demonstrate that unlike other 
nucleotide signalling molecules such as ATP, release of which following mechanical stimulation of 
cells reaches a peak at ten minutes and diminishes rapidly, UDP-glucose release is initially 
relatively minor. However, levels of UDP-glucose remain stable for several hours, suggesting that 
the rate of metabolism of extracellular UDP-glucose is much lower than that of ATP. These data 
add credence to the suggestion that a critical threshold of UDP-glucose may have to be reached for 
GPRl 05 signalling to be initiated.
Recently Lee et al. have reported GPRl 05 expression identifies a subset of haemopoietic cells 
within foetal bone marrow (Lee et al., 2003). They also demonstrate chemotaxis of these cells to a- 
conditioned medium from bone marrow stroma and that this migration is specifically blocked by an 
anti-GPR105 antibody, implicating GPRl 05 in the homing of bone marrow stem cells. The bone 
marrow microenvironment is a rich source of immature dendritic cells and it is possible that the 
bone marrow stem cell subset described by Lee et al. is a precursor population for DCs. 
Interestingly, the authors also describe more efficient responses of GPRl 05-transduced human 
CD34-positive cells to bone marrow stroma-conditioned media than UDP-glucose and suggest the 
possibility of a distinct ligand.
The work described in this chapter demonstrates GPRl 05 expression on immature monocyte- 
derived DCs and its absence from mature DCs and monocyte precursors. Initial evaluation of the 
functional effects of UDP-glucose on immature DCs was complicated by the presence of low levels 
of endotoxin in the UDP-glucose preparations. However, initiation of DC maturation by endotoxin 
free UDP-glucose was achieved in some donors. In response to UDP-glucose intracellular calcium 
increased in immature DCs, but not mature DCs and monocytes. These data were confirmed using
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endotoxin-free UDP-glucose. The increase in intracellular calcium induced by UDP-glucose 
demonstrated partial sensitivity to pertussis toxin, consistent with the previous description of this 
receptor as a Gi linked receptor (Chambers et al., 2000). Finally, necrotic cell supernatants initiated 
an increase in intracellular calcium in a GPR105-expressing cell line and not the non-transfected 
parent cell line. These data demonstrate signalling by UDP-glucose in immature DCs, correlating 
with the expression profile of GPRl 05. Possible downstream effects of this UDP-glucose-mediated 
signal are suggested, although an unequivocal role remains elusive at this time.
Further evaluation of the significance of GPRl 05 expression on immature DCs would require 
demonstration of GPRl 05 on purified blood DCs. Although extensively used as tools for 
investigating myeloid DCs, representation of the true in vivo myeloid population by in vitro 
monocyte-derived DCs is still open to question. Definitive confirmation that UDP-glucose is acting 
through GPRl 05 on immature DCs awaits verification with either specific anti-GPR105 antibodies 
or antagonising chemical entities or other specific gene targeting approaches. Therefore the 
tentative role we describe for UDP-glucose-induced signalling in DC maturation requires further 
confirmation with better tools than were available for these studies.
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Chapter 6
CXCL5 in osteoclasts
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Chapter 6
6.1 Introduction
Osteoclasts are specialised cells of haematopoietic origin, belonging to the myeloid cell lineage. 
The importance of chemokines and chemokine receptors in the biology of other myeloid cell types 
is well documented. However, despite some emerging information little is known of the 
significance of these molecules in osteoclast physiology and function. With this in mind, the custom 
made gene microarray was used to examine expression of mRNA transcripts encoding chemokines 
and chemokine receptors, as well as additional selected GPCRs, in human monocytes and in vitro 
monocyte-derived osteoclasts as described in Chapter 4. The resulting gene expression data 
revealed much similarity of expression of these genes by the two cell types, perhaps reflecting the 
relative insignificance of these molecules in osteoclast specialisation. However, some genes did 
show distinct expression patterns as previously discussed in Chapter 4, most interestingly CXCL5 
(ENA-78), an ELR motif-containing CXC chemokine implicated in neutrophil recruitment and 
angiogenesis, showed increased expression in the osteoclast samples.
CXCL5 also called epithelial neutrophil activating peptide 78 (ENA-78) or lipopolysaccharide- 
induced CXC chemokine (LIX), is a potent chemoattractant and activator of neutrophil functions. It 
shares a receptor, CXCR2, and neutrophil activating properties with CXCL8 (IL-8) (Ahuja et al., 
1996). CXCL5 is produced at low levels by many cell types and is elevated in the inflamed tissues 
of patients with rheumatoid arthritis (RA); Crohn's disease; ulcerative colitis; acute appendicitis and 
allergic airway inflammation (Walz et al., 1997). CXCL5 is also a potent angiogenic factor in non 
small cell lung cancer and attracts endothelial cells with the same influence as CXCL8 (Arenberg et 
al., 1998; Strieter et al., 1995).
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The CXC chemokine family can be subdivided by the presence of the tri-amino acid motif Glu-Leu- 
Arg (the ELR motif): CXCL5 and CXCL8 form part of the ELR-positive CXC chemokine 
subfamily, along with CXCLl (Gro-a), CXCL2 (Gro-(3), CXCL3 (Gro-y), CXCL6 (GCP2) and 
CXCL7 (NAP-2). This motif affords activity through the chemokine receptors CXCRl and 
CXCR2, although the ELR motif containing chemokines display differing abilities to agonise these 
receptors (Clark-Lewis et al., 1993; Baggiolini et al., 1994). Chemokines that do not contain the 
ELR motif, such as CXCL4 (PF4), CXCL9 (MIG) and CXCLIO (IP 10) do not bind these receptors 
(Clark-Lewis et al., 1993). Furthermore, characterisation of these CXC chemokines as angiogenic 
or angiostatic has been linked to the presence or absence of the ELR motif; family members that 
contain the ELR motif are potent promoters of angiogenesis, whereas members that lack this motif 
are inhibitors of angiogenesis (Arenberg et al., 1998; Belperio et al., 2000). CXCL8, CXCLl, 
CXCL5 and CXCL6 are all capable of inducing endothelial cell chemotaxis in vitro and promoting 
angiogenic activity in the rat comeal micropocket model of neovascularisation (Strieter et al., 
1995). Conversely CXCL4 demonstrates anti-angiogenic affects both in vitro and in vivo and 
CXCL4, CXCL9 and CXCLIO have been shown to potently inhibit angiogenesis induced by both 
ELR-positive CXC chemokines and basic fibroblast growth factor (bFGF) (Maione et ah, 1990; 
Strieter et ah, 1995)
The role of CXCL5 and CXCL8 in angiogenesis is particularly interesting with respect to the 
biology of osteoclasts; not least because of the intimate relationship between angiogenesis and bone 
resorption, both at the site of normal physiologic bone turnover and in pathological conditions such 
as rheumatoid arthritis (Paleolog, 1996). Indeed Vascular Endothelial Growth Factor (VEGF), an 
important inducer of angiogenesis and endothelial cell proliferation (Veikkola and Alitalo, 1999) 
has direct effects on osteoclast formation and function (Nakagawa et ah, 2000; Collin-Osdoby, 
1994) and can substitute for M-CSF in the support of osteoclastic bone resorption (Niida et ah, 
1999). Consequently human microvascular endothelial cells (HMVEC) have been shown to express
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RANKL, while HMVEC treated with TNF-a can support the formation and fusion of osteoclasts 
from human monocyte precursors with concomitant bone resorption by these in v/7ro-derived 
osteoclasts (Collin-Osdoby et ah, 2001; McGowan et ah, 2001). Furthermore, a hypoxic 
environment, known to be an inducer of the angiogenic mediator VEGF (Neufeld et ah, 1999), has 
recently been shown to enhance both osteoclast formation and bone resorption in vitro (Amett et ah, 
2003). It is an attractive hypothesis that actively resorbing osteoclasts at the site of bone turnover 
may secrete CXCL5 and CXCL8 in response to angiogenic signals, thereby potentiating endothelial 
cell recruitment and new blood vessel formation. In addition, differential receptor usage by CXCL5 
and CXCL8 adds the possibility of disparate roles for these chemokines.
High levels of CXCL8 production have already been attributed to osteoclasts in vitro and CXCL8 
mRNA has been detected in osteoclasts present in RA joints by in situ hybridisation (Rothe et ah, 
1998). This chapter aims to demonstrate expression of CXCL5 and CXCL8 proteins by osteoclast 
cultures and to attribute the expression to multinucleated cells by immunocytochemistry. The 
functionality o f CXCL5 secreted by osteoclasts will be confirmed by induction of neutrophil 
chemotaxis. Lastly, the influence of inflammatory and angiogenic mediators on CXCL5 and 
CXCL8 production by osteoclasts will be evaluated.
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6.2 Results
6.2.1 Transcription and translation o f  CXC chemokine genes in osteoclast cultures
Four ELR-positive CXC chemokine transcripts were significantly expressed (>20 arbitrary units) in 
osteoclasts, as revealed by gene microarray profiling (Fig. 6.1 and Appendix 1). These included 
CXCLl (Gro-a), CXCL7 (NAP-2) and CXCL8 (IL-8), each of which was also transcribed in 
monocytes. CXCL5 (ENA-78) demonstrates much higher mRNA expression in the osteoclast 
preparations than the monocytes (Table 4.1; Fig. 4.13; Fig. 6.1). Interestingly, none o f the four 
myeloid cell types tested had significant expression of the ELR-negative chemokine genes CXCL9 
-  CXCLl4. However, the ELR-negative angiostatic chemokine CXCL4 was expressed at low levels 
in both osteoclasts and monocytes.
To confirm expression of these chemokines at the protein level, time course studies o f in vitro 
osteoclastogenesis were performed and supernatants assayed using specific ELISAs. Since CXCL5 
transcripts were not present in monocytes, cultures were set up with and without RANKL, which is 
necessary for multinucleated cell formation (Fuller et al., 1998), to help assess the relationship 
between CXCL5 production and osteoclast formation. Osteoclast cultures generated from 
monocytes of three donors were evaluated for production of CXCL5 as well as CXCLl, CXCL7, 
CXCL8, CXCL9 and CXCLIO over a period of 9 days. On day 9, cultures were assessed for 
formation of TRAP-positive multinucleated cells. RANKL positive cultures demonstrated an 
average of 134 +/- 32.8 (SEM) TRAP-positive multinucleated cells per field of view. No 
multinucleated cell formation was detected in the absence of RANKL. Figure 6.2 reveals 
production of CXCLl and CXCL7 at similar levels in both the presence and absence o f RANKL. 
CXCL8 levels, although higher in the later time points of the RANKL cultures, were similar in both 
cultures at the early time points. Production of CXCL5 appeared to be dependent on the presence of 
RANKL in the cultures and increased dramatically on days 5 and 6 of culture. ELR-negative
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chem okines C XCL9 and CXCLIO were m ostly  b elow  the lim it o f  detection o f  the ELISAs. V ery  
low  levels o f  CXCLIO could be measured at day 9 in both cultures.
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Figure 6.1 Expression of CXCLl, CXCL5, CXCL7, CXCL8, CXCL9 and CXCLIO mRNA 
transcripts in monocytes and osteoclasts
M onocytes were purified from PBM C and osteoclasts were derived from m onocytes in the presence  
o f  M -C SF and R A N K L for 9 days. R N A  w as extracted and reverse transcribed into ^^P-labelled 
cD N A , w hich w as hybridised to a gene microarray. Expression levels w ere calculated by  
norm alising data to a panel o f  forty housekeeping genes. Data are m eans (+SEM ) o f  6  (m onocytes) 
or 7 (osteoclasts) experim ents.
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Figure 6.2 Levels of CXC chemokines in the supernatants of osteoclast cultures with or 
without RANKL
O steoclast cultures, derived from PBM , were established in the presence o f  M -C SF with (closed  
bars) or without (open bars) R A NK L for 9 days. Supernatant was rem oved on days 0, 2, 4, 5, 6 , 7 
and 9. ELISA s were used to m easure the CXC chem okines present in the supernatants, in duplicate. 
Data are m eans + SEM  o f  3 donors.
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6.2.2 Immunocytochemical analysis o f  osteoclast chemokine production
As osteoclast cultures are not homogeneous, immunocytochemistry was applied to in vitro 
differentiation cultures on culture slides to identify the cell type responsible for production of 
CXCL5. Day 9 osteoclast cultures were treated with GolgiStop™, which contains the protein 
transport inhibitor monensin, for 4 hours to allow the chemokine to accumulate in the cytoplasm of 
cells. Slides were fixed in a paraformaldehyde solution, permeabilised and blocked, before 
incubation with either goat IgG control, goat anti-CXCL5 or goat anti-CXCL8. Figure 6.3 
demonstrates both CXCL5 and CXCL8 staining in multinucleated osteoclast cells. Staining of some 
of the mononuclear cells can also be seen in both cases, but that in multinucleated cells was most 
pronounced. No positive staining could be seen with the isotype control antibody.
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Figure 6.3 CXCL5 and CXCL8 production in osteoclast cultures
Osteoclast differentiation cultures were grown on 6-well culture slides (Falcon) for 9 days, in the 
presence of GolgiStop™ (4pl/ml) for the last 3 hours of culture. Slides were fixed in PBS/ 3.5% 
paraformaldehyde/ 2% sucrose, permeabilised in 20mM Hepes/ 300mM sucrose/ 50mM NaCl, 
3mM M gC y 0.5% triton-xlOO, and blocked in PBS/ 5% FCS/ 2% sucrose, before incubation with 
lOpg/ml goat IgG control (A), lOpg/ml goat anti-human CXCL5 {B) or lOpg/ml goat anti-human 
CXCL8 (Q . Bound antibody was revealed using HRP conjugated mouse anti-goat Ig and AEG 
substrate. Slides were then counterstained with Haematoxylin Gill no. 3, mounted and pictures were 
taken using a Zeiss axioscope with a JVC 3 chip colour camera (magnification x200).
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6.2.3 Chemotaxis to osteoclast supernatants
In an attempt to elucidate a role for CXCL5 production by osteoclasts, I sought to examine the 
potential pro-angiogenic activity of osteoclast supernatants. To achieve this, endothelial cell 
chemotaxis assays were set up using human embryonic kidney endothelial cells (HUVEC). 
Unfortunately the ability of HUVEC to respond to serum-containing medium ruled out the 
possibility of investigating chemotaxis to osteoclast supernatants, which routinely contain 15 % 
serum (Fig. 6.4).
As CXCL5 and CXCL8 are both capable of attracting neutrophils, experiments were performed to 
demonstrate the functionality of the chemokines produced in these osteoclast cultures using 
neutrophil chemotaxis as a read-out. Standard curves of neutrophil chemotaxis to recombinant 
human CXCL5 and CXCL8 are shown in Figure 6.5. CXCL8 is a much more powerful 
chemoattractant than CXCL5 in this system. Thereafter, chemotaxis of neutrophils to the osteoclast 
supernatants was investigated, using neutralising antibodies to CXCL5 and CXCL8 to attribute any 
chemotaxis seen to these chemokines. Osteoclast supernatants from three individual donors all 
showed powerful chemoattractant properties that could be significantly blocked by pre-treatment 
with an antibody to CXCL8. The probability that decreased chemotaxis to the osteoclast samples, in 
the presence of blocking antibodies, is due to random events is < 0.05 as determined by paired t-test 
analysis. Treatment with an antibody to CXCL5 resulted in statistically significant blocking of 
chemotaxis to one osteoclast supernatant and the CXCL5 standard. While chemotaxis to the other 
two osteoclast supernatants was not significantly blocked, a decrease in the percentage of cells 
migrating to these antibody treated supernatants was apparent (Fig. 6.6).
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Figure 6.4 Endothelial cell chemotaxis to 10% serum
HUVECs were labelled with Calcein AM and placed in the top chamber of 96 well fluoroblok 
plates. Chemoattractants (10% serum or diluent as a control) were then place in the bottom wells 
using the sample ports. The plates were incubated for 4 hours at 37°C, 5% CO2 and migrated cells 
were estimated by measuring the fluorescence intensity of the bottom chamber using an LJL analyst 
and bottom read optics at 485nm (excitation) and 530nm (emission). Data shown are mean of 
duplicates. The error bars represent minimum and maximum values.
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Figure 6.5 Chemotaxis of human peripheral blood neutrophils in response to CXCL5 and 
CXCL8
Neutrophils were purified from PBMC. Chemokines were added to the bottom of 3pm transwell 
chemotaxis chambers, and neutrophils were placed in the top chambers. The plates were incubated 
for 60 minutes at 37°C, 5% CO2, following which the top wells were discarded before migrated 
cells were recovered by vigorous pipetting and counted on a flow cytometer. Data is expressed as 
the percentage of neutrophils that migrated to the positive control, fMLP. Data is mean +/- SEM of 
3 separate experiments.
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Figure 6.6 Blocking of neutrophil chemotaxis to osteoclast supernatants by anti-CXCL5 and 
anti-CXCL8 antibodies
Neutrophils were purified from PBMC. Chemokines or osteoclast supernatants, plus anti-CXCL5
(A) or anti-CXCL8 (B) where appropriate, were placed in the bottom of 3pm transwell chemotaxis 
chambers and pre-incubated at 37°C, 5% CO2, for 1 hour. Neutrophils were added to the top 
chambers. The plates were incubated for a further 60 minutes at 37°C, 5% CO2 , following which 
the top wells were discarded and migrated cells were removed from the bottom wells by vigorous 
pipetting and counted on a flow cytometer. Neutrophil chemotaxis to osteoclast supernatants or 
controls was measured in the presence (solid bars) or absence (open bars) of (A) anti-CXCL5 and
(B) anti-CXCL8. Data is mean + SEM of 3 separate experiments; * p < 0.05, paired t test.
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6.2.4 Induction o f CXCL5 and CXCL8 production by angiogenic and inflammatory
mediators
To investigate whether osteoclasts produce increased levels of CXCL5 in response to angiogenic 
stimuli, the effect of VEGF on these cultures was examined. No increase in the levels of CXCL5 or 
indeed CXCL8, were seen in response to VEGF (Fig. 6.7). TRAP-positive multinucleated cell 
numbers were similar in wells with or without VEGF (data not shown). To determine whether there 
could be a significant role for osteoclast production of CXCL5 in inflammation, chemokine levels 
were measured in response to the inflammatory stimuli TNF-a and IE-1(3. Both inflammatory 
stimuli caused an increase in CXCL5 and CXCL8 levels (Fig. 6.8). Consequently, a two-fold 
increase in the number of multinucleated cells in these cultures was also seen (data not shown).
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Figure 6.7 The effect of VEGF on CXCL5 and CXCL8 production from osteoclast cultures
Monocytes were purified from PBMC. Osteoclasts were derived from monocytes in the presence of 
M-CSF and RANKL for 8 days. VEGF was added to day 6 osteoclast cultures. The cells were then 
incubated for a further 48 hours, following which supernatants were removed and chemokine levels 
measured by ELISA. Data is expressed as a percentage of the chemokine levels produced in the 
absence of VEGF. Data shown are mean of two independent experiments. The error bars represent 
minimum and maximum values.
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Figure 6.8 The induction of CXCL5 and CXCL8 from osteoclast cultures by inflammatory 
mediators
Monocytes were purified from PBMC. Osteoclasts were derived from monocytes in the presence of 
M-CSF and RANKL for 9 days. lOng/ml IL-1(3 or lOng/ml TNF-a was then added to day 6 
osteoclast cultures. The cells were incubated for a further 72 hours, following which supernatants 
were removed and chemokine levels measured by ELISA. Data is expressed as fold induction of 
chemokine production in the absence IL-1(3 or TNF-a. Data shown are mean of duplicates. The 
error bars represent minimum and maximum values.
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6.3 Discussion
The microarray data detailed in Chapter 4, revealed expression of the ELR motif-containing CXC 
chemokine genes CXCLl, CXCL5, CXCL7 and CXCL8 in osteoclast cultures. In particular the 
expression of CXCL5 was of interest as this appeared to be elevated in the osteoclast samples (Fig. 
6.1). Expression of mRNA encoding CXCLl, CXCL5, CXCL7 and CXCL8 in the osteoclast 
cultures was substantiated by detection of the corresponding proteins in osteoclast culture 
supernatants. Time course experiments further demonstrated a correlation between levels of CXCL5 
protein and the formation of TRAP-positive multinucleated osteoclasts. TRAP-positive 
multinucleated cells were shown previously to appear at day 6 of culture, with numbers rising 
sharply between day 7 and day 8 (Fig. 3.9). The CXC chemokines, CXCLl, CXCL7 and CXCL8 
were all present in RANKL-independent cultures, in which no multinucleated cell formation was 
seen, and at early time points in the RANKL containing cultures, thereby failing to demonstrate a 
clear correlation with the formation o f multinucleated cells. The non-ELR containing angiostatic 
chemokines CXCL9 and CXCLIO were not detected in the osteoclast cultures, aside from very low 
levels of CXCLIO at day 9 of culture. Although CXCL5 levels were undetectable in the cultures 
stimulated with M-CSF only, ruling out the possibility that CXCL5 production could be attributed 
to macrophage-like cells contaminating the RANKL-positive cultures, the possibility of RANKL 
induction of CXCL5 from monocytes remains a possibility. Therefore immunocytochemistry was 
performed on the osteoclast cultures to confirm the cell types associated with the production of the 
CXC chemokines, CXCL5 and CXCL8. This analysis clearly attributed CXCL5 and CXCL8 
production in the osteoclast cultures to multinucleated osteoclast cells. Although some synthesis of 
these chemokines in mononuclear cells was also evident, many of these mononuclear cells had an 
appearance that could be associated with the TRAP-positive osteoclast precursor cells seen in 
osteoclast differentiation cultures.
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To examine the functionality of CXCL5 in the osteoclast supernatants, endothelial cell chemotaxis 
was investigated. Endothelial cell chemotaxis as a readout for CXCL5 activity is preferable to 
neutrophil chemotaxis, since CXCL5 and CXCL8 share equivalent activities with respect to 
endothelial cell chemotaxis (Strieter et ah, 1995) whereas CXCL5 demonstrates a much reduced 
ability to induce neutrophil chemotaxis than CXCL8 (Clark-Lewis et ah, 1993; Baggiolini et ah,
1994). Unfortunately a potent inducer of endothelial cell chemotaxis is serum (Harvey et ah, 2002) 
and as the osteoclast supernatants contain a high level o f serum, the ability of endothelial cells to 
migrate to serum was first evaluated. As expected the large response to serum eliminated the use of 
this cell type in evaluating the chemotactic function of CXCL5 protein in the osteoclast 
supernatants and the small amounts of supernatant obtained from these cultures made the removal 
of serum proteins through dialysis or chromatography unfeasible.
CXCL8 demonstrated greater induction of neutrophil chemotaxis than CXCL5 (Fig.6.5) (Clark- 
Lewis et ah, 1993; Baggiolini et ah, 1994). A neutralising antibody to CXCL8 could significantly 
block the osteoclast supernatant-induced chemotaxis of neutrophils. In contrast, although an 
antibody to CXCL5 decreased the osteoclast supernatant-mediated chemotaxis significantly in only 
one donor, the number of cells migrating to the osteoclast supernatants decreased in all three cases 
studied. Overall, functionality o f CXCL5 and CXCL8 in osteoclast supernatants was demonstrated 
in these assays.
The correlation between osteoclast formation and CXCL5 production suggests a distinct role for 
CXCL5 in osteoclast biology. CXCL5 is a potent chemoattractant and activator of neutrophil 
functions and shares neutrophil activating properties with CXCL8 (Ahuja et ah, 1996). However 
CXCL8 appears to have a much more significant role in the assays described in this chapter (Clark- 
Lewis et ah, 1993; Baggiolini et ah, 1994), whereas both CXCL5 and CXCL8 are equipotent in 
their ability to attract endothelial cells (Strieter et ah, 1995). Given that no ELR-negative CXC 
chemokines could be detected in osteoclasts (Chapter 3), and since there are many links between
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osteoclast formation, activity and angiogenesis, the angiostatic nature of these ELR-negative 
chemokines versus the angiogenic nature of CXCL8 and CXCL5 is intriguing. The angiogenic 
activities of CXCL8 on human intestinal microvascular endothelial cells are mediated through 
CXCR2 (Heidemann et al., 2003), which is the receptor of choice for CXCL5 (Ahuja et ah, 1996), 
suggesting an element of redundancy for CXCL5 and CXCL8 in this response.
Considering these differential activities of CXCL5 on neutrophils and endothelial cells, it is 
attractive to suggest that CXCL5 production is, despite an element of redundancy, a specific 
mechanism for osteoclast induced angiogenesis at the site of new bone formation. Nakagawa et al 
have reported enhancement of osteoclastic activity by the angiogenic factor VEGF, mediated 
through its receptors KDR and Flt-1 (Nakagawa et ah, 2000). With this in mind, the effect of VEGF 
on CXCL5 production by osteoclasts was evaluated. VEGF does not increase CXCL5 levels in 
osteoclast cultures, however this does not rule out an active angiogenic role for CXCL5 produced 
by osteoclasts.
The effects of inflammatory stimuli on CXCL5 levels in osteoclast cultures were also investigated. 
Increased production of both CXCL5 and CXCL8 was detected when TNF-a or IE-1(3 were added 
to the cultures. However, increased numbers of multinucleated cell formation was also found in 
these cultures (data not shown); therefore it is possible that the increased chemokine levels were 
simply due to an increase in multinucleated cell numbers. Furthermore, the uncharacterised 
mononuclear contaminants within these cultures are very likely to be macrophage type cells 
(Chapter 3) and an increase in production of CXCL5 and CXCL8 in these cells, at least in response 
to TNF-a, would be expected (Ciesielski et ah, 2002). Therefore, to confirm a possible correlation 
between CXCL5 production by osteoclasts and inflammatory disease states, a demonstration of 
CXCL5 in osteoclasts at sites of inflammation would be required. CXCL8 has already been 
demonstrated in osteoclasts in the rheumatoid arthritis joint and indeed, the intimate relationship 
between bone resorption and angiogenesis is also found in rheumatoid arthritis where bone
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destruction and invasion of blood vessels appear simultaneously (Paleolog, 1996). The data reported 
in this chapter demonstrate differential expression of CXCL5 in monocytes and osteoclasts and 
suggest a role for this chemokine in osteoclast biology. However, additional studies that are beyond 
the scope of this thesis work would be required to delineate a role for CXCL5 in osteoclast biology.
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Chapter 7
General discussion
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General Discussion
7.1 Overview
The work presented in this thesis evaluated the differential gene expression of a discrete selection of 
genes in divergent myeloid cell types. The common progenitor of two distinct and specialised 
myeloid cell types allowed the in vitro differentiation of these cells in such a way that changes in 
gene expression, as a result of polarised cell differentiation, could be evaluated alongside the 
characterisation of these cells with respect to their known phenotypic and functional attributes. The 
peripheral blood monocyte was chosen as a precursor for differentiation of myeloid dendritic cells 
and osteoclasts in vitro. These differentiation systems have been extensively documented in the 
literature and as such, cell populations were derived that are representative o f their in vivo 
counterparts and suitable for further study. Firstly, immature dendritic cell populations were 
obtained by culturing peripheral blood monocytes with GM-CSF and IL-4; these populations 
expressed low levels of the co-stimulatory molecule CD80, were negative for the co-stimulatory 
molecule CD86, expressed medium levels of the class II MHC molecule HLA-DR and were 
negative for the dendritic cell maturation marker CD83. Mature dendritic cells were isolated by 
further differentiating the immature cells with monocyte-conditioned medium, resulting in cells 
with high levels of CD80, CD86, HLA-DR and CD83. Consistent with their roles in vivo, immature 
DCs demonstrated high antigen uptake capacity and moderate ability to stimulate allogeneic T cells, 
whereas mature DCs had decreased antigen uptake function and increased ability to stimulate 
proliferation and IFN-y production by allogeneic T cells. Osteoclast populations were generated by 
culturing peripheral blood monocytes in the presence of M-CSF and RANKL; these cell 
populations contained a high percentage of TRAP-positive / aV(33-positive multinucleated cells 
with detectable levels of mRNA encoding RANK (the receptor for the osteoclast differentiation 
factor RANKL) and calcitonin receptor (a receptor routinely used in the identification of
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osteoclasts). Functionally, the differentiated osteoclasts were capable of bone resorption upon 
reseeding onto dentine slices.
The differential expression of chemokines, chemokine receptors, related GPCRs and a number of 
other GPCR ligands were evaluated using these populations of monocytes, osteoclasts, immature 
and mature DCs with a custom synthesised gene microarray. The gene array and protein analysis of 
chemokine production by DCs showed good correlation, where mRNA levels were present, protein 
was either constitutively produced or could be induced by further activation of the DCs. This study 
demonstrated constitutive production of the homeostatic chemokines CCL18 (PARC) in immature 
DCs and CCL17 (TARC) and CCL22 (MDC) in mature DCs, consistent with the role of CCL18 in 
attracting naïve T cells (Adema et al., 1997) and CCL17 and CCL22 in the formation of 
lymphocyte-dendritic cell clusters at sites of inflammation (Katou et al., 2001). The inflammatory 
chemokines CCL13 (MCP-4) and CCL23 (CK-^8) were demonstrated in immature DCs without the 
requirement of further stimulus; CCL13 is widely expressed at disease sites and involved in 
recruitment of inflammatory cells (Miotto et al., 2001). CCL23 binds to the CCRl receptor and is a 
potent activator of monocytes (Nardelli et al., 1999b). Other inflammatory chemokines, such as 
CCL3 (M IP-la), CCL4 (MIP-ip) and CCL15 (MIP-1Ô) were induced in immature DCs with 
inflammatory mediators. This is in accordance with the role of these inflammatory chemokines as 
inducible chemokines, functioning through the receptors CCRl, CCR3 and CCR5 and recruiting 
macrophages, lymphocytes, eosinophils, dendritic cells and NK cells to sites of infection (Driscoll, 
1994; Cook, 1996). The fact that the expression profiles for chemokines and chemokine receptors in 
DCs are consistent with published reports validates not only the significance of transcript 
expression, as determined by the custom gene microarray, but further validates the in v/?ro-derived 
dendritic cell populations used in this study. The expression of chemokines and chemokine 
receptors by osteoclasts was mostly unremarkable, but they showed a decrease in several monocyte- 
derived chemokines. Expression of CCL3, CCL4 and CCRl in these human in v//ro-derived
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osteoclasts requires further confirmation. However, differential expression of one chemokine gene, 
CXCL5, was detected in osteoclasts and a detailed investigation is detailed in Chapter 6 of this 
thesis.
The gene microarray analysis also revealed differential mRNA expression of the recently described 
G protein-coupled receptor GPR105 (Chambers et al., 2000) in immature DCs. Expression of 
GPR105 and functional activation of this receptor with its putative agonist ligand, UDP-glucose, as 
well as the consequences of activating this receptor on immature DCs were investigated. The 
expression pattern of GPR105 in monocytes, immature and mature DCs was confirmed by Northern 
blot analysis. UDP-glucose was corroborated as an agonist ligand for this receptor by the 
demonstration of a calcium flux and EC50 analysis in a HEK293 cell line co-transfected with 
GPR105 and the promiscuous G protein subunit G a l 6. Investigation of calcium responses to UDP- 
glucose in either monocytes or in viYro-derived immature and mature DC confirmed expression of a 
functional UDP-glucose receptor on immature DCs only. Treatment of immature DCs with UDP- 
glucose revealed a gene expression profile, as represented by screening with the custom gene 
microarray, synonymous with DC maturation. These DCs also displayed the phenotype of mature 
DCs, with respect to protein expression of the co-stimulatory molecules CD80 and CD86, CD83 
and HLA-DR and demonstrated a down-regulation in endocytic ability, again paralleling DC 
maturation. However, analysis of the UDP-glucose preparations used in these initial experiments 
revealed endotoxin contamination and further experimentation using these contaminated UDP- 
glucose preparations revealed a correlation between up-regulation of the co-stimulatory molecule 
CD86 and the level of endotoxin contamination, with a subsequent neutralisation of these effects in 
the presence of the endotoxin-binding agent polymyxin B. The endotoxin contamination had no 
effect on the UDP-glucose-induced calcium flux detected in immature DC, as demonstrated by an 
equivalent calcium response in the presence of polymyxin B. Further experiments using endotoxin- 
free UDP-glucose preparations from ICN Biomedicals revealed an increased CD86 expression in
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immature DCs in some donors, with a correlation between this UDP-glucose-induced CD86 up- 
regulation and the magnitude of a UDP-glucose-induced calcium response. Experiments were also 
performed to test if endotoxin-free UDP-glucose could enhance EPS-induced effects in DCs. EPS- 
activated DCs exhibited enhanced CD86 and CD83 expression with a decrease in endocytic ability, 
although these effects were not as potent as those seen with MCM. The addition of UDP-glucose 
further enhanced CD86 expression in the presence of EPS, whereas no effect was evident on CD83 
expression and endocytic ability. Immature DCs treated with endotoxin-free UDP-glucose 
demonstrated enhanced allogeneic T cell activation potential with induction of IFN-y production, 
both in the presence and absence of EPS. While an unequivocal role for GPR105 in DC maturation 
was not determined by our studies, GPR105 does appear to be specifically expressed by immature 
DCs and to be physiologically active on these cells, as evidenced by the calcium flux data. To 
further substantiate that UDP-glucose-mediated calcium fluxes are functioning through GPR105, 
the pertussis toxin sensitivity of the G proteins coupled to this receptor was exploited (Chambers et 
al., 2000). Pertussis toxin pre-treatment of immature DCs resulted in a decrease of the UDP- 
glucose-induced calcium flux; however the signal was not completely abolished. This demonstrates 
that the calcium signal obtained in response to UDP-glucose is, at least in part, working through 
pertussis toxin sensitive G proteins. As previously discussed, it is possible for G protein-coupled 
receptors to associate with different G protein classes and therefore display incomplete sensitivity to 
pertussis toxin (Haribabu et al., 1999; Ahamed and Ali, 2002). Moreover, HEK293 cells co­
expressing GPR105 and Gaie demonstrated a calcium flux in response to necrotic cell supernatants. 
As discussed previously, the release of UDP-glucose on mechanical stimulation of cells is low but 
levels remain stable for several hours. This inefficient metabolism of UDP-glucose may allow for 
critical thresholds of UDP-glucose to be ahieved under certain circumstances. Perhaps GPR105 
signalling requires this critical threshold of ligand, thereby avoiding inappropriate activation of 
DCs. In conclusion, these data demonstrate a correlation between UDP-glucose-induced signalling
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in immature DCs and the expression profile of GPR105. A possible role for UDP-glucose in DC 
maturation is described, although further investigation is required to ascribe a functional response to 
this receptor in DCs.
The expression of CXCL5 in osteoclast cultures was evaluated alongside CXCL8 (IL-8), a CXC 
chemokine previously described in osteoclasts (Rothe et al., 1998). Firstly, high levels of CXCL5 
protein production were demonstrated to correlate with the formation of multinucleated cells in in 
v//ro-derived osteoclast differentiation cultures; other CXC chemokines, CXCLl, CXCL7 and 
CXCL8 were found at consistent levels throughout the time course. Immunocytochemistry 
confirmed multinucleated osteoclasts as a source of both CXCL5 and CXCL8 protein production in 
these cultures. Chemotaxis experiments demonstrated powerful chemoattraction of neutrophils to 
osteoclast supernatants and this activity could be blocked with an antibody to CXCL8. Although an 
antibody to CXCL5 could only significantly block neutrophil chemotaxis to one of three osteoclast 
culture supernatants, chemotaxis was reduced in all culture supernatants and the poor contribution 
of CXCL5 to neutrophil migration may make significance difficult to attain. Chemotaxis 
experiments utilising endothelial cells, where CXCL5 is equipotent to CXCL8 (Strieter et al.,
1995), were not possible due to the large serum component of the osteoclast supernatants. Lastly, 
the effects of angiogenic and inflammatory stimuli on the production of CXCL5 in osteoclast 
cultures were investigated. Inflammatory stimuli increased CXCL5 production in accordance with 
an increase in multinucleated cell formation in these cultures; in contrast the angiogenic stimulus 
VEGF had no effect. The data reported demonstrates differential expression of CXCL5 in 
osteoclasts versus monocytes and suggests a role for this chemokine in osteoclast biology.
7.2 Discussion
Despite the reported successful differentiation of DCs from myeloid and lymphoid precursors in 
vitro, the differentiation pathways that generate DCs in vivo remain largely unknown (Ardavin et
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al., 2001). However recent experiments have been able to track the differentiation of DCs in vivo, 
through the adoptive transfer of green fluorescent protein-labelled monocytes from two distinct 
monocyte subsets, which has added to the weight of evidence that at least some in vivo DC 
populations are monocyte-derived (Geissmann et al., 2003). Although these experiments directly 
demonstrate in vivo differentiation of DCs from monocyte precursors in an experimental mouse, the 
authors were able to identify putative human counterparts of these distinct monocyte subsets. Some 
of the differences between results in human and mouse DCs may result from differences in the 
isolation or in vitro differentiation techniques used. With the knowledge of the existence of tissue- 
specific DC populations, as well as distinct stages of maturation/activation of DCs, it is becoming 
clear that human and mouse DC subpopulations share many phenotypic and functional 
characteristics (Shortman and Liu, 2002; O'Keeffe et al., 2003). Although no direct in vivo evidence 
exists for the differentiation of osteoclasts from monocytes, perhaps the most compelling data 
comes from the study of the op/op mice, which have a mutation in the gene encoding the critical 
macrophage growth and survival factor M-CSF, also called colony-stimulating factor type 1 (CSF- 
1) (Cecchini et al., 1994). These mice are deficient in several mononuclear phagocyte 
subpopulations, including osteoclasts. However, it remains a pertinent point that the most 
appropriate cells for the gene transcript expression studies described in this thesis are fully 
differentiated cells purified from blood or tissues. However, large numbers of purified cells from 
human blood or tissue may be difficult to obtain, restricting studies to a more limited number of 
genes, such as those identified in this study.
Microarray technology has already provided an unanticipated and novel finding with respect to DC 
biology. Granucci et al. (Granucci et al., 2001) performed gene expression analysis on immature 
murine DCs stimulated at different time-points with Gram-negative bacteria. In their study a gene 
microarray representing 11,000 genes and ESTs was screened. Gene clustering methods revealed 
differential expression of approximately 3,000 genes and ESTs, including TNF-a, CCL3, CCL4
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and IL-12, which are well-established markers for DC activation. Unexpectedly, expression of the 
IL-2 gene in DCs following bacterial challenge was also observed. IL-2 has long been recognised as 
a key molecule in the growth and proliferation of activated T cells. The impaired ability of DCs 
infected with cytomegalovirus to produce IL-2 and subsequently to prime alloreactive T cells has 
since been demonstrated (Granucci et al., 2002). This thesis describes the use of a gene microarray 
to analyse differential expression of mRNA transcripts encoding a discrete selection of genes in 
human monocytes, monocyte-derived immature and mature DCs, as well as monocyte-derived 
osteoclasts. There are no reports in the literature of gene microarray analyses involving in vitro- 
derived osteoclasts. However, other studies comparing the transcript profiles of human monocyte- 
derived immature and mature DCs have been reported; Dietz et al. utilised a DNA microarray 
containing fragments for 4,110 known genes, demonstrating differential transcript expression in 369 
genes (Dietz et al., 2000). The most impressive data set from their study was the upregulation of 
mRNA transcripts encoding the chemokine and chemokine receptor genes CCL17, CCL22 and 
CCR7 upon DC maturation. These findings are reinforced by the results obtained in this thesis. 
Other DNA microarray data presented by Dietz et al. allowed the authors to propose novel 
hypotheses for maturation-associated changes in dendritic cells and their interactions with the 
microenvironment, such as the proposal that the upregulated expression of membrane bound TGF-a 
upon DC maturation could aid in the attachment of DCs to stromal elements in the lymph nodes, or 
that TGF-a released from DCs might stimulate stromal cells over a longer range. Le Naour et al. 
(Le Naour et al., 2001) compared mRNA transcript profiles of immature and mature DCs and their 
monocyte precursors, by hybridising cDNA samples to DNA microarrays comprising 
oligonucleotides specific for 6,300 known genes. A total of 255 genes, mostly not previously 
associated with DCs, were found to be differentially regulated during DC differentiation and 
maturation, including genes related to cell adhesion, motility and regulation of the immune 
response. The authors combined the gene expression profiling with a proteomics approach, whereby
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protein analysis utilising two-dimensional gel electrophoresis and mass spectrometry identified 
differentially expressed proteins. This provided additional information that could not be obtained at 
the mRNA level, due to a poor correlation between mRNA expression and protein synthesis, or 
post-transcriptional modifications that may result in several spliced isoforms generated from 
precursor RNA. Another consideration when analysing mRNA transcript expression data revealed 
by microarray profiling is that at any particular time frame highly regulated transcripts may not be 
detected. As mentioned in the discussion of Chapter 4, transcripts encoding the inflammatory 
chemokines CCL3 and CCL4, although widely reported to be produced by mature / activated DCs 
(Sallusto et al., 1999), were not seen in mature DCs. It is also important to recognise that 
degradation of mRNA is tightly regulated and many mammalian inducible mRNA species have 
been shown to have a short half-life due to the presence of regulatory elements in their sequences 
that target them for efficient degradation (Bevilacqua et al., 2003). Conversely, the presence o f an 
mRNA species does not ensure synthesis of the corresponding protein, as translation is not only 
regulated by universal mechanisms but more specific mechanisms exist that influence individual 
mRNAs (Cazzola and Skoda, 2000). It remains highly pertinent that all transcript expression data 
generated by gene microarray profiling should be confirmed, by a second or third technique, 
preferably by identification of the expressed protein.
Critics of microarray profiling, at least where thousands of genes are screened at once, have referred 
to these data driven approaches as fishing expeditions. The approach taken in this thesis was to 
analyse a discrete selection of genes in related cell types. The main hypothesis being that by using 
microarray technology to examine the distinct gene expression patterns of highly related, yet 
fimctionally distinct cell types, one may identify genes with functional relevance to the specific cell 
types. Candidate genes for further work included the orphan GPCR, H963, which showed 
upregulation of message on the mature DC population. Little is known about H963 except that its 
closest human ortholog is the platelet activating factor receptor (Jacobs et al., 1997). This
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unconfirmed finding of expression in mature DCs might suggest a role in antigen presentation or T 
cell activation by these cells. In fact, platelet-activating factor receptor is present on immune cells 
and its ligand, platelet activating factor, is secreted by immune cells (Camussi et al., 1990). Thus, it 
is possible to postulate an immunological role for the expression of the ortholog H963 on mature 
dendritic cells. Another candidate for further work was the CCL15 gene, mRNA encoding CCL15 
was upregulated in immature DCs. Production of this chemokine on stimulation of immature 
dendritic cells with IFN-y and LPS or SAC was confirmed in Chapter 4 of this thesis. The 
characterisation of CCL15 as a chemoattractant for monocytes, eosinophils, T cells, dendritic cells, 
and neutrophils, mediated through CCRl and CCR3, is consistent with the production of this 
chemokine by immature DCs at sites of inflammation (Nardelli et al., 1999b). Two further genes, 
previously uncharacterised in the cell type expressed, were extensively evaluated.
The transcript encoding GPR105 was demonstrated in immature DCs by DNA microarray profiling 
and confirmed by Northern blot analysis. Specific antibodies to GPR105 were not available during 
this study, preventing direct confirmation of the expressed GPR105 protein. Lee et al. (Lee et al., 
2003) have recently described the use of a polyclonal anti-GPRl 05-peptide antibody to demonstrate 
the expression of GPR105 on a subset of haemopoietic cells within the foetal bone marrow, by 
immunofiuoresence and flow cytometry. Confirmation of GPR105 expression on immature DCs 
using this antibody would support the work reported in this thesis. However, demonstration of 
UDP-glucose-initiated signalling in immature DCs and not in monocytes and mature DCs, in which 
GPR105 transcript expression is decreased, adds support for the functional expression of GPR105 
on immature DCs. A neutralising antibody to GPR105 could also be used to confirm that UDP- 
glucose initiated signalling is mediated via GPR105 and not via another, as yet unidentified, UDP- 
glucose receptor. The emergence of UDP-glucose as an extracellular signalling molecule 
(Lazarowski et al., 2003) and evidence that DC maturation can be induced through exposure to 
necrotic tumour cells (Sauter et al., 2000), lead to the proposal that UDP-glucose could be acting as
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a danger signal. The data presented in Chapter 5 of this thesis demonstrating activation of GPR105 
by necrotic cell supernatants adds to the possibility that UDP-glucose, in concert with other signals, 
may be promoting the activation / maturation of DCs on its release. Confirmation of an increase in 
the concentration of UDP-glucose in the necrotic cell supernatants would strengthen this argument 
and assays to measure this have recently been developed (Lazarowski et al., 2003). The enhanced 
levels of UDP-glucose and other glycolytic metabolites in tumour cells (Eigenbrodt et al., 1992) 
suggest a role for GPR105 expression on immature DCs in tumour surveillance. Another 
possibility, that GPR105 could be involved in dendritic cell homing, warrants investigation. Indeed 
GPR105 has some homology to chemokine receptors (20 -  30% amino acid homology) and has the 
sequence motif DRYYKIV, located at the end of transmembrane III (Lee et al., 2003), similar to the 
DRYLAIV motif, a signature sequence for chemokine receptors (Youn et al., 1997a). The enhanced 
metabolism seen in cancer tissues (Eigenbrodt et al., 1992) is also likely to be seen in other actively 
proliferating cell systems, such as embryonic tissues (Ito et al., 1999). Perhaps lymphoid tissues 
such as lymph node, spleen or thymus, to which immature DCs home, contain high levels of UDP- 
glucose as a result of the actively proliferating cells present during times of immune activation or 
development. In fact, Lee et al. (Lee et al., 2003) used conditioned media from bone marrow stroma 
to attract GPR105 expressing cells, and the source of these stromal cells, the bone marrow, can also 
be described as an actively proliferating cell system.
The second gene that warranted further investigation was CXCL5, demonstrated in osteoclasts by 
gene microarray profiling and confirmed by showing presence of secreted CXCL5 protein by both 
ELISA and immunocytochemistry. The presence of CXCL5 in primary in v/vo-derived osteoclasts 
awaits demonstration. However, techniques for the isolation of in v/vo-derived osteoclasts 
commonly use cells from chickens or rabbits, where orthologs for CXCL5 have not been described. 
Demonstration of human osteoclasts expressing CXCL5 by immunohistochemistry remains a 
possibility. Chemotaxis experiments were utilised to exhibit the functional activity of osteoclast-
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produced CXCL5 and the possibility that this chemokine is involved in the process of angiogenesis 
was discussed. Demonstration of CXCL5-producing osteoclasts in close proximity with endothelial 
cells during bone remodelling, would suggest a role for osteoclasts in attracting these cells to an 
area of bone where new blood vessel formation is required. The effect of VEGF on the production 
of CXCL5 by osteoclasts was examined in Chapter 6 of this thesis; no increase in CXCL5 
production was seen. However, recent reports demonstrate the upregulation of RANK, the RANKL 
receptor, on endothelial cells in response to VEGF (Min et al., 2003) and the enhancement of 
endothelial cell capillary tube formation in response to RANKL (Kim et al., 2002). It would 
therefore be interesting to evaluate the effects of VEGF with respect to RANK expression on 
osteoclasts or osteoclast precursors. Although no direct relationship could be demonstrated between 
CXCL5 production from osteoclasts and the angiogenic factor VEGF in this non-exhaustive study, 
it is clear that there are many relationships emerging between osteoclastogenesis and angiogenesis. 
Certainly, unequivocal evidence of CXCL5 induced endothelial cell migration to the site of bone 
turnover would be an attractive addition to this story. In addition, the inflammatory cytokines TNF- 
a  and IE-1(3 were shown to increase CXCL5 production from osteoclast cultures in Chapter 6 of 
this thesis, albeit maybe just as a result of increased osteoclastogenesis. Equally CXCL5 has 
recently been shown to induce TNF-a and IE-1(3 expression by endothelial cells (Chandrasekar et 
al., 2003). TNF-a and IL-ip are capable of promoting further osteoclastogenesis, suggesting a self­
regulating role for osteoclast-produced CXCL5. Lastly, RANKL production from endothelial cells 
in response to TNF-a has also been reported (Collin-Osdoby et al., 2001). Taken together, this 
information supports the concept of a network of interactions between osteoclasts and endothelial 
cells in bone formation and angiogenesis. Furthermore a role for CXCL5 in angiogenesis in 
inflamed tissue in rheumatoid arthritis has been proposed (Koch et al., 2001). The data generated in 
this thesis identifies osteoclasts as possible contributors to the presence of CXCL5 in these diseased 
tissues and further implicates an important role for CXCL5 in bone remodelling and inflammation.
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7.3 Summary
Microarray gene technology applied to specialised in v/fro-derived myeloid cell types has lead to 
the investigation of two distinct genes in divergent areas of biology. Perhaps the greatest point for 
discussion is that cells arising from a single peripheral blood precursor are involved in such diverse 
functions as the initiation of an immune response and bone remodelling. At the outset of this thesis 
the hypothesis was to use microarray technology to examine the distinct gene expression patterns of 
highly related, yet functionally distinct cell types, in an effort to identify genes with functional 
relevance to the specific cell type. The characterisation of functionally active GPR105 on immature 
DCs and the demonstration of biologically active CXCL5 production by osteoclasts validate this 
hypothesis.
One further aim for this thesis was to demonstrate a role for a crucial set of proteins, chemokines 
and chemokine receptors, in osteoclast biology and compare this to the well-documented role for 
this family in highly migratory dendritic cells. Perhaps the in situ nature of osteoclast formation 
should have highlighted the probability of a less important role for this family in osteoclasts. What 
emerged from the DNA microarray data was the novel and differential expression of two genes; 
GPR105 in immature dendritic cells and CXCL5 in osteoclasts. As neither of these findings were 
expected, this demonstrates the power of microarray profiling, where numerous, indeed even 
thousands of genes may be investigated at one time, resulting in novel findings. The expression of 
GPR105 on immature DCs has led to the investigation of a putative role for this receptor in the 
initiation of an immune response, with confirmation of GPR105 mRNA transcript expression, as 
well as demonstration of signalling via a G protein-coupled receptor in response to the GPR105 
agonist UDP-glucose. The expression of mRNA transcripts encoding CXCL5 in osteoclasts has 
resulted in a proposed role for osteoclast-secreted CXCL5 in angiogenesis, with confirmation of 
CXCL5 protein production by in v//ra-derived osteoclasts.
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Appendix 1
Immature DC 
day 6
Immature DC 
day 9
Mature DC 
day 9
Monocyte 
day 0
Osteoclast 
day 9
FPRL1 -9 + / - 4 -1 + / - 2 -4 + / - 2 -2 + / - 2 -2 + / -  1
P2Y5 15 + / - 2 15 + / - 2 3 + / - 1 8 + / - 1 6 + / - 2
CML2 24 + / - 6 16 + / - 6 7 + / - 3 14 + / - 4 17 + / - 3
0GR1 short 1 + / - 3 3 + / - 2 -1 + / - 1 0 + / - 1 1 + / - 1
0GR1 long 13 + / - 3 5 + / - 1 6 + / - 2 8 + / - 2 9 + / - 2
GPR18 7 + / - 1 3 + / - 1 8 + / - 2 5 + / - 1 3 + / - 1
H963 short - 8 + / - 1 -7 + / - 3 -4 + / - 2 -7 + / - 1 -6 + / - 1
H963 long 4 + / - 2 10 + / - 2 43 + / - 7 1 + / - 1 3 + / - 1
TDAG8 9 + / - 4 8 + / - 1 2 + / - 2 31 + / - 8 11 + / - 2
C3AR 19 + / - 5 26 + / - 6 -2 + / - 2 25 + / - 3 34 + / - 7
P2Y9 -11 + / - 3 - 6 + / - 1 -2 + / - 1 0 + / - 1 -1 + / - 1
EBI2 15 + / - 7 17 + / - 2 15 + / - 3 2 2 + / - 8 11 + / - 3
HSGPCP 8 + / - 4 4 + / - 3 9 + / - 3 9 + / - 2 11 + / - 2
GPR105 174 + / - 50 255 + / - 27 43 + / - 16 18 + / - 2 14 + / - 1
GPR34 short -5 + / - 5 3 + / - 2 3 + / - 3 1 + / - 1 4 + / - 1
GPR34 long - 1 0 + / - 6 -9 + / - 3 -4 + / - 2 -3 + / - 1 6 + / - 4
GPR38 -3 + / - 1 0 + / - 1 2 + / - 1 3 + / - 1 2 + / - 1
GPR15 4 + / - 1 5 + / - 1 1 + / - 0 1 + / - 1 7 + / - 1
GPR31 1 + / - 3 1 + / - 0 1 + / - 1 1 + / - 1 1 + / - 1
GPR32 short 12 + / - 1 17 + / - 4 11 + / - 3 32 + / - 2 32 + / - 2
GPR32 long 6 + / - 3 9 + / - 3 1 0 + / - 2 28 + / - 3 24 + / - 2
CRTH2 -1 + / - 4 2 + / - 2 0 + / - 1 3 + / - 1 4 + / - 2
GPR44 2 + / - 12 -3 + / - 1 1 + / - 3 1 + / - 1 1 + / - 1
GPR16 56 + / - 7 41 + / - 12 27 + / - 6 108 + / - 10 38 + / - 4
GPR115 0 + / - 1 6 + / - 2 9 + / - 1 3 + / - 2 3 + / - 1
GPR128 23 + / - 10 14 + / - 3 19 + / - 3 33 + / - 10 7 + / - 2
GPR132 4 + / - 2 1 0 + / - 1 5 + / - 0 19 + / - 1 .9 + / - 2
CNR2 7 + / - 3 5 + / - 1 6 + / - 1 8 + / - 1 7 + / - 1
PTAFR 73 + / - 5 63 + / - 8 25 + / - 4 83 + / - 5 65 + - 7
Orphan G-protein 7TM receptors, array data summary table
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and IL-4. Day 6 immature DCs were incubated with or without MCM 
(mature DCs and immature DCs respectively) for 72 hours. Osteoclasts were derived from 
monocytes in the presence of M-CSF and RANKL for 9 days. RNA was extracted and reverse 
transcribed into ^^P-labelled cDNA, which was hybridized to a gene microarray. Scanned 
phosphorimage data was extracted using IMAGENE software and normalised to the average 
expression level of the housekeeping gene panel, with final expression levels expressed as % 
average of this panel. Data are means of 3 (day 6 immature DCs), 6 (monocyte, day 9 immature 
DCs and day 9 mature DCs) or 7 (osteoclast) experiments, SEMs are shown.
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Immature DC 
day 6
Immature DC 
day 9
Mature DC 
day 9
Monocyte 
day 0
Osteoclast 
day 9
Thrombin 12 + - 1 1 0 + / - 3 2 + - 1 4 + / - 1 14 + / - 6
Trypsin 1 8 + - 5 8 + / - 2 5 + - 1 8 + / - 6 5 + / - 1
Trypsin 2 26 + - 6 2 2 + / - 4 15 + - 2 15 + / - 2 15 + / - 3
Trypsin 3 1 0 + - 3 16 + / - 3 14 + - 6 8 + / - 3 4 + / - 4
Trypsin 4 16 + - 5 16 + / - 3 13 + - 2 9 + / - 2 26 + / - 5
Tryptase a 2 2 + - 6 2 2 + / - 6 2 0 + - 3 17 + / - 3 44 + / - 7
Tryptase b 34 + - 3 33 + / - 7 2 0 + - 4 18 + / - 4 46 + / - 7
Elastase 2A 2 2 + - 6 16 + / - 6 9 + - 2 19 + / - 4 2 0 + / - 3
Elast 28 Short -9 + - 2 -2 + / - 2 6 + - 6 -2 + / - 3 -4 + / - 2
Elast 28 Long 8 + - 4 7 + / - 3 6 + - 2 11 + / - 2 14 + / - 3
Elastase 3A 21 + - 6 18 + / - 6 11 + - 3 18 + / - 3 1 2 + / - 3
Elastase 38 27 + - 7 19 + / - 6 16 + - 3 21 + / - 3 2 2 + / - 5
Caldecrin 23 + - 6 17 + / - 5 14 + - 3 12 + / - 2 15 + / - 1
Neuromedin_U 1 + - 6 0 + / - 0 1 + - 1 0 + / - 1 0 + / - 1
P2Y2 4 + 2 6 + / 3 31 + - 6 2 0 + / - 6 3 + / - 1
PAR1 6 6 + - 18 77 + / - 15 30 + - 3 78 + / - 4 81 + / - 5
PAR2 -1 + - 3 0 + / - 1 -3 + - 1 4 + / - 3 0 + / - 0
PAR3 39 + - 2 37 + / - 3 31 + - 2 69 + / - 6 62 + / - 5
PAR4 39 + - 7 24 + / - 11 25 + - 9 34 + / - 5 17 + / - 4
C5aR 30 + - 10 37 + / - 6 6 + - 2 31 + / - 3 37 + / - 9
C3aR 30 + - 8 34 + / - 5 5 + - 2 21 + / - 1 34 + / - 8
Edg1 3 + - 2 6 + / - 2 7 + - 2 4 + / - 3 7 + / - 3
Edg2 - 1 0 + - 2 -5 + / - 2 -2 + - 2 -4 + / - 2 -2 + / - 1
Edg3 1 0 + - 4 6 + / - 2 26 + - 4 8 + / - 1 8 + / - 1
Edg4 11 + - 2 10 + / - 1 3 + - 1 19 + / - 3 4 + / - 2
Edg5 6 8 + - 6 46 + / - 8 64 + - 9 71 + / - 4 43 + / - 5
Edg6 25 + - 6 2 0 + / - 3 15 + - 2 43 + / - 5 8 + / - 1
Edg7 25 + - 13 1 0 + / - 3 6 + - 1 8 + / - 3 1 0 + / - 2
EdgS 4 + - 6 8 + / - 2 6 + - 1 7 + / - 1 9 + / - 2
082 2 + - 2 5 + / - 2 4 + - 2 6 + / - 2 5 + / - 1
EMR1 3 + - 1 3 + / - 1 2 + - 1 2 2 + / - 3 4 + / - 1
CD97 33 + - 2 2 0 + / - 4 9 + - 1 93 + / - 6 41 + / - 3
Known GPCR and GPCR ligands of interest, array data summary table
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and IL-4. Day 6 immature DCs were incubated with or without MCM 
(mature DCs and immature DCs respectively) for 72 hours. Osteoclasts were derived from 
monocytes in the presence of M-CSF and RANKL for 9 days. RNA was extracted and reverse 
transcribed into ^^P-labelled cDNA, which was hybridized to a gene microarray. Scanned 
phosphorimage data was extracted using IMAGENE software and normalised to the average 
expression level of the housekeeping gene panel, with final expression levels expressed as % 
average of this panel. Data are means of 3 (day 6 immature DCs), 6 (monocyte, day 9 immature 
DCs and day 9 mature DCs) or 7 (osteoclast) experiments, SEMs are shown.
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Immature DC Immature DC Mature DC Monocyte Osteoclast
day 6 day 9 day 9 day 0 day 9
CCL1 short -27 + / - 19 - 2 2 + / - 7 -15 + / - 3 1 + / - 1 0 + / - 1
CCL1 long 0 + / - 2 1 + / - 1 -4 + / - 2 -5 + / - 2 4 + / - 1
CCL2 34 + / - 15 33 + / - 9 326 + / - 38 -7 + / - 4 11 + / - 2
CCL3 34 + / - 10 40 + / - 10 5 + / - 2 261 + / - 60 48 + / - 10
SCYA3L 111 + / - 4 5 166 + / - 4 6 13 + / - 10 268 + / - 60 56 + / - 8
CCL4 33 + / - 5 29 + / - 6 -8 + / - 4 189 + / - 57 19 + / - 4
CCL5 Short 13 + / - 4 2 2 + / - 4 29 + / - 7 34 + / - 2 44 + / - 2
CCL5 Long 78 + / - 4 59 + / - 10 53 + / - 13 157 + / - 13 143 + / - 11
CCL7 Short -4 + / - 1 - 2 + / - 1 -1 + / - 1 -3 + / - 2 6 + / - 5
CCL8 -5 + / - 3 -1 + / - 2 -2 + / - 2 -2 + / - 1 9 + / - 2
CCL11 67 + / - 2 53 + / - 8 62 + / - 12 134 + / - 11 168 + / - 20
CCL13 192 + / - 4 0 251 + / - 26 33 + / - 17 3 + / - 1 4 + / - 1
CCL14 58 + / - 12 57 + / - 9 2 2 + / - 12 2 2 + / - 5 13 + / - 3
CCL15 97 + / - 29 74 + / - 2 2 15 + / - 5 -6 + / - 2 -3 + / - 2
CCL16 10 + / - 6 6 + / - 3 11 + / - 2 41 + / - 3 37 + / - 4
CCL17Short 77 + / - 3 129 + / - 29 488 + / - 20 7 + / - 1 4 + / - 1
CCL17 Long 140 + / - 6 235 + / - 29 749 + / - 33 4 + / - 2 8 + / - 1
CCL18 304 + / - 134 519 + / - 120 58 + / - 39 15 + / - 6 21 + / - 6
CCL19Short -2 + / - 3 -1 + / - 1 - 6 + / - 3 0 + / - 1 4 + / - 1
CCL19 Long 10 + / - 9 -4 + / - 5 38 + / - 8 16 + / - 3 21 + / - 3
CCL20 3 + / - 3 -1 + / - 1 -14 + / - 4 35 + / - 14 2 + / - 1
CCL21 44 + / - 13 29 + / - 9 15 + / - 3 24 + / - 3 2 0 + / - 3
CCL22 49 + / - 16 47 + / - 5 343 + / - 37 11 + / - 2 13 + / - 3
CCL23 149 + / - 28 111 + / - 27 21 + / - 10 1 + / - 2 2 + / - 2
CCL24 55 + / - 2 91 + / - 21 6 8 + / - 7 33 + / - 3 2 0 + / - 4
CCL25 12 + / - 5 9 + / - 4 6 + / - 2 9 + / - 3 17 + / - 2
CCL26 0 + / - 4 -2 + / - 1 1 + / - 1 1 + / - 3 4 + / - 1
CCL27 8 + / - 5 1 0 + / - 3 7 + / - 1 3 + / - 2 8 + / - 2
CCL28 59 + / - 4 60 + / - 4 48 + / - 3 8 8 + / - 3 44 + / - 6
XCL1 13 + / - 2 13 + / - 1 1 2 + / - 2 14 + / - 1 15 + / - 2
CX3CL1 19 + / - 8 17 + - 7 6 + / - 2 2 + / - 1 2 + / - 1
CC and CX3C chemokines, array data summary table
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and IL-4. Day 6 immature DCs were incubated with or without MCM 
(mature DCs and immature DCs respectively) for 72 hours. Osteoclasts were derived from 
monocytes in the presence of M-CSF and RANKL for 9 days. RNA was extracted and reverse 
transcribed into ^^P-labelled cDNA, which was hybridized to a gene microarray. Scanned 
phosphorimage data was extracted using IMAGENE software and normalised to the average 
expression level of the housekeeping gene panel, with final expression levels expressed as % 
average of this panel. Data are means of 3 (day 6 immature DCs), 6 (monocyte, day 9 immature 
DCs and day 9 mature DCs) or 7 (osteoclast) experiments, SEMs are shown.
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Immature DC 
day 6
Immature DC 
day 9
Mature DC 
day 9
Monocyte 
day 0
Osteoclast 
day 9
CCR1 43 + / - 6 58 + / - 5 3 + / - 5 38 + / - 6 55 + / - 6
CCR2 9 + / - 4 2 + / - 5 0 + / 35 + / - 6 3 + / - 1
CCR3 Short -1 + / - 0 0 + / - 1 0 + / -1 + / - 1 0 + / - 1
CCR3 Long -3 + / - 1 2 + / - 4 0 + / -2 + / - 2 4 + / - 1
CCR4 -5 + / - 4 1 + / - 1 0 + / -2 + / - 3 3 + / - 1
CCR5 42 + / - 7 27 + / - 4 2 + / 4 + / - 2 24 + / - 3
CCR6 1 0 + / - 6 5 + / - 2 3 + / 1 + / - 1 4 + / - 1
CCR7 11 + / - 3 11 + / - 2 117 + / - 12 13 + / - 1 12 + / - 2
OCRS short 0 + / - 1 2 + / - 1 1 + / 5 + / - 1 3 + / - 2
CCR8  long 3 + / - 2 4 + / - 2 -2 + / -4 + / - 2 6 + / - 1
CCR9 0 + / - 2 1 + / - 1 0 + / 6 + / - 1 3 + / - 1
CCR10 50 + / - 7 41 + / - 13 36 + / - 10 54 + / - 3 37 + / - 5
CCR11 5 + / - 5 4 + / - 1 8 + / - 4 7 + / - 2 8 + / - 1
CXCR1 2 + / - 2 3 + / - 2 0 + / - 1 2 + / - 1 5 + / - 1
CXCR2 36 + / - 10 24 + / - 5 8 + / - 2 18 + / - 2 8 + / - 2
CXCR3 46 + / - 8 30 + / - 11 29 + / - 7 40 + / - 5 44 + / - 2
CXCR4 48 + / - 1 58 + / - 3 76 + / - 6 89 + / - 15 70 + / -  7
CXCR5 5 + / - 1 13 + / - 1 11 + / - 1 7 + / - 1 11 + / - 1
CX3CR1 -3 + / - 3 4 + / - 2 2 + / - 1 25 + / - 5 5 + / - 1
CCXCR1 1 2 + / - 7 17 + / - 5 11 + / - 1 19 + / - 3 18 + / - 4
D6 15 + / - 4 15 + / - 3 1 + / - 2 9 + / - 3 19 + / - 2
DARC 27 + / - 4 16 + / - 5 9 + / - 1 5 + / - 5 18 + / - 3
CCRL2 -1 + / - 2 6 + / - 2 2 + / - 1 6 + / - 3 9 + / - 2
hm74 13 + / - 8 7 + / - 3 4 + / - 2 25 + / - 8 5 + / - 1
RDC1 8 + / - 2 11 + / - 3 9 + / - 0 9 + / - 2 9 + / - 2
TYMSTR -5 + / - 2 -3 + / - 2 3 + / - 3 -4 + / - 3 - 2 + / - 2
Chemokine Receptors, array data summary table
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and IL-4. Day 6 immature DCs were incubated with or without MCM 
(mature DCs and immature DCs respectively) for 72 hours. Osteoclasts were derived from 
monocytes in the presence of M-CSF and RANKL for 9 days. RNA was extracted and reverse 
transcribed into ^^P-labelled cDNA, which was hybridized to a gene microarray. Scanned 
phosphorimage data was extracted using IMAGENE software and normalised to the average 
expression level of the housekeeping gene panel, with final expression levels expressed as % 
average of this panel. Data are means of 3 (day 6 immature DCs), 6 (monocyte, day 9 immature 
DCs and day 9 mature DCs) or 7 (osteoclast) experiments, SEMs are shown.
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Immature DC 
day 6
Immature DC 
day 9
Mature DC 
day 9
Monocyte 
day 0
Osteoclast 
day 9
CXCL1 -1 + / - 2 2 + / - 2 6 + / - 2 19 + / - 10 24 + / - 7
CXCL2 1 + / - 1 6 + / - 3 3 + / - 3 58 + / - 17 13 + / - 3
CXCL3 27 + / - 1 12 + / - 5 17 + / - 6 44 + / - 9 18 + / - 2
CXCL4 19 + / - 4 15 + / - 3 1 2 + / - 3 18 + / - 2 15 + / - 2
CXCL5 -2 + / - 3 2 + / - 4 6 + / - 4 -3 + / - 1 46 + / - 14
CXCL6 -2 + / - 2 2 + / 1 + / - 1 -11 + / - 4 8 + / - 3
CXCL7 -1 + / - 3 2 + / 4 + / - 2 38 + / - 9 77 + / - 30
CXCL8 0 + / - 2 1 + / 7 + / - 4 175 + / - 45 23 + / - 4
CXCL9 - 1 0 + / - 6 - 2 + / - 4 0 + / - 1 3 + / - 1 0 + / - 1
CXCL10 0 + / - 1 1 + / -1 + / - 1 2 + / - 1 1 + / - 2
CXCL11 2 + / - 4 1 + / 0 + / - 1 0 + / - 1 1 + / - 1
CXCL12 -9 + / - 7 -9 + / - 2 -19 + / - 4 1 + / - 1 4 + / - 1
CXCL13 -8 + / - 4 -7 + / -28 + / - 3 -1 + / - 1 1 + / - 1
CXCL14 0 + / - 2 3 + / 4 + / - 1 4 + / - 2 3 + / - 1
Hu_genomic_75_ng 197 + / - 13 173 + / - 23 130 + / - 17 172 + / - 15 241 + / _ 52
Hu_genomic_75_ng 187 + / - 16 153 + / - 27 114 + / - 23 171 + / - 17 234 + / - 42
Hu_genomic_75_ng 177 + / - 14 142 + / - 26 103 + / - 18 167 + / - 12 250 + / - 46
Hu_genomic_75_ng 204 + / - 16 156 + / - 28 116 + / - 2 2 203 + / - 12 251 + / - 48
Hu_genomic_75_ng 218 + / - 6 189 + / - 29 147 + / - 21 249 + / - 20 308 + / - 40
H u_genom ic_7 5_ng 209 + / - 7 179 + / - 33 139 + / - 2 2 237 + / - 20 292 + / - 40
Hu_genomic_75_ng 160 + / - 14 133 + / - 18 97 + / - 13 154 + / - 9 228 + / - 50
Hu_genomic_75_ng 239 + / - 23 173 + / - 40 131 + / - 28 2 2 1 + / - 15 248 + / - 48
H u_genom ic_7 5_ng 227 + / - 5 195 + / - 35 156 + / - 27 258 + / - 18 284 + / - 31
Hu_genomic_75_ng 243 + / - 21 204 + / - 42 146 + / - 26 256 + / - 13 269 + / - 40
Cot-1 _1000_ng/ul 115 + / - 6 96 + / - 9 99 + / - 15 124 + / - 7 117 + / 18
Cot-1 _50_ng/ul 2 + / - 5 1 0 + / - 2 4 + / - 2 5 + / - 1 16 + / - 3
Cot-1 500 ng/ul 48 + / - 4 56 + / - 3 33 + / - 2 55 + / - 3 74 + / - 14
CXC-Chemokines, array data summary table
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and IL-4. Day 6 immature DCs were incubated with or without MCM 
(mature DCs and immature DCs respectively) for 72 hours. Osteoclasts were derived from 
monocytes in the presence of M-CSF and RANKL for 9 days. RNA was extracted and reverse 
transcribed into ^^P-labelled cDNA, which was hybridized to a gene microarray. Scanned 
phosphorimage data was extracted using IMAGENE software and normalised to the average 
expression level of the housekeeping gene panel, with final expression levels expressed as % 
average of this panel. Data are means of 3 (day 6 immature DCs), 6 (monocyte, day 9 immature 
DCs and day 9 mature DCs) or 7 (osteoclast) experiments, SEMs are shown.
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Immature DC 
day 6
Immature DC 
day 9
Mature DC 
day 9
Monocyte
dayO
Osteoclast 
day 9
Human mRNA for platelet-typejDhosphofmctokinase 93 + -15 75 + -4 47 + -4 28 + -4 84 + /-5
Human lysosomal giycosyiasparaginase gene 13 + -3 17 + - 1 14 + - 1 17 + -3 24 + /-3
Human ETS2 oncogene 4 + - 2 9 + - 2 10  + - 2 54 + - 6 20 + /-4
Human capping protein a-mRNA partial cds 37 + -5 40 + - 1 0 17 + -7 21 + -7 32 + / - 6
Human mRNA for mitochon 60 + -5 60 + -4 38 + -3 50 + -3 56 + /-5
Human cytoplasmic l>actin gene 557 + - 12 514 + -31 670 + -33 657 + -36 475 +/-31
Unknown est hits only 2  + -5 6  + -3 6  + - 2 6  + - 1 4 + /- 1
Human mitochondrial ADP/ADT translocator mRNA 23 + -7 30 + -7 17 + -4 2 2  + - 8 46 + / - 6
Human superoxide dismutase mRNA 65 + -7 79 + -3 49 + -4 70 + -5 57 + / - 8
Homo sapiens protein tyrosine kinase (Syk) mRNA 65 + -3 74 + -4 40 + -3 71 + -5 60 + / - 6
Lipoamide dehydrogenase (NAD) 2 2  + - 2 30 + -5 29 + -4 23 + - 2 30 +1-2
Unknown -20 est only -6 + -5 3 + - 2 4 + - 2 6  + - 2 8  + / - 1
Human mRNA for lactate dehydrogenase-A 125 + - 6 112 + -5 140 + -7 76 + - 2 212 + / - 13
Human glutamate receptor 2 mRNA -4 + -3 0  + -4 - 6 + -3 -9 + - 2 1 + /-3
Human a-2-macroglotxjlin mRNA 77 + - 2 1 125 + - 2 2 40 + -7 2 2  + -5 59 + / - 14
Human glyceraldehyde 3-phosphate dehydrogenase 247 + - 6 257 + -7 233 + -7 340 + - 13 622 +Z-36
DAD-1 pBSAS 43 + -4 42 + -5 31 + - 2 40 + -5 44 + /-  4
SLUG-1 pBSAS -14 + -4 5 + -3 -1 + -5 -13 + - 2 4 +1-2
Actin 5' fragment 160 + -25 165 + -26 188 + -30 121 + -27 135 +/-21
Actin Mddle fragment 197 + -24 181 + - 2 2 217 + -26 185 + - 2 1 2 0 0  +Z-28
Actin 3' Fragment 572 + -25 543 + -34 696 + -25 652 + -40 426 +Z-29
deo^ypusine synthase mRNA 44 + - 2 43 + - 6 45 + -3 47 + -4 58 +Z-3
eukaryotic initiation factor 2B-e 16 + -4 21 + - 2 16 + - 1 2 0  + -3 15 +Z-4
90-kDa heat-shock protein gene 99 + -3 102 + -5 87 + - 6 77 + - 2 85 +Z-5
histone H2B.1 mRNA3'_end 31 + -5 39 + -4 47 + - 8 41 + - 2 85 +Z- 8
ADP-ritosylation factor 1 gene 105 + - 1 0 123 + - 6 93 + -7 1 20  + -9 103 +1-7
enylyl cyclase associated protein 136 + -4 140 + -7 131 + -4 150 + -5 124 +Z-5
cytosolic malate dehydrogenase 93 + -3 115 + - 14 73 + - 8 33 + - 1 77 +Z- 8
haperonin protein (Tcp20) 46 + - 2 50 + -4 45 + -5 56 + -4 41 +Z-5
glutamate dehydrogenase (GDH) 51 + -7 59 + -3 38 + -5 55 + - 2 42 +Z-4
DNA repair helicase (ERCC3) 42 + -3 44 + - 2 36 + - 2 34 + - 2 33 +1-2
endothelin-1 gene 13 + - 1 14 + - 1 9 + - 2 11 + - 2 13 + Z -1
(cytosin-5) methyltransferase 94 + -7 8 6  + -6 31 + - 2 42 + -5 47 +Z- 6
uroporphyrinogen 111 synthase mRNA 52 + - 1 54 + - 2 48 + - 1 46 + -3 59 +1-2
calmodulin 183 + - 8 192 + - 14 331 + - 2 1 180 + - 15 111 + Z -19
MRL3 = mammalian ritxosome L3 26 + - 1 30 + -4 33 + -5 19 + - 2 19+Z-3
ADP/ATP translocase mRNA 3' end done 176 + - 1 0 160 + - 11 146 + -6 237 + - 10 198 +1-1
cytochrome tx>1 complex core protein 11 63 + -6 64 + -7 47 + -4 70 + - 1 2 69 +Z- 6
hnRNP C2 protein mRNA 108 + -5 109 + -4 96 + - 6 111 + -5 98 +Z-7
Housekeeping genes, array data summary table
Monocytes were purified from PBMC. Dendritic cells were differentiated from monocytes by 
incubation with GM-CSF and IL-4. Day 6 immature DCs were incubated with or without MCM 
(mature DCs and immature DCs respectively) for 72 hours. Osteoclasts were derived from 
monocytes in the presence of M-CSF and RANKL for 9 days. RNA was extracted and reverse 
transcribed into ^^P-labelled cDNA, which was hybridised to a gene microarray. Scanned 
phosphorimage data was extracted using IMAGENE software and normalised to the average 
expression level of the housekeeping gene panel, with final expression levels expressed as % 
average of this panel. Data are means of 3 (day 6 immature DCs), 6 (monocyte, day 9 immature 
DCs and day 9 mature DCs) or 7 (osteoclast) experiments, SEMs are shown.
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A ppendix 2
Chem okine
R eceptors
A ccession
Num ber
CCR1 L10918
CCR2 D29984
CCR3 U28694
CCR4 X85740
OCRS U54994
CCR6 U45984
CCR7 L31584
CCR8 U45983
CCR9 U45982
CCR10 U13667
CCR11 API93507
CXCR1 U11870
CXCR2 LI9593
CXCR3 X95876
CXCR4 AF005058
CXCR5 NM001716
CX3CR1 P49238
CCXCR1 L36149
D6 Y12815
DARC U01839
7-TM R eceptors A ccession
Num ber
P2Y2 U07225
PAR1 M62424
PAR2 U34038
PAR3 U92971
PAR4 AF080214
C5aR M62505
C3aR U28488
Edg1 M31210
Edg2 U78192
Edg 3 X83864
Edg4 AF011466
Edg 5 AF034780
Edg 6 NM 003775
Edg 7 NM 012152
Edg 8 AC011461
CB1 U73304
CB2 X74328
EMR1 X81479
CD97 U76764
C hem okines A ccession
Num ber
CXCLl P09341
CXCL2 M36820
CXCL3 M36821
CXCL4 M25897
CXCL5 X78686
CXCL6 U83303
CXCL7 M54995
CXCL8 P10145
CXCL9 Q07325
CXCLl 0 P02778
CXCLl 1 U66096
CXCL12 U16752
CXCLl 3 AF044196
CXCL14 AF073957
CCL1 P22362
CCL2 PI 3500
CCL3 M23452
SCYA3L M23178
CCL4 P I3236
CCL5 P13501
CCL7 P80098
CCL8 P80075
CCL11 P51671
CCL13 U46767
CCL14 AF031587
CCL15 NM 004167
CCL16 ABO18249
CCL17 NM 002987
CCL18 AB012113
CCL19 Q99731
CCL20 P78556
CCL21 U88320
CCL22 U83171
CCL23 U85767
CCL24 NM 002991
CCL25 015444
CCL26 ABO10447
CCL27 AJ243542
CCL28 AF220210
XCL1 NP 002986
CX3CL1 U91835
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7-TM R eceptor 
Ligands
A ccession
Num ber
Thrombin J00307
Trypsin 1 M22612
Trypsin 2 M27602
Trypsin 3 XI5505
Trypsin 4 X72781
Tryptase a M30038
Tryptase b M37488
Elastase 2A M16631
Elastase 2B Ml6653
Neutrophil Elastase M34379
Elastase 3A D00306
Elastase 3B NM 007352
Caldecrin (elastase S82198
IV)
Neuromedin U X76029
7-TM O rphan A ccession
R eceptors Num ber
FPRL1 M84562
G2A AF083955
P2Y5 AF000546
CML2 U77827
0GR1 U35398
GPR 18 L42324
H963 AF002986
TDAG8 NM 003608
C3AR AAC50374
P2Y9 NM 005296
EBI2 L08177
HSGPCP Y13583
GPR105 D13626
GPR34 AF039686
HS0GPCR1 NM 006056
GPR 38 AF034632
GPR15 U34806
GPR31 U65402
GPR32 AF045764
CRTH2 AB008535
GPR44 AF118265
GPR16 X98356
GPR115 AJ249248
GPR128 D10923
GPR132 AA827664
CNR2 NM 001841
PTAFR D1 0 2 0 2
CCRL2 U97123
CMKLR1 U79527
hm74 D10923
RDC1 U67784
TYMSTR U73531
H ousekeeping G enes A ccession
Num ber
alpha-catenin T65118
platelet-type phosphofructokinase R38433
lysosomal giycosyiasparaginase R42153
ETS2 oncogene R42479
capping protein alpha R42609
mitochondrial short-chain enoyl-CoA R43558
hydratase
cytoplasmic beta-actin M l0277
Unknown est hits R20593
mitochondrial ADP/ADT translocator R53942
superoxide dismutase R52548
protein tyrosine kinase (Syk) R59598
Lipoamide dehydrogenase (NAD) L03490
Unknown - 2 0  est only N48956
mRNA for lactate dehydrogenase-A H05914
glutamate receptor 2 H06193
alpha-2 -macroglobulin H06516
glyceraldehyde 3-phosphate dehydrogenase HI6958
deoxyhypusine synthase R37766
eukaryotic initiation factor 2B-epsilon R54818
90 kD heat shock protein R44334
histone H2B.1, 3' end H06295
ADP-ribosylation factor 1 H I1049
adenylyl cyclase-associated protein R37953
malate dehydrogenase R15814
chaperonin protein (Tcp20) H07880
liver glutamate dehydrogenase R54424
DNA repair helicase (ERCC3) H20856
endothelin-1 H11003
DNA (cytosin-5)-methyltransferase H09055
uroporphyrinogen III synthase T82469
mRNA for calmodulin R44288
ribosomal protein L3 homologue H05820
ADP/ATP translocase R61295
cytochrome bc-1 complex core protein II R12802
nuclear ribonucleoprotein particle (hnRNP) C H05899
Beta Actin 5' Fragment M l0277
Beta Actin middle Fragment Ml0277
Beta Actin 3' Fragment Ml0277
DAD-1 D15057
SLUG-1 NM003068
Genes represented on the DNA microarray with GenBank accession numbers
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